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Abstract 
Malformations in humans at birth have been recorded since ancient times. These 
malformations are anatomical or physiological anomalies present at the time of birth 
that may be caused by genetic or environmental factors or a combination of both. 
The pathogenesis is only known in 10%, of which 1% or less are caused by drugs 
and medications. Certain disease states, like maternal epilepsy and depression 
during gestation itself, contribute to abnormal development. Further, this dilemma is 
augmented by the use of medications during pregnancy. The antiepileptic (AEDs) 
and antidepressant drugs (ADPs) with a history of producing malformed neonates 
are mostly classified as moderate teratogens. This study was designed to evaluate 
teratogenic potential at the cellular and molecular levels of AEDs and ADPs on 
cardiomyocytes at different stages of development and the neural stem cell derived 
neurons using in vitro systems.  
In the micromass system (MM), five day old embryonic chick cardiomyocytes were 
cultured to form beating foci, while embryonic stem cell were differentiated into 
contracting cardiomyocytes (ESDC) using the hanging drop method. In a third in 
vitro system early chick Neural Stem Cells (NSC) were diverted to a neuronal 
lineage. Drug toxic effects were estimated on cultured cell viability and protein 
content. The effects on gap junctions (Cx43) in cardiomyocytes and neurofilament 
(NF) in NSC were also evaluated because of their important role in cell differentiation 
and regulation. Oxidative stress, being the potential source of xenobiotic toxicity 
induction, was also analysed and toxic effects were counteracted using antioxidants 
and other molecules. 
In AEDs, valproic acid (VPA) mainly targeted the cardiomyocyte differentiation and 
contractile activity with reduced Cx43 turnover. In NSC the VPA effects were 
different and it did not inhibit the neuronal differentiation. With carbamazepine 
(CBZ) the low doses showed no effect on NSC compared to high doses. In ESDC, the 
contractile activity stops at a 200µM dose with reduced cell viability and 
proliferation. Cx43 phosphorylation was reduced after CBZ treatment which might 
have affected the contractile activity. An increase ROS production with CBZ 
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treatment was recorded, which was protected either by the addition of Ascorbic acid 
(AA) or superoxide dismutase (SOD). The other AEDs, Phenytoin (PHT) and 
Primidone (PRM), mainly affected the cardiomyocyte contractile activity with some 
chronic exposure effects. In ADP, bupropion (BPN) severely affects cell proliferation 
in all systems. The NF-L was not statistically reduced in neurons but Cx43 expression 
in cardiomyocytes declined which might result in reduced contraction. The other 
ADP, lithium carbonate showed developmental stage dependent effect on 
cardiogenesis, where contractile activity ceased completely at higher dose in the 
ESDC with increased cell proliferation. Lithium mimics the :QWǃ-catenin pathway 
and also inhibits the PI cycle, effects which were reversed by the addition of myo-
inositol in the ESDC system. In NSC the lithium showed no significant inhibitory 
effects on neural differentiation at and above drug serum therapeutic concentrations. 
7KHDFWLYHFRQVWLWXHQWVRIWKHKHUEDODQWLGHSUHVVDQWGUXJ6W-RKQ¶VZRUWK\SHULFLQ
and hyperforin, showed synergistic inhibition of contractile activity with reduced 
proliferation at higher doses in the MM system.  
Drug interference at the molecular level during development may induce 
modification at the gene and protein levels with altered signalling. The tissue specific 
effects depend on the drug mechanism, while increased oxidative stress in part has a 
contribution in initiating the embryopathies. By identifying the exact mechanism of 
toxicity induction, the molecular mechanism can be protected against and thus 
abnormal development be avoided. 
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1.1 Chemical testing (Chemical regulation) 
With advancements in research and technology, the production and use of chemicals 
has been dramatically increased and their related toxicological hazard led to the 
establishment of various chemical regulation policies. In the white papers entitled 
³Strategy for the future chemical policy´ WKH (XURSHDQ FRPPLVVLRQ SURSRVHG
comprehensive chemical regulation policies REACH (Registration, Evaluation, 
Authorization and Restriction of Chemicals) (Scialli, 2008). These policies aim to 
generate relevant risk assessment and management knowledge for the classification 
and precautions for chemicals (Rudén & Hansson, 2008). REACH aims to harmonise 
testing requirements for chemicals already in use with those already in place for new 
chemical substances. Hence all chemicals should have the same portfolio of hazard 
data, i.e. have completed testing using the same single system that is now adopted 
for new chemicals since 1981 (Scialli, 2008). As a consequence, in February 2001 
the EU released a white paper stating approximately 30,000 chemicals already in use 
would require some additional hazard toxicity testing assessment by 2012. The EU 
regulations, apart from other requirements, demanded further information about the 
chemicals in terms of reproductive and developmental toxicology. Furthermore, the 
EU has plans for a future chemical policy with regulation of new and existing 
chemicals. Registration of chemical substances which are already on the EINECS 
(European Inventory of Existing Chemical Substances) will undergo phased hazard 
toxicity assessment between 2010 and 2018, depending upon the substance volume 
and whether it is being manufactured in or imported into the EU (Lilienblum et al., 
2008). The major issue raised within this policy was the chemical testing method for 
completing the potential risk portfolio. The traditional methods using in vivo animal 
testing are not practically feasible in the time frame and require a very large number 
of animals. This also totally contradicts EU and national government aims to reduce 
the number of animals used in research, thus alternative 
embryotoxicity/teratogenicity assays were in strong demand at least for the initial 
evaluation phase (Lilienblum et al., 2008). This thesis evaluates and examines the 
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teratogenic effects of selected drugs on the developing heart and the molecular 
mechanisms of related toxic effects using in vitro systems. 
1.1.1 Chemical testing in animals 
Chemical testing on humans solely for hazard identification is not permissible (Höfer 
et al., 2004), but the ultimate proof of a human teratogen can only come from 
human exposure (Brown & Fabro, 1983). Extrapolation of animal data for chemical 
and drug safety evaluation is the initial basis prior to human exposure (Schardein et 
al., 1985). Animals are considered as an alternative to humans for chemical testing - 
virtually all the chemicals which induce toxic effects in humans are expected to 
produce toxic effects in animals (Brown & Fabro, 1983). Animal use in chemical 
screening prior to marketing provides basic information regarding drug induced 
effects and has certainly improved our knowledge and understanding of diseases, 
diagnosis and treatment (Carere et al., 2002; Piersma, 2004). Development toxicity 
testing in animals involves chemical exposure followed by assessment of toxic effects 
in dams and fetuses (Piersma, 2004). Animal use in teratogenicity testing for already 
identified teratogens and for drug screening before marketing has also improved our 
understanding of drug related effects, especially at the molecular level, including the 
role and importance of micronutrients and disease states during development. Some 
disadvantages of interspecies difference, difference to humans and high dose 
exposure compared to humans may affect the outcome (Brown & Fabro, 1983). The 
European commission animal welfare guideline 1986 required any person planning to 
undertake animal testing to consider alternatives prior to beginning their research 
(Lilienblum et al., 2008). Teratogenicity testing in animals requires large number of 
embryos with the mother also sacrificed in most in vivo systems (Piersma, 2004). 
Home Office licences and project reviews have certainly reduced experimental 
animal usage (Balls & Fentem, 1999; Fuscoe, 2007; Walmond et al., 2002). 
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1.1.2 Reduction, RefinemeQWDQG5HSODFHPHQW7KH7KUHH5¶V 
:LOOLDP 5XVVHOO DQG 5H[ %XUFK LQ WKHLU ERRN ³KXPDQH H[SHULPHQWDO WHFKQLTXHV´
(1959) described the three alternative principles to minimize the number of animals 
use in research (Lilienblum et al., 2008)7KH5¶VVWDQGVIRUUHGXFWLRQUHILQHPHQW
and replacement; it encourages the reduction in number of animals used in general 
by improved experimental design and minimizing the volume of testing (Fuscoe, 
2007; Lilienblum et al., 2008), the use of available alternative methods and where 
possible development of early biomarkers to make results more reliable and quick 
thereby replacing the use of animals (Fuscoe, 2007; Lilienblum et al., 2008), and 
refinement to minimise animal suffering and distress during experimental procedures 
(Fuscoe, 2007). The ECVAM (European Centre for the Validation of Alternative 
Methods) and NICEATM-ICCVAM (National Toxicology Programme Interagency 
Centre for the Evaluation of Alternative Toxicological Methods (NICEATM) and the 
Interagency Coordinating Committee on the Validation of Alternative Methods 
(ICCVAM)) organisations were initiated in Europe and the USA for this purpose and 
they support the development of alternative methods to animal use, their evaluation, 
validation and regulatory acceptance for new chemicals (Scialli, 2008; Walmod et 
al., 2004). Also the UK based FRAME (Fund for the Replacement of Animals in 
0HGLFDO([SHULPHQWVSULQFLSDOO\IRFXVHVRQWKHSULQFLSOHVRI5¶VEHFDXVHRIWKHKLJK
requirement for funding and animals (Scialli, 2008). The 3R principles include 
alternative methods for example using in vitro cell lines, lower organism embryos, ex 
vivo or in vivo with reduced and refined methods. With the advancement of 
technology non-testing methods are applicable using computer systems or referring 
to the effects of structurally related compounds (Lilienblum et al., 2008; Scialli, 
2008). Early biomarkers using trans proteomics, proteomics and metabolic studies 
may provide more insight into drug related effects on development (Fuscoe, 2007). 
1.2 Teratology and teratogens 
7KHZRUG WHUDWRORJ\KDV*UHHN URRWV ³7HUDV´PHDQLQJPRQVWURVLW\RUSURGLJ\DQG
was originally referred as the study of monsters (Kalter, 2002). Simply teratology is 
the study of abnormal prenatal physiological and anatomical development, which 
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results in congenital defects. These malformations can be induced by exogenous 
chemicals or by physicals agents (Bailey et al., 2005; Chung, 2004).  
Teratogens have been defined as agents or factors that produce physical defects in 
the developing embryo/fetus. In a broader sense it not only includes physical defects 
with in utero exposure but deficits in organ function; hormonal, behavioural or 
immunological changes or growth deficiencies (Brown & Fabro, 1983), although only 
some 10% of all congenital defects have known pathogenesis. These malformations 
affect the quality of life and are associated with enormous emotional and fiscal costs 
(Bailey et al., 2005; Brent, 1995).  
1.2.1 Congenital malformations 
7KHZRUG FRQJHQLWDO LVGHULYHG IURP µ/ FRQJHQLWXV¶PHDQLQJ ³born with´ (Moore & 
Persaud, 1998). A congenital malformation is an anatomical or physiological anomaly 
present at the time of birth that may be caused by genetic or environmental factors 
or a combination of both during prenatal development (Chung, 2004; De Santis et 
al., 2001). Congenital malformations affect 5% of all births (De Santis et al., 2001) 
and account for approximately 20% of deaths in the perinatal period. An average of 
3% of new-born infants has major malformations and another 3% malformations are 
detected later in life (Chung, 2004). The cause is only detected in 10% of the new 
born while the remaining 90% remain unknown; among this known group, 1% or 
less are due to known drugs and medications (De Santis et al., 2001). These 
malformations are the leading cause of infant mortality. The majority of congenital 
malformation affected infants die during the first year of their life. An estimated of 
495,000 deaths are recorded worldwide every year (Rosano et al., 2000). Prenatal 
malformation diagnosis followed by prenatal surgeries, pregnancy termination or 
susceptible factors consideration in highly pre-disposed patients may provide the 
solution to these problems (Rosano et al., 2000). 
1.2.2 Background, history and principles 
Teratology is the science of abnormal development induced by exogenous agents 
(Bailey et al., 2005). Through artistic interpretations and written scriptures abnormal 
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development has been recorded over centuries in legend (Warkany, 1977). An 
earlier explanation of abnormal development was that it was solely the result of 
genetic defects (Warkany, 1977) but maternal nutrition, life style, disease states and 
exposure to toxic chemicals refuted the earlier ideas and broadened the term 
teratogen (Keen et al., 2003). The science of teratology was born between 1920s 
and 1930s when Hale confirmed malformed piglets were born to a mother with 
retinol deficiency during pregnancy (Bailey et al., 2005; Kalter, 2003). Subsequent 
evidence after a decade came to light in 1941 with the identification of congenital 
cataract in children born to mothers who had suffered from rubella virus infection, 
and mercury poisoning effects in 1956 (Igata, 1993; Kalter, 2003). These were 
followed by many other studies which confirm many chemicals and physical agents 
like nitrogen mustard, hormones, antimetabolites, alkylating agents have a role in 
producing anomalies in mammalian species (Warkany, 1965). The Dutch wartime 
famine (Hunger winter) during the Second World War further highlighted the 
importance of micronutrients during pregnancy (Smith, 1947). 
However, the thalidomide catastrophe brought immediate attention to modern 
studies on developmental toxicology. Thalidomide was developed as mild sedative in 
1950s. It was used to prevent nausea during pregnancy. The drug produces children 
with deformed limbs including phocomelia and approximately 8000 neonates 
worldwide were affected with thalidomide before its identification as teratogen. 
Thalidomide was not tested comprehensively for its teratogenic effects before 
marketing. After the catastrophe it was shown to induce similar pattern of 
malformation in the rabbit and non-human primates. However in rodents no 
malformation was seen. This highlighted the complexity and requirements of 
teratogenicity testing (Bailey et al., 2005; Jergil, 2009). It was following the 
thalidomide epidemic that studies and research on teratogens were given importance 
and new guidelines were set regarding introduction and safe exposure of 
pharmaceuticals and chemicals. This resulted in identification of many teratogens 
including infectious diseases, drugs, radiations and maternal factors by various 
studies (Moore & Persaud, 1998). 
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In 1959 Wilson, based on a firm groundwork of surveys and experimental work, laid 
the formulation of principles to underlie teratological susceptibility to environmental 
agents (Kalter, 2003). 
1. The susceptibility to teratogenesis depends on the fetus genotype and the manner 
in which it interacts genetically with adverse factors. 
2. The susceptibility to teratogenesis depends on adverse influence at the particular 
stage of development. 
3. Teratogens act via specific toxic mechanism on developing cells and tissue to 
initiate abnormal development. 
4. The extent of teratogenesis depends on teratogens nature of influence on 
developing tissue. 
5. The manifestation of adverse effects results in death, malformation, growth 
retardation and functional deficit. 
7KHPDQLIHVWDWLRQRIWHUDWRJHQHVLVGHSHQGVRQDGYHUVHDJHQWV¶GRVHDQGGXUDWLRQ
of exposure. 
1.3 Teratogenicity testing and developmental biology 
Teratogens are agents that increase the incidence of congenital malformations 
(Chung, 2004). The mechanism of induction of teratogenesis involves either 
alteration of the genotype or the adverse effect of an environmental agent or factor 
during gestation (Beckman & Brent, 1984). In developmental toxicology the effects 
are observed from the zygote stage through organogenesis and the fetal period to 
the term of pregnancy (Jergil, 2009). Gestation in the human involves three major 
development stages: pre-organogenesis, active organogenesis and the fetal period. 
The pre-organogenesis period is generally not as susceptible to teratogens as the 
active organogenesis period, due to the formation of the organs, but some organs 
like teeth, external genitalia and the brain continue to develop even after this period. 
That is why teratogens like antiepileptic drugs (AEDs) continue to affect the brain 
beyond the first trimester of pregnancy (Ornoy, 2009). At the earlier stages 
totipotent stem cells have a great capacity to grow and repair. Teratogenic insult at 
this stage either results in embryo lethality or the alteration is repaired. The adverse 
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effect during the time of organogenesis results in congenital malformation (Beckman 
& Brent, 1984). The exposure at late stages results in cell depletion and growth 
retardation (Beckman & Brent, 1984). $SDUW IURPGHYHORSPHQWDO VWDJH WKHGUXJV¶
dose and the exposure time critically interferes with normal development (Beckman 
& Brent, 1984). The knowledge of the teratogenic potential of substances would 
minimize the hazards (Bailey et al., 2005). Identification of teratogenic potential of 
chemicals that come into contact with pregnant women every day is crucial (Brent, 
1995). Cohort studies and surveys in humans may provide the basic preliminary 
information, but it is necessary to screen and prepare comprehensive teratogenic 
profiles of agents before being marketed. A number of in vivo and in vitro testing 
procedures in animals are currently in regulation for teratogenicity testing. Beside 
this, the US food and drug administration agency (FDA) has categorized the 
chemicals according to their teratogenic potentials. 
Pregnancy 
Category 
Description 
A Adequate and well controlled studies have failed to                   
demonstrate risk to the fetus. 
B Animal studies have failed to demonstrate a risk to fetus and there are 
no adequate and control studies in humans. 
C Animal studies have shown adverse effects on fetus and there are no 
adequate and well controlled studies in humans. 
 
D 
There is positive evidence of human fetal risk based on adverse 
reaction data from investigational or marketing experience or studies in 
humans, but potential benefits may warrant use of the drug in 
pregnant women despite potential risks. 
 
X 
Studies in animals or humans have demonstrated fetal abnormalities 
and/or there is positive evidence of human fetal risk based on adverse 
reaction data from investigational or marketing experience, and the 
risks involved in use of the drug in pregnant women clearly outweigh 
potential benefits.  
Table 1.1 FDA pregnancy category of chemicals (De Santis et al., 2001). 
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1.3.1 In vivo teratogenicity testing 
The preliminary teratogenic profile of a drug or chemical is usually obtained by in 
vivo teratogenicity testing (Pratt et al., 1982), including the type of developmental 
defects and the basic information about site of toxic action, time of administration 
during development and organs affected. In humans the basis for this information is 
mostly reported cases. In vivo teratogenicity testing in humans is unethical, because 
of the mother and fetus involvement and the risk to their life (Steele & Copping, 
1993). Normally mothers are asked to complete a survey during pregnancy for the 
analysis of drug and disease related effects (Brown & Fabro, 1983; Hanson et al., 
1978). The data obtained is statistically analysed to reach some conclusion. Normally 
these types of studies involved various factors along with particular medicine like 
combination therapy, depression, disease states, smoking, genetic carriers, 
socioeconomic conditions, the number of patients and the extent of their information 
sharing and cooperation (Grisso et al., 1984; Hanson et al., 1978). Alternatively 
rodents like rat, mice and rabbit or some higher animals are most frequently used 
for in vivo teratogenicity testing, none of these animals, even their strains, possess 
the same metabolic system or the same placental transport as the human (Pratt et 
al., 1982). The standard requirement for an in vivo testing system is at least 20 
pregnant animals per dose ranging from low to highly toxic (Pratt et al., 1982). This 
UHTXLUHVDODUJHQXPEHURIDQLPDOVIRUHDFKVWXG\ZKLFKLVWRWDOO\DJDLQVWWKH5¶V
principles (Fuscoe, 2007; Lilienblum et al., 2008). In in vivo studies the biggest 
advantage is the use of natural process for estimating the toxic effects. Most of the 
drugs act through their toxic metabolic products (van Gelder et al., 2010), which in 
the case of in vitro testing is difficult to produce even after administration of liver S9 
fractions, the effects observed are indistinguishable between drugs or metabolites. 
Some in vitro teratogenicity testing methods have been developed and validated to 
overcome the shortcomings of in vivo procedures and to study the mechanisms at 
the molecular level (Schwetz et al., 1991). 
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1.3.2 In vitro teratogenicity testing   
In vitro teratogenicity testing provides an alternative to in vivo animal testing. The  
in vitro methods overcome the intrinsic problems and differences in in vivo animal 
teratogenicity testing (Brown et al., 1995) and provide quick, cheap and 
reproducible chemical teratogenicity screening. The biggest advantage of in vitro 
tests is the requirement for a lower number of animals compared to its in vivo 
counterpart (Bournias-Vardiabasis & Teplitz, 1982; Walmod et al., 2004). Due to the 
increased demand of research in drug discovery and treatment; hundreds of drugs 
are marketed every year and are exposed during pregnancy. In vivo methods for 
teratogenicity testing requires a lot of animals for each drug screening before 
marketing. The use of in vitro methods is less time and animal consuming and the 
results are often comparable to in vivo testing (Bournias-Vardiabasis & Teplitz, 
1982).  In vitro methods indicate potential teratogenic hazards at an early stage of 
screening. These methods primarily focus on specific mechanisms such as cell 
adhesion and proliferation (Bacon et al., 1990), but by adding different end points 
and molecular markers to the in vitro system, reliability and efficiency can be 
improved (Seiler et al., 2004). Three in vitro teratogenicity tests have been validated 
by ECVAM these include the embryonic stem cell test, limb bud micromass and 
whole embryo culture. Beside these a number of other tests have also been 
developed which are in the process of refinement or validation (Scialli, 2008). These 
tests depend upon organ, tissue or embryo exposure to drugs. Embryonic tissue 
micromass has been adopted for teratogenicity testing decades ago. In limb bud 
micromass, rat gestation day 14 limb bud cells are isolated and cultured; the limb 
bud mesenchymal cells differentiate into chondrocytes, the extent of which is 
estimated using Alcian blue staining (Scialli, 2008). Flint using the same culturing 
method exposed embryonic brain cells to chemicals (Invittox Protocol no 112). 
Beside these, micromass of heart tissue has also been developed for teratogenicity 
testing (L'Huillier et al., 2002), which is discussed in detail in section 1.3.2.1. Whole 
embryo culture (WEC) was the first validated procedure to undergo industrial 
application (Schmid et al., 1993). The WEC relies on rat embryo culture at an early 
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somite 1-5 stage. Embryos are exposed to chemicals with growth medium for 48h 
and substantial differentiation examined (Scialli, 2008). The third ECVAM validated 
method is the embryonic stem cell test (EST). The EST uses in vitro D3 mouse 
embryonic cell line differentiation into cardiomyocytes, along with the 3T3 adult 
fibroblast cell line for comparison. The test chemical effects on cardiomyocyte 
differentiation and cell viability is estimated and toxicity is predicted (see section 
1.3.2.2) (Scholz et al., 1999). Using lower organisms such as Hydra, Johnson and 
colleagues proposed a teratogenic substance detection assay (Johnson & Gabel, 
1983). The Hydra is a fresh or salt water lower animal with radial symmetry. Hydra 
reproduces asexually by producing buds, which simply break away when they are 
mature. Using their regeneration ability the teratogenicity of water soluble 
compounds can be detected. But this assay is not reliable due to its single end point 
(Wilby & Tesh, 1990). The fruit fly drosophila has also been utilized in teratogenicity 
testing. The adult flies are anesthetized and exposed in vials to distilled water 
containing instant drosophila medium with test chemicals. The flies are allowed to 
mate and lay eggs. The eggs are exposed to test chemicals and take 9-10 days for 
hatching. The adult flies are morphologically examined and scored (Bournais-
Vardiabasis, 1994; Bournias-Vardiabasis & Teplitz, 1982; Bournias-Vardiabasis et al., 
1983 ). The South African clawed frog (Xenopus laevis) embryo is another source of 
detecting teratogenicity testing. ECVAM has approved The Frog Embryo 
Teratogenesis Assay (FETAX) as a non-mammalian assay because of its resemblance 
to early major human development. The endpoints of embryo mortality, 
malformation and growth inhibition are used in FETAX (Douglas et al., 1989).  
In this study two in vitro systems for teratogenicity testing were utilized - the chick 
cardiomyocyte micromass system and the embryonic stem cell test with some 
modification.  
1.3.2.1 The micromass system 
Umansky in 1966 devised a method to study the development and differentiation 
processes of chick mesenchyme limb bud cells into chondrocytes, which became the 
basis of the micromass test. Later on in 1983 Flint, using rat embryo midbrain, 
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detected the effects of teratogenic agents on differentiating neurons (Invittox 
Protocol no 112). The micromass system involves the primary cell culture of different 
organs (Spielmann et al., 2001 )7KHEDVLVRIWKLVWHVWLVWKHFKHPLFDO¶VGLVUXSWLRQ
of embryonic cell differentiation and re-establishment of the system (Flint & Orton, 
1984). The micromass culture system detects chemical interference in the normal 
process of cell differentiation, development, cell proliferation, cell-cell 
communication and cell matrix interactions (L'Huillier et al., 2002). Using the chick 
micromass system has advantages over that of rats and mice. Firstly, because it 
obviates the step of sacrifice of the mother in order to culture the embryo. There is 
rapid development of the embryo on the fifth day of incubation and heart, brain and 
cartilages are developed to considerable size. It is easy to handle, with no need for 
animal house or mating procedures, and easy to predict the exact development 
stage. Up to day 9 the embryo can be used without a Home Office license (L'Huillier 
et al., 2002) and chick limb bud micromass shows similar responses to chemicals as 
rat micromass (Brown & Wiger, 1992 ). In chick embryonic cardiomyocyte 
micromass culture, 5 day old cardiomyocytes are cultured at a very high cell 
density, so they proliferate and differentiate to form foci and in the case of 
cardiomyocytes these foci shows phases of contraction and relaxation (Hurst et al., 
2009). The test chemicals were exposed and cytotoxicity is observed using relevant 
endpoints (Atterwill et al., 1992 ). 
1.3.2.2 Embryonic stem cell test (EST) 
The blastocyst derived pluripotent mouse embryonic stem cells (Murabe et al., 
2007a) have the ability to differentiate into all three germ layers, including 
spontaneous differentiation into contracting cardiomyocytes. These cardiomyocytes 
exhibit the appropriate proteins, receptors and ion channels that closely resemble  
in vivo cardiogenesis (Wei et al., 2005). Therefore ES cells are used as a tool to 
predict tissue specific mutagenic, cytotoxic and embryotoxic effects of chemicals 
using in vitro systems (Kusakawa et al., 2008; Murabe et al., 2007a). The D3 
embryonic stem cells can be grown in an undifferentiated state in the presence of 
Leukemia inhibitory factor (LIF), which controls STAT signalling via the membrane 
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bound gp130 signalling complex (Wei et al., 2005; Yamanaka et al., 2008). When 
the cells are allowed to differentiate in hanging drops (without LIF), which provides 
an excellent three dimensional environment for development (Banerjee & Bhonde, 
2006), they form embryoid bodies which resemble the blastocyst exhibiting all three 
germ layers (Koike et al., 2007; Murabe et al., 2007b). EBs are formed in hanging 
drops as a result of the highly expressed Ca2+ dependent adhesion molecule E-
cadherin homophilic binding in the ES cells (Kurosawa, 2007; Larue et al., 1996; 
Yoon et al., 2006). Upon plating of these embryoid bodies, the cardiomyocyte 
lineage becomes predominant and spontaneously differentiates into contractile areas 
(Anneelieke et al., 2007; Wei et al., 2005). This differentiation represents three 
stages; the pace maker like cells, the intermediate and terminal like atrial, sinus 
nodal, ventricular and Purkinje-fibres (Boheler et al., 2002). A number of 
improvisations have been made in the embryonic stem cell test (EST) using different 
molecular markers and end points. The fibroblast cell line is used to mimic maternal 
toxicity, but inhibition of fibroblast proliferation does not represent the in vivo 
situation and is omitted in number of studies (Anneelieke et al., 2007; Marx-
Stoelting et al., 2009). 
The EST was designed to test drug and chemical embryotoxicity. The previously 
validated in vitro teratogenicity testing assays required the use of embryos or their 
tissues while in EST immortal D3 ES cells eliminate this factor and reduce time, cost 
and animals (Anneelieke et al., 2007; Scholz et al., 1999). The European Centre for 
the Validation of Alternative Methods (ECVAM) has approved the EST as a valuable 
tool to investigate the embryotoxic potential of chemicals on the differentiation 
process as an alternate to animal use (Rohwedel et al., 2001). According to the 
ECVAM validation study the accuracy of EST is 78% for all experiments, and 100% 
for strongly embryotoxic chemicals. It can easily differentiate between strong, weak 
and non-teratogen chemicals (Buesen et al., 2009; Scholz et al., 1999) and provides 
an opportunity to study the cellular and molecular mechanism of early development 
and the effects of teratogens (Kitazawa et al., 2005; Takahashi et al., 2003).  
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1.4 Stem cells  
Functionally stem cells are defined by their ability to produce identical daughter cells 
(self-renew) and to generate progeny with new morphological and functional 
characteristics (differentiation) (Davila et al., 2004). Stem cells are undifferentiated 
or unspecialized cells with unlimited selfrenewal capacity without undergoing 
senescence, which is clearly distinct from progenitors and precursor cells (Lanza, 
2006). These characteristics are critically involved in development and tissue 
regeneration (Li & Xie, 2005). 
1.4.1 Stem cell classification 
Stem cells are primitive cells present in all organisms, generally classified into 
embryonic and adult types according to their origin (Davila et al., 2004). The morula 
stage derived embryonic stem (ES) cells are totipotent (differentiate into all 
embryonic and extra embryonic tissues), as development proceeds the ES cells at 
blastula stage are restricted to pluripotent potentials (differentiate into all embryonic 
tissues only) (Davila et al., 2004; Friel et al., 2005). The adult stem cells 
differentiate into different cell types (multipotent) and have limited selfrenewal 
abilities or become further lineage committed with unipotent differentiation 
potentials (Friel et al., 2005). The adult stem cells and progenitors are essential 
component of cell homeostasis and repair (Davila et al., 2004; Filipczyk et al., 
2007).  
1.4.2 Stem cells research-Potential benefits and drawbacks 
Embryonic stem cells isolated from blastocysts can be expanded immortally without 
losing their pluripotency and can be differentiated into several tissue types. This 
provides their biggest advantages over primary cell cultures which have limited 
proliferation capacity. The differentiation process in many respects resembles normal 
in vivo development which provides an easy tool to investigate the basic processes 
that are difficult to explore in vivo (Lanza, 2006; Lanza, 2004). Pluripotent stem 
cells are difficult to differentiate into a uniform cell type and mostly they represent a 
heterogeneous population of cells. In the case of ES cell derived cardiomyocyte the 
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atrial, ventricular and SA node cell types were observed, alongside endodermal and 
ectodermal markers positive staining (Boheler et al., 2002). Due to their pluripotent 
potentials when the undifferentiated stem cells are transplanted into tissue they may 
form teratomas (Lanza, 2006; Lanza, 2004). Apart from forming teratomas they 
may cause immune reactions in the recipient. For the isolation of human stem cells 
the human embryo at a very early stage is used which poses some ethical problems. 
The derivation of stem cells from adult tissue is another option but these cells are 
mostly lineage committed and exhibit low differentiation capacities (Lanza, 2006; 
Lanza, 2004). Induced pluripotent stem cells may provide the solution in which stem 
cells are produced using fibroblast cells which are then differentiated into 
cardiomyocytes (Zwi et al., 2009).   
1.4.3 Embryonic stem cells isolation and characterization 
Mouse ES (mES) cells are the in vitro counterparts of in vivo epiblast cells (Burdon et 
al., 2002). The pluripotent embryonic stem cells are derived from the blastocyst 
inner cell mass of the pre-implantation embryo. The blastocyst is a ball shape 
structure (fig 1.1) with an outer covering trophoblast layer, the hollow space 
blastocoel and inner cell mass (the group of cells) (Friel et al., 2005; Li & Xie, 2005). 
Embryonic stem cells were first isolated from mouse by Evan and Kaufman and 
independently by Martin in 1981, while in 1998 from humans. In vitro the ES cells 
are maintained in an undifferentiated state by growing on mitotically inactivated 
mouse embryonic fibroblasts (feeder layers) or by addition of a differentiation 
inhibition factor (Doetschman et al., 1985; Filipczyk et al., 2007). The cells under 
these conditions are believed to maintain the normal karyotype and unlimited self-
renewal (Boheler et al., 2002). Upon differentiation inhibitor removal ES cells form 
cystic embryoid bodies, and that is believed to initiate signalling and spontaneous 
differentiation into germ layers (Doetschman et al., 1985; Sachinidis et al., 2002), 
which resembles the blastocyst stage. Their developmental characteristics were 
confirmed: when ES cells were implanted into blastocysts, they develop into a 
complete embryo (Gajovic & Gruss, 1998). Various transcription factors and proteins 
LQ (6 FHOOV FRQWULEXWH WRZDUG µVWHPQHVV¶ VXFK DV 67$7 2&7 62; 1DQRQJ
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(Yamanaka et al., 2008), SSEA1 and alkaline phosphatase activity (Zandstra et al., 
2000), and these are used to characterize the stem cells presence. 
 
 
Fig 1.1 Stem cells hierarchy. Zygote and early stage development of stem cells to 
the generation of complex organism (Wobus & Boheler, 2005). 
1.4.4 Molecular facets of self-renewal and pluripotency (stemness) 
The stem cell microenvironment (niche) is thought to play the major role in the self-
renewal or differentiation decision making (Lanza, 2006). In vitro mES cells are 
maintained in undifferentiated state by the addition of cytokines from the interleukin 
(IL)-6 families (Zandstra et al., 2000). Leukemia inhibitory factor (LIF), an IL-6 
family cytokine (Bader et al., 2000), is either provided by feeder layers or as the 
recombinant protein (Burdon et al., 2002). Upon inhibitor withdrawal the mES cells 
spontaneously differentiate into all three germ layers (Pandur, 2005). In human ES 
cells the cytokine LIF is not sufficient to retain pluripotency, mainly due to the 
decreased number of LIF receptors (Aghajanova et al., 2006). Fibroblast growth 
factor is used as alternative in human ES cells to maintain pluripotency (Vallier et 
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al., 2005). LIF acts via a LIF-specific receptor and signal transducer gp130 complex 
(Bader et al., 2000; Zandstra et al., 2000). This complex signals activates JAK/STAT 
and MAPK pathways (Bader et al., 2000). This finally stimulates STAT3 which is 
necessary to maintain the ES self-renewal, while MAPK has a role in cell proliferation 
and differentiation (fig 1.2) (Burdon et al., 2002). The balance between JAK/STAT 
cascade and MAPK cascade is crucial for determining cell fate. LIF signalling is poorly 
understood post STAT3 activation. LIF is considered an important supplement in the 
medium to support cell establishment and self-renewal (Lee et al., 2009). LIF over 
expression in mice during gastrulation inhibits mesodermal differentiation (Bader et 
al., 2000). The OCT4, SOX2 and Nanong transcription factors control pluripotency, 
self-renewal and cell fate determination pathways (fig 1.2). In the absence of serum, 
LIF is insufficient to maintain pluripotency or block neuronal differentiation 
(Yamanaka et al., 2008). 
 
Fig 1.2 The regulation of stem cell pluripotency (Shenghui et al., 2009). 
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1.4.5 Embryonic stem cell differentiation into cardiac lineage 
The role of signalling molecules and transcription factors in cardiogenesis has 
already been identified (Sachinidis et al., 2003), but still the molecular mechanism 
that drives stem cells toward the cardiac lineage is nebulous (Pandur, 2005). Cardiac 
transcription factors control the expression of various genes that regulate cardiac-
specific differentiation (Akazawa & Komuro, 2003). These includes the GATA family 
transcription factors, cardiac specific homeobox transcription factor (Csx/Nkx2.5), 
MEF2 and T-box transcription factor (Akazawa & Komuro, 2003). GATA transcription 
factors are the key regulator molecules in development. GATA-4, 5 and 6 is detected 
and persists later in the developing heart. GATA promotes various cardiac specific 
JHQHV $1) %1) F7QO Į-MHC, MLC (Akazawa & Komuro, 2003; Sachinidis et al., 
2003). GATA null embryos showed various cardiac developmental defects. The 
transcription factors like Nkx2.5 and GATA clearly have a role in cardiogenesis but 
the exact mechanism is not fully understood (Akazawa & Komuro, 2003; Sachinidis 
et al., 2003). Nkx2.5 is one of the earliest markers of the heart field mesoderm in 
vertebrates. Loss of function of Nkx2.5 is associated with congenital heart defects 
(Sachinidis et al., 2002). Over expression of Nkx2.5 causes myocardium hyperplasia 
(Cleaver et al., 1996). On the other hand inhibition of Nkx2.5 resulted in complete 
absence of heart formation (Fu et al., 1998; Grow & Krieg, 1998). Nkx2.5 interacts 
with other transcription factors including GATA transcription factor, T-box factors and 
serum response factor. Nkx2.5 is also involved in the roles of cardiogenic 
extracellular signalling proteins including BMPs and Wnts (Akazawa & Komuro, 
2003). The T-box proteins belong to a family of transcription factors that are 
essential for early cardiac lineage determination, chamber specification and 
valvuloseptal development (Naiche et al., 2005). At the receptor level many 
molecules like Wnt, BMP have been shown to play important role in stem cells and 
stem cell differentiation (Filipczyk et al., 2007). Signalling downstream of various 
classical signalling pathways including PI3K, PKC, MAPK and others have been 
implicated to have roles to play in stem cell differentiation into cardiomyocytes, but 
the exact molecular mechanism by which these may mediate the stem cell 
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cardiomyocyte lineage commitment and differentiation is not fully understood 
(Brand, 2003; Sachinidis et al., 2003; Sachinidis et al., 2002; Sauer et al., 2000). 
Extracellular signalling factors are central for stem cells differentiation or for 
remaining in the undifferentiated state. Stem cell lineage commitment involves 
complex networks of extracellular signalling molecules that activate various 
signalling pathways. These activated signal transduction pathways in turn exert 
complex positive or negative controls on this process. A number of growth factors or 
extracellular signalling molecules have been identified that are involved in stem cell 
differentiation into cardiomyocytes including bone morphogenetic proteins (BMP), 
sonic hedgehog (SHH), fibroblast growth factors (FGF), Wnt and Notch proteins 
(Filipczyk et al., 2007). BMP and its family members play crucial role during 
embryonic development, cell division or proliferation, differentiation, organisation, 
migration, adhesion, extracellular matrix production and apoptosis (Pardali & Dijke, 
2012). BMP signalling occurs via two pathways MAPK and Smad (Monzen et al., 
1999; Zaffran & Frasch, 2002). BMP has an important role in in vivo cardiogenesis 
and the differentiation of stem cells into cardiomyocytes (Zaffran & Frasch, 2002). 
BMP are expressed very early in the endoderm and ectoderm and play critical roles 
in the induction of heart formation in the vertebrate embryo (Andrée et al., 1998; 
Schlange et al., 2000; Schultheiss et al., 1997; Tzahor & Lassar, 2001). In addition 
to Smad pathways BMP signalling also occurs via MAPK signalling pathways. This is 
very important since phosphorylation is a key post-transcription mode of gene 
control. The MAPK signalling when activated could control many other targets 
including transcription factors and other kinases (Monzen et al., 1999). Application of 
BMP-2  in vivo elicited ectopic expression of the cardiac transcription factors Nkx2.5, 
transcription factors of the GATA family, and ventricular myosin heavy chain 
(Sachinidis et al., 2002). Insulin like growth factor and FGF are essential for the 
regulation of early cardiac development (Sachinidis et al., 2003). Mutation in FGF 
results in decrease expression of cardiac markers (Sachinidis et al., 2002):QWǃ-
catenin signalling negatively regulates cardiogenesis and the activation of pathways 
     
20 
 
WKDW LQKLELWV:QWǃ-catenin signalling is required for the induction of cardiogenesis 
(Sachinidis et al., 2003).  
In vitro ES differentiation into cardiomyocytes depends on number of factors like the 
number of cells forming EBs, serum, media, growth factors, time of EBs plating. The 
in vitro differentiated cells represent three stages - early (pacemaker like cells), 
intermediate and terminal (atrial, ventricular, nodal-His, and Purkinje like cells) 
(Boheler et al., 2002; Sachinidis et al., 2002). 
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1.5 Aims and objectives 
The aims and objectives of current study are  
¾ To utilize in vitro techniques for teratology screening of selected antiepileptic 
and antidepressant drugs. 
¾ To develop and evaluate the chick embryonic cardiomyocyte micromass 
system and ES cell differentiation into cardiomyocytes for teratogenicity 
testing. 
¾ To estimate and compare the teratogenic potential of antiepileptic and 
antidepressant drugs in micromass and ES derived cardiomyocytes using 
different end points. 
¾ To determine the potential teratogenic mechanism of drugs at the molecular 
level and to counteract any toxic effects using different molecules. 
¾ To determine the possible role of gap junction Connexin 43 in drug induced 
toxic effects. 
¾ To develop and utilize a chick neural stem cells system for the 
neurodevelopment teratogenicity testing.  
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Chapter 2 
Materials and Methods 
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2.1 Cells source 
2.1.1 Chick embryonic cardiomyocytes 
For the micromass culture system chick embryonic cardiomyocytes were obtained 
from five day old white fertile Leghorn chicken eggs (Henry Stewart & Co.UK). 
2.1.2 D3 mouse embryonic stem cell line 
The D3 mouse embryonic stem cells were obtained from the American Tissue Culture 
Collection (ATCC, Rockville, USA; cat no. CRL-1934). The ES D3 cell line is derived 
from day 3.5 old mouse blastocyst inner cell mass of strain 129S2/SvPas 
(Doetschman et al., 1985). 
2.2 Materials 
For the list of materials see appendix 1. 
2.3 Design of Experiment 
This study utilizes two in vitro systems, the chick micromass and D3 ES cell derived 
cardiomyocytes, for the evaluation of cardiotoxic effects of teratogens at the tissue 
specific and molecular levels. The study was primarily based on embryonic 
cardiomyocyte treatment with drugs both when the undifferentiated cells (stem 
cells) are not lineage (cardiac) committed and once they become cardiac lineage 
committed (micromass). For each drug dose at least three repeats were performed 
and analysed statistically. The drug doses used in both systems ranged from well 
below the blood serum therapeutic levels to higher levels as used in some other 
studies. In MM and D3 ESCs derived cardiomyocytes a well-known teratogen valproic 
acid (L'Huillier et al., 2002) was used as a reference drug because of its known 
effects in these systems. Beside that some drugs with known effects at particular 
doses were also tested to confirm system reliability. For the micromass system the 
day of heart explantation and cell seeding density were evaluated before starting the 
experiments with teratogens. For D3 ESCs derived cardiomyocytes no changes were 
made in the cell differentiation protocol, as it is already ECVAM validated (Buesen et 
al., 2009). The 24 well plates used in both systems were divided in columns of 
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blank, control and drug treated groups for easy comparison (fig 2.1) (Ahir & Pratten, 
2011). 
 
 
 
 
 
 
 
 
 
 B        C        D         D         D         D 
Fig 2.1 Schematic diagrams showing the cell culture lay out in 24 well plates. 
B=Blank, C=Control, D= Drug (arrow indicates increase in drug dose). 
The cardiomyocytes with drugs were first analysed for contractile activity then 
subjected to cell viability and total protein content endpoints for toxicity estimation 
in comparison to control. The drugs were also evaluated for the production of free 
radicals as a potential mechanism to produce toxicity. At the molecular level the 
effect on cell communication was targeted by estimating connexin43 gap junction 
proteins using western blots and immunohistochemistry for protein localization in the 
cells.       
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Fig 2.2 Schematic flow chart showing the design of the experiments for MM and 
ESDC systems. MM=micromass, WEC=whole embryo culture, ECVAM=European 
commission for the validation of alternative methods, FETAX=The Frog Embryo 
Teratogenesis Assay Xenopus, ES cells=embryonic stem cells, EST=embryonic stem 
cell test, IHC= Immunohistochemistry. 
Embryotoxicity Testing 
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2.4 Methods 
2.4.1 Micromass chick cardiomyocytes culture 
2.4.1.1 Eggs storage and incubation 
White fertile leghorn chicken eggs (labelled with the date of delivery) were stored in 
a cooled incubator at 12oC, during which embryonic development remains suspended 
(Slack, 2006). The eggs were used within two weeks of the day being laid. A 
minimum of 24 eggs were incubated by placing on automatic egg turner at 38oC, 
100% relative humidity for five days. The day eggs were incubated was marked as 
day zero. 
2.4.1.2 Cardiomyocytes isolation and culture 
On the fifth day of eggs incubation (Hamburger and Hamilton chick development 
stage 26) (Hamburger & Hamilton, 1992), the class I Laminar flow hood was 
prepared by swabbing first with TrigeneTM (Medichem international, UK), followed by 
sterilization with 70% ethanol. Curved and straight forceps were cleaned with 70% 
ethanol. Six eggs were removed at a time from the incubator, swabbed with 70% 
ethanol and transferred into the hood. Using the broader end of the curved forceps 
the egg shell (near the air sac region) was broken by gentle striking. The shell was 
peeled off and the vitelline membrane was gently removed to reveal the 
chorioallantoic membrane with blood vessels. The membrane was pierced; the 
HPEU\RZDVOLIWHGRXWDQGWUDQVIHUUHGWRDPP3HWULGLVKFRQWDLQLQJFROG+DQN¶V
Balanced Salt Solution (HBBS). The embryo was killed by decapitation under the 
dissecting microscope; the hearts were removed and placed in 50% v/v horse 
serum/HBSS. When all the eggs were transplanted, the hearts were washed twice 
with HBSS to remove serum. 2ml (for 24 hearts) of warm trypsin 0.05%/EDTA 
0.02% was added and incubated at 370C, 5% CO2 for 20 min, with frequent shaking 
(after every 5 min). Trypsin action was neutralized by adding 8ml culture medium 
and the suspension was centrifuged at 1500rpm for 5 min. The supernatant was 
removed and pellets were resuspended in 1ml warm culture medium. 
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 )LYHGD\¶VROGFKLFNLQHJJ  
 
 20µl aliquot of 3×106 cellml-1 plated in 24-well plates 
 
Culture chick cardiomyocyt es 
Relaxation phase          Contraction phase  
 
Fig 2.3 Diagram showing the micromass culture system. Cultured chick 
cardiomyocytes showing phases of contraction and relaxation. Arrows indicating the 
FRQWUDFWLQJIRFL¶V 
 
Using a haemocytometer to count the cells, the cell density was kept at 3×106 cells 
ml-1 (see appendix 5). A 20µl aliquot of cell suspension was pipetted at the centre of 
each well of the 24 well plates, and cells were allowed to attach to the surface in an 
incubator. After 2h, cells were flooded with 500µl of culture medium, and placed 
again in the incubator. The drugs (500µl) at double the required concentration in 
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medium were added after 24h. The contractile activity was recorded at 24h, 48h and 
144h of cell seeding (see section 2.5.1). 
2.4.2 D3 mouse embryonic stem cells culture and differentiation 
2.4.2.1 Cryopreservation of D3 ES cells 
D3 embryonic stem cells were cryopreserved using 10% DMSO as cryopreservation 
agent in a liquid nitrogen (British oxygen company, UK) Dewar. 1-5×106 cellsml-1 
were cryopreserved using medium containing 50% of D3 ES culture medium with 
40% FBS (see appendix 2, section 2.2) and 10% DMSO. The cryovials were stored in            
Mr FrostyTM at -80oC, for long term storage cryovials were transferred to a liquid 
nitrogen Dewar. 
2.4.2.2 Resuscitation and routine culture of D3 ES cells 
Cryovials removed from the liquid nitrogen Dewar were quickly thawed. The 
FU\RYLDOV¶FRQWHQWVZHUHVXVSHQGHGLQPOSUH-warmed D3 ES culture medium and 
centrifuged at 900rpm for 5 min. The pellets were suspended in 5ml D3 ES culture 
medium (with LIF) in 25cm2 tissue culture flasks (0.1% gelatin coated flasks were 
used for the first few passages) and kept in the incubator at 37oC with 5%CO2. The 
culture medium was changed at every 24-48hr and the cells passaged once the flask 
was 70-80% confluent. Before performing cytotoxicity testing ES cells were 
passaged 2 to 3 times. 
2.4.2.3 Subculture of D3 ES cells 
Once the flask was 70-80% confluent with ES cells it was either passaged or 
differentiated. The culture medium in the flask was aspirated and the cells were 
washed twice using phosphate buffer saline (PBS) without calcium and magnesium. 
Cells were dissociated using trypsin 0.05%/EDTA 0.02% solution by placing in 
incubator for a few seconds. Trypsin action was neutralized by adding ES culture 
medium with FBS. The ES cell suspension was centrifuged (900rpm for 5 min) and 
pellets were suspended in pre warmed culture medium with LIF at a cell density of 
5×104 cellsml-1 in a tissue culture flask. 
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2.4.2.4 D3 ES cells differentiation into cardiomyocytes  
Day 0 
A D3 ES cell suspension of 3.75×104 cellml-1 (without LIF) with experimental 
chemicals was prepared for the hanging drop method as described in 2.4.2.3. Using 
a multichannel pipette the 20µl aliquots were pipetted on the inner side of a 100mm 
square Petri dish lid. The lid was carefully inverted over the Petri dish containing 
10ml PBS. The drops in the hanging position were incubated for the next 3 days in 
the incubator. 
Day 3  
5ml the D3 stem cell culture medium with appropriate concentration of the test 
chemicals was placed in a 90mm bacteriological Petri dish and this was used to 
harvest the embryoid bodies (EBs) by keeping the lid slightly tilted at a 45o angle. 
The EBs were further incubated for 2 days at 370C in the incubator. 
Day 5 
The same range of test chemicals was prepared as on day zero. 1ml culture medium 
with or without test chemicals was pipette into each well of the 24 well plates. The 
end portion of yellow pipette tip was cut with sterilized scissors and one EB was 
transferred to the centre of each well. The plates were labelled and kept in the 
incubator for another five days for proliferation, attachment and differentiation of ES 
cells into contracting cardiomyocytes. 
Day 10 
On the 10th day EBs differentiated into cardiomyocytes were observed under the 
light microscope to determine their contractile activity. Day 10, 11 and 12 contractile 
activities of cardiomyocytes were recorded as described in section 2.5.1. 
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2.5 End points 
For the estimation drug produced toxic effects on cardiomyocytes, different end 
points were included in the study. 
2.5.1 Contractile activity 
The heart is the first mesodermal organ that starts to function (Sachinidis et al., 
2003), because a blood supply is necessary for the continuous supply of nutrients 
and oxygen to the developing tissues. Contractile activity is an intrinsic property of 
heart cells. Different cardiomyopathies affect the cardiomyocyte ability to show 
synchronized rhythmical phases of contraction. Morphogens may affect the ability of 
D3 ES cultured in T-25 Flask with LIF 
ESD3 in hanging drop without LIF 
EBs cultured in Petri dish  
EBs plated in 24-well 
plates for differentiation 
         Relaxation Phase      Contraction Phase 
         ES cell derived Cardiomyocytes  
      Three day old EBs    Five day old EBs  
Undifferentiated mouse D3 ES cells  
            Fig 2.4 Schematic diagram of ES D3 differentiation into Cardiomyocytes. 
                       Arrows indicating the contracting foci (magnification x25). 
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differentiating cardiomyocytes to establish a contractile unit during development. 
Aberrant heart development and function indirectly affects the other organs 
development. For these reason cardiomyocyte contractile activity was chosen as an 
endpoint to evaluate the effects of different teratogens on differentiation and 
establishment of contractile unit in both the systems. 
2.5.1.2 Cardiomyocytes contractile activity scoring 
The cardiomyocytes contractile activity was manually recorded using inverted 
microscope. The contractile activity scoring system depends on the number of the 
foci contracting in a well and their pace of contraction. If all the foci were contracting 
a score 3 was given, which decreased with decreased number of foci contracting and 
became zero for no contraction. 
Morphological Score Contractile Activity of Cardiomyocytes 
3 Entire well contracting 
2 Numerous foci contracting 
1 Few foci contracting 
0 No contractile activity 
    Table 2.1 Morphological scoring system for cardiomyocytes contractile activity. 
 
2.5.2 Resazurin Assay 
Resazurin, a 7-Hydroxy-3H-phenoxazin-3-one 10-oxide redox dye (Bueno et al., 
2002), is used in a sensitive non-radioactive one step cell viability measurement 
assay. It is also called the Alamar blue assay (Nakayama et al., 1997). It involves 
the reduction of resazurin to resorufin which is commonly used as a tool to identify 
cell proliferation and cytotoxic potential of chemicals (Anoopkumar-Dukie et al., 
2005). This assay is non-destructive to cells, allows the continuous proliferation of 
cells (Anoopkumar-Dukie et al., 2005) and indicates the presence of viable and 
metabolically active cells that reduce the blue non-fluorescent resazurin dye to pink 
fluorescent resorufin intracellularly (Anoopkumar-Dukie et al., 2005). Upon further 
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reduction it forms colourless dihydroxyresorufin (O'Brien et al., 2000). This reduction 
can be quantified by measuring optical density (Nakayama et al., 1997). This redox 
indicator conversion is facilitated by mitochondrial, microsomal and cytosolic 
oxidoreductases present within the cells (Anoopkumar-Dukie et al., 2005). The 
Resazurin assay is very sensitive, only 80 cells can give a reading (O'Brien et al., 
2000). 
                                                              
Fig 2.5  Resazurin reduction to Resorufin (O'Brien et al., 2000). 
2.5.2.1 Resazurin assay-Cell viability measurement 
100µgml-1 of resazurin stock solution was prepared in HBSS (with calcium and 
magnesium), filtered, aliquoted, wrapped in aluminium foil and stored at -20oC. On 
6th day of micromass and 12th day of ESDC, the resazurin stock solution was diluted 
in HBSS to 10µgml-1. The culture medium in each well was replaced with 500µl of 
pre-warmed resazurin solution; the cells were then incubated at 37oC with 5% CO2 
for one hour. Using FLUORstar plate reader, the optical density was determined, with 
an excitation filter wavelength of 530±10nm and emission filter wavelength of 
590±12.5nm, and a gain of 60. The numerical data indicates the amount of resorufin 
produced which in turn determines the cell activity. Once the optical activity was 
recorded the resazurin solution was replaced with 300µl of kenacid blue fixative and 
plates were incubated overnight at 4oC before the kenacid blue assay. 
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2.5.2.2 Resazurin standard curve 
The resazurin standard curve was performed for the interpretation of data. The 
optical density values obtained from the plate reader were converted to the amount 
of resorufin produced by plotting the resorufin standard curve. Resorufin solutions of 
different concentration 125, 250, 500, 1000, 2000ngml-1 in HBSS were prepared. A 
500µl aliquot of each concentration was added into the wells of a 24-well plate, 
keeping the blank only with HBSS. The optical density was determined, with an 
excitation filter wavelength of 530±10nm and emission filter wavelength of 
590±12.5, with a gain of 60. The results were plotted on a scatter graph and values 
were linked in order to get the best fit straight line. 
 
Fig 2.6 Resazurin reduction assay standard curves. For linear section; y = 0.62x 
where y is emission at 590±12.5nm and x is resorufin concentration (ngml-1). 
2.5.3 Kenacid Blue Assay 
The protein content of cells can be used as a tool to determine their proliferation and 
differentiation and chemicals which are cytotoxic or alter the growth of cells 
decrease the production of protein (Memon & Pratten, 2009). The protein content of 
cells can be determined by using kenacid blue dye, which in turn indicates the 
cellular toxicity of chemicals (Clothier et al., 2002). It acts by measuring the binding 
of dye by cellular proteins: the kenacid blue dye binds to the ±NH3+ terminal of the 
amino acid irrespective of active or non-active protein (De St. Groth et al., 1963). 
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The kenacid blue method gives a direct relationship between protein content, cell 
number and binding of the dye (Knox et al., 1986).  
2.5.3.1 Kenacid blue-Protein content measurement 
After the resazurin assay the cells were fixed with 300µl of kenacid blue fixative 
(ethanol 500ml, distilled water 490ml and glacial acetic acid 10ml) overnight at 40C. 
Fresh kenacid blue working solution was prepared by adding 6ml glacial acetic acid 
in 44ml kenacid blue stock solution (kenacid blue dye 400mg, ethanol 250ml and 
distilled water 630ml). An aliquot of 500µl of kenacid blue working solution was 
added to each well and the plate kept on a plate shaker for 2h. During this time the 
dye reacts with the cell protein. Excess dye was removed by rinsing first then 
agitating with 500µl washing solution (acetic acid 50ml, ethanol 100ml and distilled 
water 850ml) for 20 min. Washing solution was replaced by 400µl kenacid blue 
desorb (ethanol 700ml, potassium acetate 98.1g and distilled water 300ml), which 
takes off the dye and cells from the surface, and the plate was agitated for 1 hour. 
Optical density was recorded using ASYS HITEC Expert 96 well plate reader with 
reading filter 570nm and reference filter 405nm.  
2.5.3.2 Kenacid blue standard curve 
In order to calculate the amount of protein, a kenacid blue standard curve using 
bovine serum albumin was plotted. For this 2.4mg BSA was dissolved in 3ml distilled 
water followed by addition of 7ml ethanol to produce 70% ethanol solution. 80µgml-1 
albumin concentration is produced by dissolving 3ml albumin solution in 6ml 70% 
ethanol. This was then serially diluted to produce 80µgml-1, 70µgml-1, 60µgml-1, 
50µgml-1, 40µgml-1, 30µgml-1, 20µgml-1 and 10µgml-1. The plate was kept in 
refrigerator overnight, the ethanol was evaporated and the protein adhered to the 
surface. On the next day the plate was fixed with 300µl kenacid blue fixative 
overnight. The kenacid blue assay was performed as described in section 2.5.3.1. 
The results were plotted on a scatter graph and the best fit line was drawn to 
interpret the results. 
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Fig 2.7 Kenacid blue assay standard curve. For linear section; y=0.016x where y is 
absorbance at 570nm and x is protein content (µgml-1). 
2.5.4 Reactive oxygen species assay 
Reactive oxygen species (ROS) are produced as a by-product of aerobic metabolism. 
Aerobic organisms possess a passive defence mechanism against ROS and actively 
use ROS in signal transduction pathways for cell survival and proliferation regulation 
(Kobayashi & Suda, 2012). Reactive oxygen species (ROS) accumulation is coupled 
with an increase in oxidative stress, which has been implicated in the pathogenesis 
of several disease states (Guo et al., 2010 ). 
The assay employs the cell permeable fluorogenic pUREH ¶ ¶ dichlorofluorescein 
diacetate (DCFH-DA). The non-ionic non-polar DCFH-DA (non-fluorescent) passively 
enters the cells; the diacetate group is cleaved by cellular esterase. The reactive 
oxygen species (ROS) in the cell oxidise the DCFH to produce highly fluorescent 
dichlorofluorescein (DCF). The fluorescence measured is proportional to the ROS 
levels within the cell. The effects of antioxidants or free radical compounds on DCFH-
DA can be measured against the fluorescence of the DCF standard. H2O2 was used as 
a positive control because it is the major oxygen species responsible for oxidative 
stress and has been implicated as a cellular toxin (Lee et al., 2008). 
DCF-DA esterase cleavage results in charged molecule productions which are better 
retained by cells than is the parent compound. In earlier studies it was observed that 
some cells do not retain the dye and it was leaked out of the cells. To counteract this 
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problem the same approach was applied as by Garle et al., in 2000. The DCF 
formation was measured with the continuous presence of DCFH-DA in the medium. 
This represent the total DCF produced in intracellular and extracellular spaces. 
Culture medium readily oxidises DCFH-DA to DCF but this is slow in the case of 
HBSS (Garle et al., 2000).  
 
 
Fig 2.8 Uptake of non-fluorescent ¶¶GLFKORURIOXRUHVFHLQGLDFHWDWHDCF-DA) into 
the cell followed by removal of acetate groups and oxidation to form fluorescent DCF 
(Shen et al., 2006).  
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2.5.4.1 Reactive oxygen species measurement 
For reactive oxygen species (ROS) analysis the cells were grown in black walled clear 
bottom 96-well plates. For micromass (6000cellswell-1) the assay was performed 
after 24h of cell seeding, while in ES ESCD five days old EBs (3 EBswell-1) were 
plated with dye and drug. 4mM fresh stock solution of 2¶,7¶-dicholorofluorescin 
diacetate (DCFH-DA) dye was prepared by dissolving in methanol. This was further 
diluted to 200 folds in HBSS to give 20µM final concentration. The cells were washed 
with HBSS twice. 100µl of drug solution prepared in HBSS along with dye was added 
to each well of 96 wells plate keeping the blank without cells. The fluorescence was 
recorded using excitation filter 485nm and emission filter 520nm at time points 0h, 
1h, 2h and 4h. The conversion of DCFH-DA to DCF (Dicholorofluorescein) was 
determined by reference to a DCF standard (5 µM). The fluorescence of DCF was 
linear over the concentration of 0.3-5µM.  
 
                 
Fig 2.9 DCF standard curve showing the linear relation with increase in dose. 
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2.6 Preparation of Drug Solutions 
The drug stock solutions were prepared either by dissolving directly in the culture 
PHGLXP RU E\ GLVVROYLQJ ILUVW LQ '062PHWKDQRO RU ǃ-Hydroxypropyl cyclodextrin 
WKHQ DGGLQJ FXOWXUH PHGLXP GHSHQGLQJ RQ GUXJ¶V VROXELOLW\ 7KH DSSURSULDWH
concentrations of drugs required for the experiment were prepared by diluting the 
stock solutions. The final concentration of solvents in Controls and Blanks were kept 
constant.  
 
Drug Solvent 
Ascorbic acid Culture medium 
Bupropion HCl Culture medium 
Carbamazepine 0.16% DMSO 
Folic acid Culture medium 
Hyperforin 0.16% Methanol 
Hypericin 
(Calbiochem, UK) 
0.008% DMSO 
Lithium carbonate Culture medium 
Myo-inositol Culture medium 
Phenytoin 45% w/v 2±Hydroypropyl-ǃ-Cyclodextrin 
Primidone 0.10% DMSO 
Sodium valproate Culture medium 
Super oxide dismutase  
(SOD) 
Culture medium 
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2.7 Immunohistochemistry 
2.7.1 Connexin43 Immunohistochemistry 
On the 6th day of Micromass and 12th day of ESDC cultured cardiomyocytes in 8 well 
chamber slides were washed twice with PBS at room temperature (RT). The 
connexin43 (Cx43) was stained following the method as described previously by Le 
et al (Le & Musil, 1998). In brief the cells were fixed with 2% PFA [w/v] solution 
(diluted from 4% PFA stock) for 30 min at RT followed by 30 min rinse with PBS at 
RT. For Cx43 staining cell were post fixed with -20oC acetone for 5 min followed by 
30 min PBS rinse. Cardiomyocytes were permeabilized for 30 min with PBS 
containing 0.1% Triton X100, 0.2% bovine serum albumin, and 5% normal goat 
serum (PTBN). Cells were incubated with Cx43 antibody diluted in PTBN (1:500) 
overnight at 4oC. Three PTBN rinses of 10 min each were given before incubating the 
cardiomyocytes with secondary antibody (1:1000) diluted in PTBN. This is followed 
by secondary antibody washing; slides were then mounted with Vectashield 
containing DAPI stain (Vector laboratories, UK) and viewed under confocal 
microscope. 
2.7.2 SOX2, MHC and Troponin Immunohistochemistry   
For SOX2 and Myosin heavy chain (MHC) immunohistochemistry the cells were fixed 
with 4% PFA for 20 min followed by two PBS washes. The cells were then 
permeabilized with 0.3% triton X-100 for 1h followed by 1h block with 5% NGS 
solution. Cardiomyocytes were incubated over night with primary antibodies diluted 
in 5% NGS. Three 5 min and three 15 min washes were given with 0.1% BSA 
solution in PBS. The cells were then incubated with secondary antibody diluted in 
NGS for 1h in dark followed by washing with BSA solution. The slides were mounted 
with Vectashield containing DAPI stain and observed under fluorescence microscope. 
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2.8. Western blot  
2.8.1 Preparing cell lysate 
The embryonic chick cardiomyocytes (see section 2.4.1) and D3 ES cells derived 
cardiomyocytes (see section 2.4.2) were grown and treated in 24-well plates. The 
cells were washed twice with ice cold PBS on ice. Freshly prepared lysis buffer with 
protease inhibitor tablet was mixed with 1X solubilisation buffer 1:1; 100µl of this 
solution was added to each well and pipetted up and down thoroughly to take off all 
the cells. The contents of each well was transferred to a separate labelled Eppendorf 
tube, heated at 95oC for 5 min, vortexed, centrifuged and stored at -20oC for future 
use.  
2.8.2 Preparation of tissue lysate (Lowry test) 
For normalizing the protein contents, tissues (100mgml-1) were dissolved in lysis 
buffer with protease inhibitor tablet. BSA standard curve was prepared using  
1mgml-1 BSA. 1ml Lowry solution A+B 1:1 was added to all samples and standards. 
After 10 min incubation with Lowry solutions 100µl of Folin reagent in water 1:1 was 
added and incubated at RT for 45 min. 200µl of each sample and BSA standards 
were pipetted in triplicate in 96 well plates (Fig 2. 10). The plate was read at 750nm. 
The samples were normalized to 1mgml-1 by adding lysis buffer with Solubilisation 
buffer. 
B1   S8   T8      
S1   T1   T9      
S2   T2         
S3   T3         
S4   T4         
S5   T5         
S6   T6         
S7   T7         
Fig 2.10 Showing triplet arrangement of BSA standard and samples in 96 well plate 
(B=blank, S=standard, T=tissue sample). 
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2.8.3 Western blotting 
For Western blot analysis of protein, proteins were first denatured by heating the 
Eppendorf tube at 95oC for 5 min, followed by vortex and centrifuged at 13000rpm 
for 1 min. 15µl each sample was placed in a well of precast gel including 1µl 
molecular weight marker (Lonza, UK) in the first well. The gel was run in 1× 
electrophoresis buffer at 200V for 45 min. The gel was then transferred onto a 
nitrocellulose membrane and run again in cold transfer buffer for 90 min at 100V. 
Once the protein transfer was completed, the nitrocellulose membrane was collected, 
few drops of Ponceau solution was placed on the blot, to confirm protein transfer. 
The appropriate section on the blot was cut and a few quick washes were given to 
remove the Ponceau stains. 3% fish skin gelatine (FSG) solution in TBST was used 
as blocking reagent for 1h on the plate shaker. The appropriate dilutions of the 
primary antibody in 3% FSG solution were prepared and sealed in a bag with the 
blot for overnight incubation at 4oC on the plate shaker. On the next day non-specific 
primary antibody binding was removed by giving 3X quick washes, 3X 5 min and 3X 
10 min with TBST. The blot was incubated for one hour at 37oC on the plate shaker 
with the appropriate secondary antibody dilution in 3% FSG solution. After 
secondary antibody incubation the blot was washed again with TBST and scanned 
using an Odyssey scanner at resolution of 84µm. For Cx43 and phospho-Cx43, 
GAPDH was performed afterwards. Blot was incubated for 1h with GAPDH 1:10000, 
followed by washing, secondary antibody incubation for 1h and again washing with 
TBST. The blot was scanned and analysed using Odyssey3 software. 
2.9 Statistical analysis 
For MM and D3 ES derived cardiomyocytes three independent repeats were 
performed for each experiment. The data was analysed using Prism 5 statistics 
software. For Parametric tests (Resazurin assay and Kenacid blue assay) one-way 
$129$IROORZHGE\'XQQHWW¶VSRVWKRFWHVWZDVSHUIRUPHG)RU&RQWUDFWLOH$ctivity 
scoring (non-parametric data) Kruskal-:DOOLV WHVW ZLWK 'XQQ¶V SRVW KRF WHVW ZDV
used to determine significant values. P<0.05 was considered as significant 
difference from control. 
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Chapter 3 
Evaluation of chick cardiomyocyte micromass 
and embryonic stem cell derived cardiomyocyte 
systems 
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3.1 Introduction 
For any scientific study it is necessary to thoroughly investigate the experimental 
system. The experimental design, working conditions, materials, methods and the 
experimental models are normally optimized prior to use, to have a more effective, 
efficient and reproducible outcome. The MM and ESDC systems used in this study 
were examined for different experimental conditions as a part of a fuller evaluation. 
The chick cardiomyocytes micromass system is relatively new to the world of in vitro 
micromass teratogen insult estimation, compared to the limb bud micromass, which 
is ECVAM validated (Spielmann et al., 2004). In the MM system the exact stage of 
heart explantation, cell seeding density, identification of cardiomyocytes and the 
known effect of the previously tested drugs were evaluated and compared. The chick 
as a model was chosen because of its easy handling compared to rat or mice and 
chick limb bud results are comparable to rat micromass (Hurst et al., 2009; L'Huillier 
et al., 2002). 
For the D3 mouse embryonic stem cell differentiation into contracting 
cardiomyocytes, no alteration or improvisations were made to the ECVAM validated 
protocol of ES differentiation (Paquette et al., 2008; Scholz et al., 1999). Some 
experiments with known teratogens and non-teratogens were performed as a part of 
the study to confirm the reliability and reproducibility of the system in our 
laboratory. The differentiated contracting cardiomyocytes were tagged using cardiac 
protein markers and subjected to H&E staining for cellular morphology. 
3.2 Development of the chick 
The oviparous development of the chick closely resembles the mammalian viviparous 
system, and distinguishes it from lower vertebrates, but at the molecular level it has 
the same basic processes as in all vertebrates (Slack, 2006). The development of the 
chick is divided into three phases: blastoderm formation inside the oviduct lasts for 
one day, embryogenesis inside the egg shell continues for three days and then 
growth for remaining 18 days (Perry, 1988). 
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3.2.1 Development before egg laying 
After fertilization in the infundibulum, the eggs pass downward to the oviduct where 
they are first covered with albumin then shell membrane followed by shell (Bellairs & 
Osmond, 1998). The fertilized egg during this process undergoes cleavage which is 
highly meroblastic, and produces a circular blastoderm. When the blastoderm divides 
into a few hundred cells, a subgerminal cavity appears beneath it. Now the central 
translucent region of the blastoderm is called the area pellucida, the outer region is 
called the area opaca and the junction is called marginal zone. At this time primary 
DQG VHFRQGDU\ K\SREODVW GHYHORSV LQ WKH VXEJHUPLQDO FDYLW\ DQG .ROOHU¶V VLFNOH D
thickening of cells, appears in posterior marginal zone. At the time of laying the 
blastoderm consists of approximately 60,000 cells (Slack, 2006). After laying, when 
the appropriate developmental conditions are provided, development restarts 
(Bellairs & Osmond, 1998). 
3.2.2 Development after egg laying 
The gastrulation period LVLQLWLDWHGE\FHOOVLQWKH.ROOHU¶VVLFNOHFRQGHQVLQJWRIRUP
the primitive streak (Bellairs & Osmond, 1998). The primitive streak elongates both 
anteriorly and posteriorly into the area opaca. Epiblast cells migrated through the 
primitive streak to become mesoderm and the definitive endoderm part of the lower 
layer. Now the area pellucida changes to a pear shape and further condensation at 
WKH DQWHULRU HQG RI SULPLWLYH VWUHDN IRUPV +HQVHQ¶V QRGH &HOOV DUH SUHVHQW LQ
+HQVHQ¶V QRGH VRPH RI ZKLFK PLJUDWH DQWHULRUO\ WR IRUP WKH KHDG SURFHVV RU
posteriorly to form the principal structures of the body consisting of notochord in the 
middle, somite on both sides and neural plate on the anterior edge of the area 
pellucida (Slack, 2006). After 48h the blood islands start to appear and link to form 
the vascular system. The vascular system joins the heart which begins to beat. Two 
distinct vascular systems are essential for chick development, the vitelline system, 
which transports nutrients from the yolk to embryo; the other is the allantoic 
system, which is involved in respiration and transport of waste material from the 
embryo to the allantois. By the end of the 3rd day the beak begins to grow and fore 
and hind limb buds are visible and the embryo acquires a C shape. The embryo 
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continues to grow. The incubation period is normally 21 days for the chick after 
which it hatches (Bellairs & Osmond, 1998). 
A)  
A) Day 4 of incubation (HH 24) 
¾ Longer limb buds than wide. 
¾ Longer somites than wide. 
¾ No demarcation of digital plate. 
¾   Toe plate in leg but although   
          distinct toes are not  
          demarcated. 
 
 
B) Day 5 of incubation (HH 26) 
¾ Limb buds are considerably  
          longer and contour of digital  
          plate is round. 
¾ There is faint groove between  
          the second and third digits. 
¾ Beak is barely prominent. 
¾ Demarcation of first three toes  
          is distinct. 
 
C) Day 6 of incubation (HH 29) 
¾ Wings are bent at elbow. 
¾ Second digit is larger than the  
          other digits. 
¾ Grooves between digits are  
          prominent. 
¾ Beak is more prominent. 
¾ There is no egg tooth visible at  
          this stage. 
 
 
 
 
H
MB
HB
FB
E
LB
LB
H
MB
HB
FB
E
LB
LB
H
MB
HB
FB
E
LB
LB
 Fig 3.1 Development of chick on day 4, 5 and 6 of incubation. FB=fore brain, MB=mid 
brain, HD=hind brain, E=eye, H= heart and LB=limb bud. 
Vvvvvvvvvvvvvvvvvvvvv 
     
46 
 
3.2.3 Development of the Heart 
The developing heart is a highly modified muscular vessel (Harvey, 2002) and the 
first functional organ, required to support development (Lyons, 1996). According to 
the Hamburger and Hamilton (H&H) stages of chick development, the heart begins 
to develop at about stage 9-10 (Bellairs & Osmond, 1998), but the cardiac 
progenitor cells were identified even before gastrulation (Martinsen, 2005). The 
mesodermal plate on both side of the neural plate splits into upper somatic and 
lower splanchic layers. The space between these layers (which will form the future 
coelomic cavity) provides amniocardiac vesicles for the formation of amnion and the 
precardial cavity (Bellairs & Osmond, 1998). 
The splanchnic mesoderm on both side of the neural tube folds and joins to form the 
foregut and the precardiac cells from both sides move to the midline. The developing 
foregut loses contact with yolk sac and the endodermal tube and precardiac cells join 
to form a single tube below the developing V-shaped pharynx. In the tube the thin 
inner endocardium and outer thick epimyocardium are visible, which later on become 
the three layered endocardium, myocardium and epicardium (Bellairs & Osmond, 
1998). 
Heart looping begins when the right ventricular wall bulges outward and becomes 
convex, while the left becomes concave; the biophysical mechanism that controls the 
looping is not well understood (Bellairs & Osmond, 1998; Taber, 2006). The 
developing heart loops first into a C shape then into an S shape. This process of 
looping continues from stage 9-34 (Martinsen, 2005).  
Initially the heart divides into the bulboventricle, atrium and sinus venosus, which 
later on, by the development of the bulboventricular and atrioventricular grooves 
divides into right and left channels. By day 4 the atrium and ventricle divide into left 
and right and bands of muscle begin to form (Bellairs & Osmond, 1998). The first 
action potential in the cardiac mesoderm appears in the ventricle by stage 9 even 
before the atrium and sinus venosus are formed. Contractility can be seen at stage 
11 and contraction waves spread through the muscles and cause muscle contraction 
by stage 12 and at this stage blood starts to circulate. By day 3 circulatory systems, 
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vitelline, allantoic and intraembryonic, are well developed. The AV node and AV 
bundles develop by day 5.5-6 of incubation. During embryonic development the size 
of the heart increases 1000 fold (Bellairs & Osmond, 1998). 
3.3 Parallel between cardiogenesis and ESCs derived cardiomyocytes 
The process of cardiogenesis is very complicated. The signalling molecules and 
various transcription factors play an important role to drive undifferentiated stem 
cells towards the cardiac lineage (Sachinidis et al., 2003). Embryonic stem cell 
differentiation into cardiomyocytes closely resembles the in vivo process of 
cardiogenesis (Wei et al., 2005). The formation of ES cell aggregates resembles the 
early post implantation embryo, which initiates signalling and spontaneous 
differentiation into three germ layers (Sachinidis et al., 2003). 
The developing embryonic mesodermal lineage gives rise to cardiomyocytes 
(Sachinidis et al., 2003) and this is true for the D3 mouse ES derived 
cardiomyocytes. The differentiating ES cells express the mesoderm lineage 
commitment factor brachyury T, which is necessary for mesoderm establishment in 
vertebrates (Mauritz et al., 2008). NKx2.5 is one the earliest markers expressed 
during cardiac differentiation. In ESDC, Nkx2.5 is also expressed early around day 3 
of ES differentiation (Rohwedel et al., 2001; Rolletschek et al., 2004). Inhibition of 
Nkx2.5 expression results in incomplete cardiac gene expression or absence of heart 
formation (Jamali et al., 2001). The differentiating ES cells, like in vivo 
cardiomyocytes, express cardiac specific transcription factors and structural proteins 
like NKx2.5, GATA-4, MLC-2a, MLC-2v, ANF, MHC and troponin (Murabe et al., 
2007a; Murabe et al., 2007b; Rolletschek et al., 2004; Seiler et al., 2004). This 
suggests the ESDC follows the same programme as its in vivo counterpart. 
The signalling molecules like BMP, FGF and insulin like growth factors play an 
important role in cardiac differentiation (Sachinidis et al., 2003), while noggin and 
Wnt over expression inhibits cardiac differentiation (Sachinidis et al., 2003; 
Schultheiss et al., 1997). Beside these differentiated cardiomyocytes show evidence 
of A and I bands (Boheler et al., 2002) and represent atrial, ventricular and pace 
maker like cells with specific ion channels and gap junctions (Rohwedel et al., 2001; 
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Rolletschek et al., 2004; Wobus et al., 1997). There are some molecules like DMSO, 
retinoic acid and ascorbic acid which promote ES cell differentiation into 
cardiomyocytes (Heng et al., 2004; Sachinidis et al., 2003; Takahashi et al., 2003; 
Wobus et al., 1997). 
3.4 Effects of chick heart development stages on micromass culture system 
The micromass system was designed to study the cytotoxic effects of teratogens at 
the cellular level. It includes primary culture of different embryonic tissue like brain, 
limb bud (ECVAM validated method) or cardiomyocytes (Memon & Pratten, 2009; 
Reinhardt, 1993; Spielmann et al., 2004). Chick development stages and 
development speed varies a lot from other experimental animals like mouse or rat. 
The appropriate chick developmental stage for cell culture is important for accurate 
evaluation of embryotoxic effects of chemicals. If the isolated cell are not mature 
enough they cannot accurately mimic in vivo organogenesis, or if cells are isolated at 
an early stage they may not cope with the experimental conditions and may not 
provide the required number of cells to start the experiment. 
3.4.1 Materials and Methods 
For the identification of exact development day for micromass culture the same 
method of cell culture was followed as described by Memon S (Memon & Pratten, 
2009). In brief the eggs were incubated for 4, 5 and 6 days at 38oC, under humid 
conditions. 20µl of isolated heart cells suspension (see section 2.4.1) was alliquoted 
at the centre of the 24 well plates with one row for blank. The cells were seeded at 
3×106 cellml-1 density as described previously by Hurst (Hurst et al., 2009). The 
seeded cells were flooded with medium after 2h. The contractile activity (see section 
2.5.1) of the cardiomyoyctes was recorded at 24h, 48h and 144h of seeding, 
followed by the Resazurin cell viability (see section 2.5.2) and kenacid assay (see 
section 2.5.3). 
3.4.2 Results 
The chick developmental day 5 and 6 seeded cardiomyocytes behaved very 
differently compared to day 4 at all the endpoints evaluated. The cardiomyoF\WHV¶
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contractile activity was comparable between day 5 and 6, while with day 4, 
decreased number of foci formation and contractile activity was recorded (fig 3.2A). 
The day 6 cultured cells mostly formed a flat sheet and the foci were 
indistinguishable compared to day 5, where number of foci and the contractile 
activity was maximum at all the days evaluated (fig 3.2A). The cell viability (fig 
3.2B) and the protein content (fig 3.2C) of day 5 and 6 were comparable, while for 
day 4 cells, both end points drop down to significantly different values (P<0.05). The 
day 4 cells were poorly attached to the surface and frequently came off the surface 
during the kenacid blue tapping and the medium replacements. The day 6 cell were 
attached well, not detaching during medium replacement, but the cells showed poor 
attachment during the kenacid blue assay compared to day 5, which were not 
detaching during medium replacment or in the kenacid blue assay. 
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3.4.3 Conclusion 
During the evaluation of the optimum chick developmental day for micromass 
culture it was observed that day 5 chick cardiomyocytes successfully attached to the 
surface compared to day 4 which showed poor attachment. This might be because 
Fig 3.2 Effects of embryo day 4, 5 and 6 
heart explantations on the MM culture 
system. A) Effects of developmental 
stage on contractile activity, B) effects of 
developmental stage on resazurin cell 
viability assay and C) effects of 
developmental stage on Kenacid blue 
total protein content. 
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cardiomyocytes were not sufficiently developed for culture, while day 6 were too 
differentiated for the micromass system. The day 4 cultured cardiomyocytes also 
showed decreased cellular viability compared to other two days with the same cell 
number, while protein content also decreased mainly because of low attachments. 
3.5 Determination of cardiomyocytes optimal seeding density in 
micromass system 
For optimal culture conditions, the cell seeding density is a very critical step to 
determine. The appropriate number of seeding cells is important for proper cell 
communication, which in turn forms the beating foci in the case of cardiomyocyte 
micromass. The cell density was evaluated using the same end points of contractile 
activity, cell viability and total protein content. 
3.5.1 Materials and methods 
Cells derived from day 5 chick hearts were used for the cell density determination. 
20µl cardiomyocytes suspensions ranging from 0.5×106 to 5×106 cells were aliquoted 
at the centre of 24 well plates keeping the blank empty. The cells were incubated at 
37oC and 5% CO2 for 2h for the cell attachment followed by flooding with more 
medium for cell growth and differentiation (see section 2.4.1). The contractile 
activity was observed (see section 2.5.1) followed by the resazurin cell viability 
assay (see section 2.5.2) and total protein estimation using the Kenacid blue assay 
(section 2.5.3) on day 6 of MM. 
3.5.2 Results 
The cell seeding density in the micromass system showed increased resorufin 
production as the cell number increases. 0.5 million cellsml-1 converted the resazurin 
to nearly 50ngml-1 of resorufin, which increased with cell number. The 3 million 
cellsml-1 increased conversion about 5 fold compared to 0.5 million cells. The 5 
million cellsml-1 showed greater conversion compared to 3 million (fig 3.3A). The 
protein content estimation using Kenacid blue assay also followed a similar pattern 
of increased protein with increase in cell number from 0.5-5 million cellsml-1 (fig 
3.3B). The contractile activity showed different effects at different cell seeding 
     
51 
 
densities. The 0.5 million cellsml-1 did not form beating foci and the cells were apart 
from each other. Similar results were observed when 1 million cellsml-1 was seeded. 
The spaces between the cells were reduced but still the cells were unable to form 
beating foci. 2 million cellsml-1 showed different results with the cells forming 
desynchronised beating foci but the numbers of beating foci were few and the spaces 
between the foci were very large. The 3 million cells ml-1 was found to form a very 
good number of foci with less space between. The contractile activity was 
synchronised and better than low density wells. The beating continued to be of same 
magnitude for up to six days of culture. The 5 million cellsml-1 instead of forming 
separate foci formed flat synchronised contractile sheets. 
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Fig 3.3 Effects of different cell seeding density in MM system. A) Resazurin cell 
viability assay B) Kenacid blue assay for total protein content. 
3.5.3 Conclusion 
The end points of cell viability and total cellular protein content were found to be 
directly proportional to cell seeding density. But the morphological examination of 
seeded cells at different time intervals revealed the appropriate cell seeding density 
is important for the contractile system to become established. The communication 
and the signalling between the cells and the distance between the seeded cells were 
found to be important to produce a synchronised contractile unit. Cell density below 
2 million cellsml-1 failed to form the contractile system while 2 million cellsml-1 
established it, but due to large spaces between the cells the beating foci were not 
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synchronised. The 3 million cells showed improved values by forming synchronised 
contractile activity. The communication between cells was definitely improved 
compared 2 million cellsml-1. The last cell density (5 million cellsml-1) tested was able 
to make a synchronised contractile unit with indistinguishable foci which made 
contractile activity scoring difficult since it depended on the number of foci beating. 
3.6 Identification and characterization of cells in the MM and ESDC system   
In the micromass system the cardiomyocytes were isolated from five day old chick 
hearts. The isolation of hearts was performed under the dissecting microscope using 
fine forceps. But there always remains a doubt about the isolation of some other 
tissues, especially fibroblasts and endothelial cells attached with the heart. The 
cardiomyocyte primary culture when seeded at a high density exhibits the phases of 
contraction and relaxation, which is their intrinsic property. But there remains a need 
to prove the tissue type present by tagging cardiac-specific proteins or genes. In the 
case of stem cells the differentiation to cardiomyocytes remains to be identified 
using markers to render any tissue specific effects more reliable. To further remove 
the doubt about the cells isolated and produced during cell proliferation different 
cardiac specific markers and histological techniques were employed which may 
provide the answer to these questions. 
3.6.1 Histological staining  
Traditional histological staining was used to demonstrate the tissue and cell 
morphology. Using different staining techniques certain specific cells and protein 
types were identified. Haematoxylin and eosin stain, commonly called H&E, is a 
popular tissue staining method in histological studies (Steven, 1977). It is the widely 
used stain in medical diagnosis; for example for biopsy of a suspected cancer. The 
staining involves application of haemalum (Aluminium ions and oxidized 
haematoxylin complex). It stains nuclei of cells blue. The nuclear staining is followed 
by counterstaining with eosin Y, which stains other, eosinophilic structures in various 
shades of red, pink and orange (Avwioro, 2011). 
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3.6.2 Immunofluorescent staining  
Using immunofluorescence the ES cells and the cardiomyocytes in both the systems 
were stained with specific markers to characterize the type of cells present. In 
undifferentiated stem cells SOX2 was tagged. The SOX2 along with OCT4 and 
Nanong transcriptional factors maintain the undifferentiated stem cells pluripotency 
(Shenghui et al., 2009). For the cardiomyocytes cardiac MHC and Troponin T specific 
antibodies were used to tag the proteins (Antin et al., 2002; Garriock et al., 2005). 
3.6.3 Positive control 
Day 9 chick heart was used as a positive control for the differentiated 
cardiomyocytes. At day 9 the chick heart exhibits the presence of functional 
cardiomyocytes with rhythmical phases of contraction and relaxation (Martinsen, 
2005). 
3.6.4 Methodology  
3.6.4.1 Cryopreservation and cryosectioning 
The day 9 chick hearts were isolated under the microscope using fine forceps. The 
hearts were cryopreserved in OCT. The heart, suspended in an OCT mould, was 
immersed in isobutanol in a beaker and briefly exposed to liquid nitrogen. The liquid 
nitrogen -196oC temperature quickly freezes the tissue, which was then stored at     
-80oC for future use. For cryosectioning the moulds were kept in the cryostat for    
20 min before cutting the sections of required thickness. 
3.6.4.2 H&E staining 
The H&E staining method was adapted from the Stevens, 1977. The cryosectioned 
hearts or cells grown in chamber slides were first hydrated with tap water followed 
by haematoxylin incubation for 5 min. The slides were then washed with tap water 
several times until the water became clear. The slides were then differentiated using 
acid alcohol to remove the excessive stain before differentiating the nuclei in a 
saturated solution of lithium carbonate. This was followed by a tap water wash and 
the slides were placed in 1% eosin solution for 1 minute. The excessive eosin stain 
was washed using the running tap water and the sections were dehydrated through 
graded alcohol. A xylene dip was given before mounting with DPX. 
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3.6.4.3 Immunohistochemistry 
The fluorescent immunohistochemical staining method is discussed in section 2.7.2. 
3.6.5 Results  
3.6.5.1 Day 9 heart, MM and ES derived cardiomyocytes H&E staining  
The H&E demonstrates the cardiomyocytes general morphology. The day 9 heart 
staining confirms the presence of other endothelial and fibroblast cells along with 
cardiomyocytes. Fig 3.4A shows the chick day 9 complete sectioned heart with 
different regions, fig 3.4B is a view of the day 9 right auricle at greater 
magnification, showing the presence of irregular size myocytes. With H&E staining of 
chick cardiomyocytes in MM system the foci show deep red staining with large 
irregular cells. The numerous processes visible at the periphery may be involved in 
cell attachment (fig 3.4C). The ESDC H&E stain shows the different cell types with 
intensely stained foci in the centre where beating was observed. The cells were of 
different size with some visible processes that may support the cells in attachment 
(fig3.4D). 
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RA
LA
RV
LV
 
Fig 3.4 H&E staining of cardiomyocytes. A) Day 9 chick heart . RA=right auricle, LA=left auricle, RV=right ventricle and LV=left ventricle 
(magnification ×10), B) Day 9 chick heart auricle, C) chick cardiomyocytes in MM system and D) ES cells derived cardiomyocytes 
(magnification ×20).  
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3.6.5.2 Immunohistochemistry for undifferentiated ES cells 
The undifferentiated cardiomyocytes were cultured in chamber slides in the presence 
of LIF. The cells were fixed and stained with SOX2 antibody as described in section 
2.7.2. SOX2 is the marker of pluripotent stem cells. SOX2 is necessary for the 
maintenance of pluripotency along with Nanong and OCT4 transcriptional factor 
(Shenghui et al., 2009). Being a transcription factor it is expected to be mostly 
expressed in the ES cell nucleus. In fig 3.5A it is clearly observed that SOX2 is 
expressed in the nucleus, the blue staining indicates nucleus staining with DAPI (fig 
3.5B). This confirms the presence of pluripotent embryonic stem cells. 
50Pm50Pm
A B
Fig 3.5 SOX2 staining of undifferentiated ES cells. A) SOX2 staining B) nucleus 
staining with DAPI and SOX2 merge. 
 
3.6.5.3 Day 9 heart, MM and ESDC Immunohistochemistry 
The day 9 chick heart showed positive staining for cardiac myosin heavy chain along 
with cardiac troponin T (fig3.6A and B). The MM cardiomyocytes showed a striated 
appearance of MHC and troponin T because of cell monolayers (fig 3.6C and D). As 
the ESDC forms large foci the striated appearance of MHC and Troponin T stains was 
not clearly visible (fig 3.6E and F).  
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A B
C D
E F
Fig 3.6 Chick day 9, MM and ESDC cardiomyocytes staining with MHC and 
Troponin T markers. A) Day 9 chick heart cardiac MHC staining, B) Day 9 chick 
heart cardiac troponin T staining, C) Chick MM cardiac MHC staining, D) Chick MM 
cardiac troponin T staining, E) ESDC cardiac MHC staining and F) ESDC cardiac 
troponin T staining. (Blue staining represents the DAPI nuclear stain). 
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3.6.6 Conclusion 
The histological staining with haematoxylin and eosin shows the cellular morphology 
of cardiac cells and the presence of relatively low number of other cells with 
cardiomyocytes. The presence of other cell type supports the cardiomyocytes 
attachment. The ESDC shows the presence of irregular shape and different size cells. 
With immunostaining of MHC and troponin the presence of cardiac cells were 
confirmed in both the systems. 
 
3.7 Evaluation of MM and ESDC systems reliability  
Known strong, moderate teratogens and non-teratogens were selected from previous 
studies and evaluated in the MM and ESDC system, to compare and predict the 
reproducibility of results in our lab. Penicillin G (PG) is a non-teratogen compound 
even at high doses, mostly used as a positive control in teratological studies 
(Anneelieke et al., 2007). A pair of uracil derivatives was selected - 5-Fluorouracil 
(5Fu), which is commonly used a chemotherapeutic agent, with a number of studies 
confirming its strong teratogenic potential at very low doses (Anneelieke et al., 
2007), while its analogue 6-Methyluracil (6-Mu) is a non-teratogenic compound 
(Cumberland et al., 1994; Flint & Orton, 1984). Beside these teratogenic and non 
teratogenic compounds the reference drug sodium valproate (moderately 
teratogenic) was also included in this study to support the system reliability.  
The same method of MM and ESDC was used as described earlier in chapter 2. In the 
MM system 1000µM PG, which is a very high dose, does not affect the 
cardiomyocytes. Cells were contracting like the control (fig 3.7A) with no effect on 
the other two end points (fig 3.7B and C) as shown previously (Ahir & Pratten, 
2011). The 6-Mu as expected showed the same non-teratogenic effects in the chick 
MM system (fig 3.7A, B and C). While 5-Fu maintained its teratogenic attributes with 
statistically significant contractile activity inhibition at low doses (fig 3.7A). The VPA 
1000µM showed comparable inhibition over contractile activity (fig 3.7A) with earlier 
studies, while other end points remained unaffected (fig 3.7B and C) (Ahir & Pratten, 
2011). In ESDC the PG proved to be an ideal positive control with no effects 
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(fig3.7D, E and F) (Ahir & Pratten, 2011; Seiler et al., 2004). With 5-Fu when same 
dose of 5µM was used there was no formation of EBs, a reduced dose was used as 
described by Seiler et al, in 2004. 5-Fu 0.25µM reduced the contractile activity (fig 
3.7D) with no significant effect on cell viability (fig 3.7E) and protein contents (fig 
3.7F) (INVITTOX protocol no 113). For 6-Mu at the same dose of 0.25µM all end 
points were comparable to the control (fig 3.7D, E and F). While VPA at high doses 
inhibited cell contraction (fig 3.7D) and viability (fig 3.7E) with no effects on proteins 
(fig3.7F) (Ahir & Pratten, 2011). 
The results observed in our lab were comparable with the previous results. The use 
of the MM and ESDC method is reliable. This further supports the use of the method 
and techniques in this study. 
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Fig 3.7 The effects of drugs on MM and ESDC systems. A) Effects on contractile 
activity in the MM system, B) effects on cell viability (resazurin assay) in MM system, 
C) effects on total protein content (kenacid blue assay) in MM system, D) effects on 
contractile activity in ESDC, E) effects on cell viability (resazurin assay) in ESDC,    
F) effects on total protein content (kenacid blue assay) in ESDC. * represents a 
significant difference from control.  
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3.8 Discussion 
For the evaluation of selected teratogenic effects using these in vitro systems it was 
necessary to adopt a system that is reliable, reproducible and represents normal 
development. The chick cardiomyocyte micromass system is relatively recent and 
still not validated. The ESDC system is already validated in the EVCAM procedures 
and comes under the name of EST with additional use of fibroblast cells (Invittox 
Protocol no. 113). In this study the EST protocol of cardiomyocyte differentiation and 
drug treatment was adopted with no modification. Both the systems were thoroughly 
evaluated before starting the actual experiments with drugs. Cardiac cell markers 
were used to confirm the cells isolated and differentiated represent the correct tissue 
type. Beside these known drugs effects in these systems further support the 
reproducibility of results observed in other studies. 
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drugs teratogenic effects in chick 
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4.1 Epilepsy and Teratogenesis 
Epilepsy is a collection of neurological disorders exhibiting disturbance in brain 
function, characterized by abnormal electrical activity which results in seizure 
disorder (Tunnicliff, 1996). Nearly 1 million women of child bearing age in the US 
alone have been diagnosed with epilepsy. Mounting evidence suggests an association 
between epilepsy and increased perinatal risks. The use of antiepileptic drugs (AEDs) 
in epilepsy further increases the susceptibility to drug related teratogenicity (Fried et 
al., 2004).  
Fetal malformations occur in about 10% of pregnant women with epilepsy, of which 
2% are severe. In pregnant epileptic women the seizure disorder complicates less 
than 1% of the pregnancies. Depending on seizure frequency and duration, in some 
pregnancies it worsens, in some it improves and in other remains unaffected (Brewer 
et al., 2003). 33% women with epilepsy experienced an increase in seizure 
frequency during gestation, so continuing the drug therapy is necessary to avoid 
maternal and fetal life risks (Prakash et al., 2008). The congenital malformation rate 
increases in maternal epilepsy, and is complicated by uncontrolled seizures, 
especially if they occur in the first and second trimester of pregnancy, as at this time 
the fetus is most vulnerable to malformation induced by epilepsy or medications. 
Seizure activity in the third trimester puts the fetus at a risk of hypoxic episodes 
(Brewer et al., 2003). 
4.2 Teratology and Antiepileptic Drugs 
The pregnant epileptic woman who stops taking AEDs is at more risk of developing 
status epilepticus, which has a high mortality rate for mother and baby. Convulsive 
seizures in pregnancy cause fetal intracranial haemorrhage and heart rate changes 
(Fountain, 2009), so maintaining the AED serum therapeutic level during pregnancy 
is necessary to avoid maternal and fetal life risks (Prakash et al., 2008). It is always 
controversial to find out whether the malformation is caused by the epilepsy itself or 
the exposure to AEDs; however AEDs are usually the major contributor toward the 
development of malformations (Brewer et al., 2003). Earlier studies have indicated 
teratogenicity as an attribute of most AEDs (Kaneko et al., 1999) and although no 
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antiepileptic drug in the world is safe or ideal (Prakash et al., 2008), a few have less 
teratogenic effects (Pizzi et al., 1996). 
The congenital malformation rate found in AED exposed offspring is 9.0% as 
compared to unexposed RIIVSULQJ¶V (Kaneko et al., 1999). This malformation 
risk is increased two fold with AEDs polytherapy (Matalon et al., 2002). In another 
study, a reduction in daily dose of AEDs may be shown to decrease the malformation 
rates from 13.5 to 6.2% (Kondo et al., 1996). 
$('V¶WHUDWRJHQLFHIIHFWVRQWKHHPEU\RDQGIHWXVDUHHYLGHQWLQWKUHHPDMRUDUHDV 
1. Increased major congenital anomalies (MCA). Usually congenital heart defects, 
cleft lip and cleft palate, anomalies of the urinary tract, of the limbs and brain, 
especially neural tube defects (NTD). 
2. A specific syndrome of the particular AED, mainly affecting the cranio-facial 
complex causing facial dysmorphism, but often also affecting other organs such 
as external genitalia (i.e. Phenytoin syndrome) and neural tube 
(Carbamazepine and Valproate syndrome). 
3. Developmental disorders, mainly affecting cognitive function and behaviour. 
These changes may affect language development, learning abilities and even 
cause Autism (Ornoy, 2009). 
4.2.1 Sodium Valproate (Sodium 2-Propyl Pentanoate) 
The anticonvulsant properties of Valproic acid (VPA) were serendipitously discovered 
in 1962 (Gurvich et al., 2004). It was first marketed in 1974 for the treatment of 
epilepsy; later on its mood stabilizing properties were also added to its therapeutic 
profile (Ornoy, 2009). Sodium valproate, an analogue of VPA is found to be effective 
against seizures. VPA and sodium valproate ionize to the valproate ion at body pH 
(Katzung, 2000). The mechanism of action of VPA is not fully understood, but it may 
act by potentialising GABA inhibitory activity by several mechanisms, attenuating 
aspartate levels or by blocking Na+, Ca2+ and K+ channels in the brain (Chateauvieux 
et al., 2010; Umka et al., 2010). A therapeutic dose of 300-2000 mg/day controls 
seizures and may achieve plasma levels of 50-100µgml-1. Lower doses are normally 
recommended for bipolar disorder, mania and migraine (Ornoy, 2009). The drug 
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crosses the placenta and its levels in umbilical cord blood are found to be five times 
higher than maternal serum, which imposes increased risk of embryotoxicity (Ornoy, 
2009). 
VPA use during early pregnancy carries a 3-fold increased risk of congenital 
malformation (Kostrouchová et al., 2007), with 1-2% increase in NTD (including 
anencephaly and exencephaly) and that elevates to 5.4% with a higher daily dose of 
1000mg/day of VPA. The dominant teratogenic characteristic is lumbosacral 
meningomyelocele (spina bifida aperta), it also causes cardiovascular, genital and 
limb abnormalities, hypospadia, GHYHORSPHQWDOGHOD\DXWLVPDQGWKHVSHFLILF³)HWDO
9DOSURDWH6\QGURPH´(Ornoy, 2009; Ornoy et al., 1998). 
³)HWDO 9DOSURDWH 6\QGURPH´ ZDV ILUVW GHVFULEHG E\ 'L/LEHUWL LQ  ZLWK
characteristic intrauterine growth retardation (IUGR), a long and thin upper lip, 
shallow philtrum, epicanthal folds and mid face hypoplasia manifested by a flat nasal 
bridge, small up turned nose and the down turned angles of the mouth (DiLiberti et 
al., 1984). 
Valproic acid exposure in pregnancy brings about developmental delay that reduces 
cognitive function and produces attention deficit disorder and learning difficulties in 
the new born. Autism spectrum disorder (ASD) is also found to be an attribute of 
VPA teratogenicity (Ornoy, 2009). In 2005, Rasalam, found 8.9% risk of ASD in 
infants born to VPA monotherapy mothers compared with that of 11.7% with 
polytherapy, especially VPA with carbamazepine that gives 11.1%, while 
benzodiazepines generally are found to enhance the teratogenic effects of VPA. Due 
to increased teratogenic potentials of VPA it is placed in the FDA teratogenic 
FDWHJRU\³'´(Rasalam et al., 2005). 
VPA like other AEDs possess antifolate activity and disrupts gene expression, 
enhances embryonic oxidative stress and alters protein synthesis. These 
disturbances may result in NTD, cardiac anomalies and neurodevelopment delay. In 
addition its intermediate reactive metabolites may increase oxidative stress and 
irreversibly damage the embryo or fetus (Na et al., 2003; Ornoy, 2009). 
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VPA at therapeutic concentrations (0.3-0.7mM) inhibits histone deacetylase (HDACs) 
(Gurvich et al., 2004; Murabe et al., 2007a), which explains its anticancer properties 
(Chateauvieux et al., 2010). VPA teratogenic effects are thought by some to be 
mediated through HDACs inhibition rather than antiepileptic activity (Phiel et al., 
2001). VPA inhibits HDACs, preferentially class I HDACs. It decreases histone 
acetylation, and thus changes in the chromatin structure and the activity of 
transcription factors of the genes may be induced. This action may interrupt the cell 
cycle, induce growth arrest and apoptosis, and in turn affect cell proliferation, which 
may explain its teratogenic properties (Ornoy, 2009). Earlier in 2003 Detich (Detich 
et al., 2003) found that VPA triggers the active methylation of DNA along with 
acetylation of H3 Histone in human embryonic kidney cell culture. This is achieved 
by the direct action of VPA as a HDAC inhibitor, thus increasing demethylase 
accessibility to DNA, and demethylation of DNA induces changes at the gene level. 
Such changes may produce various epigenetic abnormalities (Blaheta & Cinatl, 
2002; Ornoy, 2009). Beside this VPA affects a number of molecular pathways 
LQFOXGLQJ 33$5 į ǃ-catenin, activator protein 1, PkC and Erk1/2 (Gotfryd et al., 
2011; Gurvich et al., 2004). 
Using embryoid bodies derived from murine ES cells, Lan Na found that VPA 
interrupted the cell cycle, but did not cause cytotoxic effects in the embryoid bodies 
in a dose dependent manner. The intracellular reactive oxygen species levels were 
found to be elevated and that may have inhibited cardiomyogenic differentiation (Na 
et al., 2003). In the micromass system VPA affects neural differentiation and 
chondrogenesis (L'Huillier et al., 2002). 
4.2.2 Carbamazepine 
One of the widely prescribed antiepileptic drug Carbamazepine (CBZ) acts by 
stabilizing voltage gated sodium channels or by modulating neurotransmitters 
release or uptake (Beutler et al., 2005; Kwan et al., 2001). CBZ was initially found 
to be devoid of teratogenic effects, but in 1989 it was observed that CBZ used alone 
or in combination may produce malformations similar to Phenytoin (Hansen et al., 
1996). CBZ mostly causes cardiovascular anomalies (1.5-2.0%), NTDs (0.5-1%), 
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urinary tract malformations and cleft palate (Murabe et al., 2007b). CBZ increases 
risks of congenital malformation 2.89 fold, which increases to 3 fold during first 
trimester drug use and further elevates in AEDs polytherapy. Due to non-availability 
of adequate and well controlled studies on CBZ teratogenic effects in humans, it is 
SODFHGLQ)'$SUHJQDQF\FDWHJRU\³&´(Ornoy, 2006). 
CBZ is metabolized in the body through arene oxide pathways; the chemically 
reactive epoxide produced may bind covalently with macromolecules like DNA and 
proteins and can produce teratogenic effects by disrupting normal process of fetal 
development (Kaneko et al., 1999; Lindhout et al., 1984). Phenobarbitone (PB) is 
also metabolized through the arene oxide pathways, by which xenobiotics can be 
hydroxylated through an epoxide intermediate. On the other hand VPA inhibits the 
production of epoxide hydrolase, which in VPA and CBZ polytherapy causes 
accumulation of CBZ epoxide. Therefore CBZ polytherapy with VPA or PB carries a 
greater risk of malformation (Matalon et al., 2002). CBZ and its major metabolite 
CBZ-10,11-epoxide are histone deacetylase (HDAC) inhibitors, with an IC50 value of 
2µM (Beutler et al., 2005) which is well within human therapeutic range (3-14µg/ml) 
(Murabe et al., 2007b). CBZ teratogenicity may be due to HDAC inhibition because 
HDAC inhibitors induce cell cycle arrest, apoptosis and differentiation (Beutler et al., 
2005).  
In an experiment to investigate the effects of CBZ on ES cell differentiation into 
cardiomyocytes using the R1 mouse embryonic cell line, Murabe found that 
expression of the primitive marker GATA6 increased in the differentiating 
endodermal lineage, but the expression of late differentiating markers TTR and HNF1 
decreased with increasing concentration. While ALB was not detected, this shows 
CBZ promoted initial endodermal differentiation but inhibited differentiation into 
mature endodermal lineages (Murabe et al., 2007b). In the mesodermal lineage the 
primitive marker BMP4 expression increased in a dose dependent manner. The early 
cardiac marker NKx2.5 also slightly increased, while late stage cardiac marker ANF 
was reduced. It was found that CBZ decreased the rate of undifferentiated ES cell 
differentiation into cardiomyocytes in a dose dependent manner. VPA inhibited the 
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expression of almost all the markers in all the stages of endodermal and 
mesodermal differentiation, whereas CBZ inhibits only later stages. This shows that 
VPA and CBZ exert embryotoxic effects using different mechanisms in endodermal 
and mesodermal developmental stages. In neural differentiation VPA induced 
differentiation in a lineage-specific manner, and the expression of late stage neuron 
specific markers like Nestin, Synaptophysin (Syn) and Neurofilament H (NFH) 
increased. The same increased expression is found with CBZ in a dose dependent 
manner. Expression of the glial markers GFAP, Oligo 2 and DM20 increased with CBZ 
but not with VPA (Murabe et al., 2007b). 
4.2.3  Phenytoin  
Phenytoin (PHT) is an antiepileptic drug first used in 1937, since then its therapeutic  
spectrum covers a broad range of seizures (Temiz et al., 2009). It acts primarily on 
the neuronal cell membrane sodium channel, limiting the spread of seizure activity 
and reducing seizure propagation (Kwan et al., 2001; Tunnicliff, 1996). Like other 
AEDs PHT also affects the developing conceptus resulting in mental deficiencies, 
skeletal, CVS and nervous system malformations both in human and animal models 
(Okruhlicová et al., 2003; Temiz et al., 2009). Due to the well documented PHT 
teratogenic effects in humans and animal models it is placed in FDA pregnancy 
FDWHJRU\³'´(Ozolins et al., 1995). 
In utero exposure of PHT has two to three fold increased risk of producing congenital 
malformaWLRQV ZLWK D FKDUDFWHULVWLF FRQVWHOODWLRQ RI DQRPDOLHV WHUPHG DV ³)HWDO
+\GDQWRLQ 6\QGURPH´ (Ozolins et al., 1995; Tiboni et al., 2003). This syndrome 
exhibits facial and skull abnormalities, such as short nose, low nasal bridge, 
epicanthic folds, hypertelorism, abnormal ears, wide mouth, hypoplasia of distal 
phalanges and nails, finger like thumbs, short or webbed neck, low hairline, and 
abnormalities of growth and of mental and sometimes of motor development 
(Ornoy, 2006; Tiboni et al., 2003). This specific syndrome is observed in 10% of 
children born to PHT treated mothers. PHT use during pregnancy may also cause 
increased neuroectodermal tumors in the offspring (Ornoy, 2006). At low doses 
(0.1mg closely resembles human therapeutic dose) in chick, PHT does not induce 
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NTDs, while at high doses (0.5mg) they are observed (Temiz et al., 2009). Despite 
numerous reports the exact teratogenic mechanism and dose remains elusive. Many 
hypotheses have been put forward to explain the phenytoin mechanism of 
teratogenicity, including inhibition of detoxification enzymes, embryonic oxidative 
stress, glucocorticoid receptor interactions, inhibition of folate absorption and 
inhibition of prostaglandin production (Temiz et al., 2009). Like other AEDs PHT also 
affects folate levels and produces NTD in the fetus, while folic acid supplements 
prevent these effects. (Ozolins et al., 1995; Temiz et al., 2009). Other notable 
mechanisms include production of the toxic arene oxide intermediates via enzymatic 
bioactivation by embryonic cytochrome P450. Arene oxides are highly reactive and 
can initiate the formation of reactive oxygen species, which at least in part is 
responsible for producing embryopathies (Ozolins et al., 1995; Winn & Wells, 1996).  
PHT treatment affects membrane permeability and interferes with membrane 
transport of calcium ions, which changes membrane properties and could lead to 
alterations in cell-cell interactions. This explains why Phenytoin, more than 
Phenobarbitone and Valproate caused disaggregation of neuronal cell clusters 
resulting in cell death (Sedowofia & Clayton, 1985). On embryonic heart the adverse 
pharmacological actions on ion channels induces cardiac arrhythmias, cardiac 
arrests, and transient episodes of hypoxia (Azarbayjani et al., 2006; Okruhlicová et 
al., 2003). Beside these side effects it also alters vitamin D metabolism and inhibits 
calcium absorption resulting osteomalacia with hypocalcaemia (Ozolins et al., 1995). 
PHT teratogenic effects are observed to different degrees in mice, rat, chicken and 
human. In addition to species variability there are remarkable strain differences in 
susceptibility to PHT teratogenesis (Ozolins et al., 1995).  
4.2.4 Primidone 
7KHDQWLHSLOHSWLFGUXJ3ULPLGRQH350EHORQJVWRWKH)'$SUHJQDQF\FDWHJRU\³'´
PRM was initially considered as a drug of choice in pregnant epileptic women, but 
later on this was refuted (McElhatton et al., 1977). The exact anticonvulsant 
mechanism of action is not clearly understood, but is thought to inhibit high 
frequency repetitive firing action potential by interacting with sodium channels 
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(Macdonald & Kelly, 1995). It is often prescribed with Phenobarbital as an adjunct 
therapy. PRM is metabolized to two active compounds in the body, Phenobarbital 
and Phenylethylmalonamine. The latter has 20% of the antiepileptic potency of 
Phenobarbital and is less neurotoxic (Pizzi et al., 1996). PRM is not a barbiturate but 
its anticonvulsant properties are believed to be the result of its metabolite 
phenobarbital, because of its similar behavioural effects to phenobarbital (Pizzi et al., 
1998). The PRM produced congenital malformations are dose independent, because 
even at non-toxic doses (25±150 mg/kg) it produces teratogenic effects (McElhatton 
et al., 1977). The most commonly observed malformations with PRM are palatal 
defects, which include full length clefts (2.4%), submucosal clefts (9-17%) and 
abnormally shaped palatal bones, with ossification of bones and epithelial fusions. No 
skeletal defects are seen in PRM treated mice. On the other hand the PRM metabolite 
Phenobarbital when given alone produces skeletal defects (McElhatton et al., 1977). 
PRM like other AEDs affects folic acid metabolism. The altered folic acid level may 
increases risk of DNA damage. PRM chronic exposure results in carcinoma (NTP, 
2000; Ronemus et al., 1996). 
4.2.5 Folic acid  
Folic Acid (FA), is a water soluble B-complex Vitamin (van Gelder et al., 2010). 
Humans cannot synthesize FA, so they depend on dietary sources. The daily 
recommended dose for child bearing age women is 400µg per day, and up to 4mg 
per day for the mothers with a history of producing NTD children (Ornoy, 2009; 
Tamura & Picciano, 2006). In the body, folate is reduced by dihydrofolate reductase 
to the naturally bioactive form tetrahydrofolate, which is then converted into 5-
methyltetrahydrofolate (5-MTHF). 5-MTHF enters the cells and acts as an essential 
co-enzyme being the donor or acceptor of one carbon unit, especially in nucleic acid 
metabolism and in DNA methylation (van Gelder et al., 2010). Most AEDs impair 
folate absorption or metabolism thereby interfering with the supply of nucleic acid 
precursors in rapidly dividing cells and the control of gene expression by DNA 
methylation (van Gelder et al., 2010). Decreased folic acid levels results in 
decreased conversion of homocysteine into methionine; elevated homocysteine 
     
71 
 
causes alteration in trans-sulphuration pathways, which results in increased ROS 
production. Increased homocysteine levels during pregnancy were found to produce 
malformation (Green, 2002; Rosenquist et al., 1996). Folate deficiency causes 
various congenital malformations, growth retardation and intrauterine deaths (van 
Gelder et al., 2010). It is widely accepted that the use of FA during pregnancy 
reduces the risk of malformations, especially NTDs and hearts defects (Green, 
2002). 
4.2.6 Reactive oxygen species and antioxidants 
Reactive oxygen species (ROS) are highly reactive oxygen-containing molecules with 
unpaired valence shell electrons (Cengiz et al., 2000). ROS are produced as a 
natural by-product of oxidative metabolism and have important roles in cell 
signalling and homeostasis (Devasagayam et al., 2004). ROS is a second messenger 
in the signal transduction mechanism and plays an important role in cardiomyocyte 
differentiation (Sauer et al., 2000; van Gelder et al., 2010). However, increased 
ROS production may cause oxidative stress. These excessive ROS, if not detoxified, 
can interfere with the normal process of development and produce teratogenesis by 
binding to macromolecules (lipids, proteins, DNA and RNA), or by dysregulation of 
signal transduction (Cengiz et al., 2000; van Gelder et al., 2010; Wells et al., 2009). 
In cells, antioxidants provide the defence mechanism to detoxify these species 
(Peng et al., 2005), but the imbalance between ROS production and antioxidant 
defence mechanisms may cause embryopathy (Lee et al., 2004). A number of 
xenobiotics within the embryo are enzymatically bioactivated to highly reactive 
electrophilic or free radical intermediates. If electrophilic reactive intermediates not 
detoxified they may covalently bind with embryonic macromolecules or free radical 
intermediates may reacts directly or indirectly with molecular oxygen to initiate the 
formation of reactive oxygen species which may induce oxidative stress. The 
increased ROS may interfere with embryonic signal transduction pathways and may 
adversely affect development (Wells et al., 2005). It is hypothesized that during 
pregnancy the mother utilizes Vitamin C, E and antioxidant enzymes (like SOD, 
catalase and glutathione peroxidase) to provide a defence mechanism against ROS. 
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Ascorbic acid (AA) or vitamin C is a water soluble vitamin. It acts as an antioxidant 
by counteracting several hydroxy radicals in the cell cytosol and may contribute in 
protecting the fetus from free radical damage (Cem Ekmekcioglu et al., 2010; Lee et 
al., 2004). While on the other hand through the Fenton reaction it reduces Fe3+ to 
Fe2+, which is involved in free radical formation (Cem Ekmekcioglu et al., 2010). AA 
also promotes cardiomyocyte differentiation, unlike other antioxidants (Takahashi et 
al., 2003). Superoxide dismutase (SOD) is the major superoxide anion antioxidant 
enzyme present in the cell. It catalyses superoxide anion conversion into hydrogen 
peroxide (Cengiz et al., 2000), which in turn is reduced to water by enzymes 
catalase and glutathione peroxidase (Jauniaux et al., 2004). 
 
 
 
Fig 4.1 Biochemical pathways for xenobiotics metabolism to free radical 
intermediates and detoxification by antioxidants. PHS=prostaglandin H synthase,  
LPO=lipoxygenase, P450=cytochrome P450, SOD=superoxide dismutase, 
O¯2=superoxide anion, H2O2=hydrogen peroxide, Fe=iron, HO¯=hydroxyl anion, 
GSH=Glutahione, GSSG=Glutathione disulphide, G-6-P=Glucose 6 phosphate (Wells 
et al., 2009). 
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4.3 Methodology 
4.3.1 Materials and Methods 
Four antiepileptic drugs at 8 different concentrations were exposed to the chick 
embryonic cardiomyocyte cultured at a very high density using the micromass 
system (see section 2.4.1). While the same concentrations of drugs were exposed to 
ES cell derived cardiomyocyte for a period of 12 days (see section 2.4.2). 
4.3.2 Test chemical dose preparation 
The water soluble Sodium valproate stock solution was prepared by dissolving in 
complete culture medium, while for Carbamazepine and Primidone DMSO was used 
as a solvent to dissolve the drug first followed by preparation of stock solution in 
complete culture medium (see section 2.6). For Phenytoin the 45% w/v 2-
hydroxypropyl-ǃ-cyclodextrin was used as a solubilizing agent, which is found to be 
non-toxic (Pitha & Pitha, 1985). The final concentration of DMSO and cyclodextrin 
was kept constant for all doses including control. The FA, AA and SOD doses were 
prepared in complete culture medium either alone or in combination with CBZ. 
4.3.3 End Points 
In MM and ESDC, contractile activity was used as a marker for the estimation of the 
extent of the drug effects on cardiomyocytes, while cell viability and total protein 
content were also investigated at the end of experiments (see section 2.5). 
4.3.4 Statistical analysis 
The results three independent repeats were statistically analysed using Prism 5 
software. All the drugs doses results were compared with control using one way 
$129$ ZLWK 'XQQHW¶V SRVW KRF WHVW 3 ZDV FRQVLGHUHG DV D VLJQLILFDQW
difference. 
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4.4 Results  
4.4.1  Sodium valproate 
4.4.1.1 Sodium valproate effects on cardiomyocytes in the Micromass 
system 
The Valproic acid (VPA) salt sodium valproate at a concentration ranging from 5-
800µM was tested in the MM system. The cardiomyocytes after drug exposure 
showed decreased ability to re-establish the contractile unit. A VPA dose of 100-
800µM inhibited the contractile activity to statistically significant values (P<0.05) at 
48 and 144h of cell culture (fig 4.2A). The Resazurin cell viability assay and Kenacid 
blue total protein content showed no signs of significant variations from the control 
(fig 4.2B and C). The drug treated cardiomyocytes at 144h of cell culture showed no 
large spaces between the foci, the proliferation was uniform and the numbers of 
floating cells were comparable to control. 
4.4.1.2 Sodium valproate effects on ES derived cardiomyocytes 
The same doses of VPA were used to treat the ESDC. The contractile activity of 
cardiomyocytes compared to control declined with increase in drug dose (fig 4.2D). 
A significant declining trend was observed when cardiomyocytes began to contract 
on day 10 of the experiment. The drug dose 100-800µM showed a statistically 
significant difference from control (P<0.05) on day 10, 11 and 12 of scoring (fig 
4.2D). The other end point of cell viability (fig 4.2E) also followed the same pattern 
of decreased resorufin production with increased drug dose exposure. The drug dose 
100-800µM showed some significantly decreased cell viability (P<0.05) compared to 
control. The total cellular protein content remained the same as the control (fig 4.2F) 
DWDOOGRVHVWHVWHG$W0WKHGD\DQG(%¶VZHUHVOLJKWO\UHGXFHGLQVL]H, with 
some dead floating cells on day 12 of the experiment. 
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Fig 4.2 The effects of VPA on MM and ESDC systems. A) Effects on contractile activity 
in MM system, B) effects on cell viability (resazurin assay) in MM system, C) effects on 
total protein content (kenacid blue assay) in MM system, D) effects on contractile 
activity in ESDC, E) effects on cell viability (resazurin assay) in ESDC, F) effects on total 
protein content (kenacid blue assay) in ESDC. * represents a significant difference from 
control. (C=Control).  
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4.4.2 Carbamazepine 
4.4.2.1 Carbamazepine effects on cardiomyocytes in micromass system 
In the MM system, after 24h, cultured contracting chick cardiomyocytes were treated 
with 8 different concentrations of CBZ ranging from serum therapeutic concentration 
to 10-15 times higher. CBZ effects on differentiated cardiomyocyte contractile 
activity in the therapeutic range (50µM) was not significantly different from the 
control, but as the drug dose increased inhibitory effects on contractile activity were 
evident. 200-400µM CBZ showed a statistically significant decrease in contraction 
compared to control especially at 144h of incubation (P<0.05) (fig 4.3A). The chick 
cardiomyocyte viability remained unaffected at all doses tested, using the Resazurin 
cell viability assay (fig 4. 3B), while the total protein content (fig 4.3C) also did not 
showed any significant pattern of variation from the control (P>0.05).  
4.4.2.2 Carbamazepine effects on ES derived Cardiomyocytes  
With ES derived cardiomyocytes CBZ (1-400µM) decreased the cardiomyocyte 
differentiation with increased dose. Contractile activity was inhibited within the 
serum therapeutic range (50µM P<0.05), which further declined and completely 
ceased at 200µM CBZ (fig 4.3D). The cell viability assay (fig 4.3E) clearly showed a 
pattern of significantly decreased viability from the control with increased dose (50-
400µM P<0.05). The effects on cellular Protein Content (Kenacid Blue Assay) were 
obvious as early as day 3 of the experiment, when the size of EBs decreased with 
increased in CBZ treatment dose (fig. 4.4A). On Day 12 of ES differentiation, 
cardiomyocytes also showed the same pattern of decreased Cellular Protein Content 
(50-400µM P<0.05) (fig 4.3F). 
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Fig 4.3 The effects of CBZ on MM and ESDC systems. A) Effects on contractile activity 
in MM system, B) effects on cell viability (resazurin assay) in MM system, C) effects on 
total protein content (kenacid blue assay) in MM system, D) effects on contractile 
activity in ESDC, E) effects on cell viability (resazurin assay) in ESDC, F) effects on total 
protein content (kenacid blue assay) in ESDC. * represents a significant difference from 
control. (C=Control). 
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4.4.2.3 Effects of CBZ on the size of EBs in ESDC 
The treatment of CBZ 100-400µM reduced the size of EBs, after hanging drop on day 
3 the size of EBs decreased as the drug dose increased. At 400µM EBs size reduced 
to less than half compared to Control, but still the EBs cells looked viable, containing 
less dark areas (necrotic cells) and few floating cells in the medium (fig 4.3A). On 
day five, there was not much effect on the size of EBs with 100 and 200µM CBZ, but 
EBs showed increased necrotic areas and floating cells in the medium. With 400µM 
&%= (%¶V RQ GD\ ILYH RI GLIIHUHQWLDWLRQ ZHUH IXUWKHU UHGXFHG LQ VL]H (%V EHFDPH
irregular in shape, with the number of dark areas and floating cells in the medium 
also increased (fig 4.3B). 
 
Fig 4.4A The effects of 100µM, 200µM, 400µM CBZ and untreated group (Control) 
on the size of EBs on Day 3 of ESDC system observed using the light microscopy 
(magnification ×25). 
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Fig 4.4B The effects of 100µM, 200µM, 400µM CBZ and untreated group (Control) 
on the size of EBs on Day 5 of ESDC system observed using the light microscopy 
(magnification ×25). 
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4.4.3 Phenytoin 
4.4.3.1 Phenytoin effects on cardiomyocytes in the Micromass system 
The third anticonvulsant molecule Phenytoin was used to treat the cultured chick 
embryonic cardiomyocytes in MM system at a dose ranging from 1-200µM. These 
doses did not show any specific trend of cytotoxicity. The conversion of resazurin to 
resorufin an indicator of cellular viability does not vary significantly in drug treated 
groups compared to control (fig 4.5B). The GUXJ¶VHIIHFWVRQSURWHLQFRQWHQWZKLFK
indicate cellular proliferation and total cell number also does not significantly alter 
after drug treatment compared to control (fig 4. 5C). PHT inhibitory effects on 
contractile activity at therapeutic concentrations were not significantly different from 
control compared to the higher doses at 200µM (P<0.05) (fig 4.5A). 
4.4.3.2 Phenytoin effects on ES derived cardiomyocytes 
When the drug Phenytoin concentration 1-200µM was applied to ESDC, the 
cardiomyocyte viability showed no specific declining trend with increased in drug 
dose. Only at 200µM Phenytoin dose some statistically significant decreased values 
from control was observed (fig 4.5E). The cellular protein showed no significant 
variation from control even at the highest dose tested (fig 4.5F). However the 
contractile activity of differentiating cardiomyocytes looked dose dependent. It 
decreased with increased in drug dose. The time of incubation does not show any 
significant drop in the values. 50-200µM of PHT showed statistically significant 
inhibitory effects on cardiomyocyte ability to contract at day 10, 11 and 12 of 
differentiation (fig 4.5D). The size of PHT treated EBs does not vary markedly 
compared to control. The cells looked healthy with less number of dark areas and 
floating cells. 
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Fig 4.5 The effects of PHT on MM and ESDC systems. A) Effects on contractile activity 
in  MM system, B) effects on cell viability (resazurin assay) in MM system, C) effects on 
total protein content (kenacid blue assay) in MM system, D) effects on contractile 
activity in ESDC, E) effects on cell viability (resazurin assay) in ESDC, F) effects on total 
protein content (kenacid blue assay) in ESDC. * represents a significant difference from 
control. (C=Control).  
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4.4.4 Primidone 
4.4.4.1 Primidone effects on cardiomyocytes in the Micromass system 
The fourth anticonvulsant drug Primidone effects on contractile activity were more 
pronounced in chronic exposure compared to acute at higher doses in the MM 
system (fig 4.6A). The drug dose 5-800µM inhibited cardiomyocyte contraction in a 
dose and time dependent manner. The drug dose at 48h (24h post drug incubation) 
does not inhibit the contractile activity significantly (except at 800µM). At 144h of 
cell culture, PRM 200-800µM reduces the cardiomyocyte contraction rate to less than 
half compared to control (P<0.05). The other two end points for PRM cytotoxicity 
estimation of cell viability and cellular protein do not exhibit any trend of significant 
variation from control (fig 4.6B and C). 
4.4.4.2 Primidone effects on ES derived cardiomyocytes 
The Primidone toxicity when tested using ES cell differentiation into cardiomyocytes 
showed no sign of cardiotoxicity on cardiomyocytes viability (fig 4.6E) or in cellular 
protein content (fig 4.6F). The drug treated group from 1-800µM showed no specific 
pattern of variation in resazurin assay or kenacid blue assay (fig 4.6E and F), but the 
cardiomyocyte contractile activity was inhibited with increase in drug dose. The 
decrease was not greatly different between the drug in dose in serum therapeutic 
levels and at 800µM. The drug dose 25-800µM showed some significantly decreased 
values when compared statistically with control (fig 4.6D). 
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Fig 4.6 The effects of PRM on MM and ESDC systems. A) Effects on contractile 
activity in MM system, B) effects on cell viability (resazurin assay) in MM system, C) 
effects on total protein content (kenacid blue assay) in MM system, D) effects on 
contractile activity in ESDC, E) effects on cell viability (resazurin assay) in ESDC, F) 
effects on total protein content (kenacid blue assay) in ESDC. * represents a 
significant difference from control. (C=Control). 
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4.4.5 FA and AA supplements effects on Carbamazepine toxicity 
4.4.5.1 Evaluation of non-toxic doses of FA and AA  
The potential protective effects of FA and AA were evaluated on 200 and 400µM 
CBZ induced toxic effects in the MM and ESDC systems. Using ES cells different 
doses of FA and AA were applied to differentiating stem cells to find out the non-
toxic dose. 50-500µM of both chemicals showed no signs of significant inhibition of 
cardiomyocyte viability or total protein content (fig 4.7B, C, E and F). Contractile 
activity in the 100µM AA treated group was found to be more vigorous compared to 
an increased dose, while the 100µM FA treated group showed no signs of inhibitory 
effects on contraction as compared to 250 and 500µM (fig 4.7A and D). For the MM 
system the same doses of FA (1mM) and AA (100µM) were applied for protective 
effects as were used by Memon et al., 2009. 
4.4.5.2 Effects of FA and AA supplements on Carbamazepine toxicity in MM 
system 
In MM the chick cardiomyocytes were treated with 200 and 400µM of CBZ in the 
presence of non-toxic doses of either FA 1mM or AA 100µM. No significant 
improvement in contractile activity was recorded after FA and AA addition (Fig 4.8A 
and 4.9A). The effects of FA and AA with 200 and 400µM CBZ on cardiomyocytes 
viability (fig 4.8B and 4.9B) and total cellular protein contents (fig 4.8C and 4.9C) 
did not deviate from CBZ alone. 
4.4.5.3 Effects of FA and AA supplements on Carbamazepine toxicity in 
ESDC 
When the ES Cells were treated with 400µM CBZ in the presence of either 100µM FA 
or 100µM AA the differentiating stem cells showed no significant improvement in 
any end point (Fig 4.9A, B, C), some improvement in the size of EBs was observed 
with cells treated either with FA or AA (Fig 4.11). For the lower dose of CBZ 200µM, 
an improvement in AA treated group was observed; the cardiomyocytes were 
differentiated and formed beating foci compared to the drug treated group (Fig. 
4.8D). The cell viability and protein content also improved with improvement in EBs 
size, while co administration of FA with 200 µM CBZ showed no signs of contraction 
or improvement in protein content, while cell viability improved (Fig.4.8E and F). 
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Fig 4.7 Effects of FA and AA on ESDC system. A) effects of FA on contractile activity 
in ESDC, B) effects of FA on cell viability (resazurin assay) in ESDC, C) effects of FA 
on total protein content (kenacid blue assay) in ESDC, D) effects of AA on contractile 
activity in ESDC, E) effects of AA on cell viability (resazurin assay) in ESDC, F) 
effects of AA on total protein content (kenacid blue assay) in ESDC. * represents a 
significant difference from control. (C=Control). 
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Fig 4.8 The protective effects of FA and AA on CBZ 200µM in MM and ESDC 
systems. A) protective effects on contractile activity in the MM system, B) protective 
effects on cells viability (resazurin assay) in MM system, C) protective effects on 
total protein content (kenacid blue assay) in MM system, D) protective effects on 
contractile activity in ESDC, E) protective effects on cells viability (resazurin assay) 
in ESDC, F) protective effects on total protein content (kenacid blue assay) in ESDC. 
* represents a significant difference from control (C=Control). 
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Fig 4.9 The protective effects of FA and AA on CBZ 400µM in MM and ESDC 
systems. A) Protective effects on contractile activity in the MM system, B) protective 
effects on cells viability (resazurin assay) in MM system, C) protective effects on 
total protein contents (kenacid blue assay) in MM system, D) protective effects on 
contractile activity in ESDC, E) protective effects on cell viability (resazurin assay) in 
ESDC, F) protective effects on total protein content (kenacid blue assay) in ESDC. * 
represents a significant difference from control. (C=Control).   
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4.4.6 Effects of Superoxide dismutase (SOD) supplements on 
Carbamazepine toxicity in MM and ESDC systems 
In order to confirm the protective effects of AA on CBZ cytotoxicity was due to its 
action as an antioxidant, the antioxidant enzyme superoxide dismutase (2µM) 
(Memon & Pratten, 2009) was added to CBZ treated groups in both systems. In MM 
the contractile activity (fig. 4.10A) improved at all doses of CBZ and reached near to 
control, even the 400µM CBZ showed a significant improvement, while cell viability 
and protein content remained unaffected (fig 4.10B, C). In ESDC there was not 
much change in the contractile activity of cardiomyocytes, the cell viability improved 
compared to drug treated groups (fig 4.10D and E). The protein content remained 
significantly low (fig 4.10F), but the size of EBs improved with SOD treatment (fig 
4.11). 
4.4.7 Effects of FA, AA and SOD supplements on the size of Carbamazepin 
treated EBs in ESDC systems 
When the FA or AA was added with CBZ the size of EBs improved. Day 3 EBs showed 
improved EB size especially with AA treated groups. The 400µM CBZ treated group 
showed the improved EB size with AA treatment, as with the other antioxidant (SOD) 
treated groups, while with FA the improvement was marginal (fig 4.11A). When these 
EBs were further cultured for two days in the presence of drugs with or without FA and 
AA, the 200µM group continued to grow in size and the number of dead and floating 
cells decreased. But at 400µM the size decreased and the floating and dead cells could 
be easily seen. With SOD the size of EBs improved compared to the drug treated 
groups (fig 4.11B). 
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Fig 4.10 Protective effects of SOD on CBZ toxicity in MM and ESDC systems. A) 
Protective effects on contractile activity in the MM system, B)  protective effects on cells 
viability (resazurin assay) in MM system, C) protective effects on total protein content 
(kenacid blue assay) in MM system, D) protective effects on contractile activity in 
ESDC, E) protective effects on cells viability (resazurin assay) in ESDC, F) protective 
effects on total protein content (kenacid blue assay) in ESDC. * represents the 
significant difference from control. (C=Control). 
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Fig 4.11A The protective effects of FA, AA and SOD on 200 µM, 400 µM CBZ and 
untreated group (Control) on the size of EBs at Day 3 of ESDC observed using the 
light microscopy (magnification ×25). 
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Fig 4.11B The protective effects of FA, AA and SOD on 200 µM, 400 µM CBZ and 
untreated group (Control) on the size of EBs at Day 5 of ESDC observed using the 
light microscopy (magnification ×25). 
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4.4.8 Effects on ROS production with drug treatment in MM and ESDC 
system 
4.4.8.1 Effects of VPA on ROS production in MM and ESDC system 
When Valproic acid was used to treat the 24h cultured chick cardiomyocytes in MM 
system, some increase in ROS production was observed. The increase in dose from 
400 and 800µM VPA did not produced a big difference in ROS production (fig 4.12A). 
When the results were compared with control the increase was insignificant, while 
the positive control hydrogen peroxide (10µM) increased the ROS production to 
significant levels (P<0.05). In ESDC the H2O2 proved to be a positive control again 
with increased ROS values (P<0.05). Compared to MM, VPA in ESDC showed 
increased ROS production. The VPA dose 800µM showed a statistically significant 
increase compared to the control at 2 and 4 h of treatment (fig 4.12B). 
4.4.8.2 Effects of CBZ on ROS production in MM and ESDC system 
The CBZ effects in MM system were not different from VPA at the doses tested. The 
micromass system failed to show an increase in ROS production after 200 and 
400µM treatment compared to control (fig 4.13A). The ES derived cardiomyocytes 
showed some significant increase with both doses. The 200 and 400µM drug showed 
significant ROS production compared to control, which became more evident with 
the time of incubation (fig 4.13B).  
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Fig 4.12 Effects of VPA ROS production in MM and ESDC system. A) Effects of VPA 
on ROS production in MM system and B) effects of VPA on ROS production in ESDC 
system. * represents the significant difference from control. 
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Fig 4.13 Effects of CBZ on ROS production in MM and ESDC system. A) Effects of 
CBZ on ROS production in MM system and B) effects of VPA on ROS production in 
ESDC system. * represents the significant difference from control. 
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4.4.8.3 Effects of AA and SOD supplements on CBZ ROS production  
In the micromass system the addition of AA showed no improved contractile activity 
for this reason the SOD protective effects on CBZ was only evaluated. As there was 
no significant ROS increase with CBZ addition in MM system, the addition of SOD 
with CBZ in MM system did not alter the ROS levels (fig 4.14B). In ESDC AA was 
found to be associated with decreased ROS production, the values were lower than 
control. When the AA was used with CBZ 200 and 400µM in ESDC, it showed 
protective effects on ROS production compared to drug alone (fig 4.14A). With the 
other antioxidant SOD in ESDC systems a decrease in ROS production was observed 
and protective effects were also evident on CBZ doses (fig 4.14C).   
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Fig 4.14 Protective effects of AA and SOD on CBZ ROS production in MM and ESDC 
system. A) Protective effects of AA on CBZ ROS production in ESDC system,          
B) protective effects of SOD on CBZ ROS production in MM system, C) protective 
effects of SOD on CBZ ROS production in ESDC system. * represents the significant 
difference from control. 
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4.5 Discussion 
Neurological disorders like epilepsy may have profound effects on fetal development. 
The use of AEDs during pregnancy reduces the seizure frequency, while untreated 
seizures may directly or indirectly put the life of the mother and fetus at risk (Fried 
et al., 2004). Most AEDs are teratogenic, their use during pregnancy elevates the 
occurrence and severity of congenital defects (Ornoy, 2009). It is now widely 
accepted that the combination of seizure disorders and AED use during pregnancy 
increases the incidence of dysmorphological characteristics in the new born (Adams 
et al., 1990). AED exposed children exhibit some common malformations like facial 
dysmorphism, NTD, cognitive and behavioural defects (Ornoy, 2009). There seems 
to be some common mechanism between most of the AEDs. Investigation over the 
years have found that the AED teratogenic mechanism shows some similarities. For 
example most of the AEDs interrupt folic acid absorption or inhibit its metabolism. 
Folic acid deficiency and its relationship to congenital defects is well known (van 
Gelder et al., 2010). AED induced NTD are prevented by folic acid supplements 
although the exact pathogenesis is still unclear (Dawson et al., 2006; Green, 2002). 
Another proposed mechanism is that of highly reactive intermediate metabolites 
produced with most of the AEDs. These intermediates if not detoxified may lead to 
the formation of reactive oxygen species and in turn may cause oxidative damage 
(Cengiz et al., 2000; van Gelder et al., 2010; Wells et al., 2009). Also, for VPA and 
CBZ, inhibition of HDAC cannot be ruled out (Beutler et al., 2005). Histone acetyl 
transferases (HATs) loosen and HDAC compacts chromatin structure and regulates 
gene expression. HDACs repress transcription and are involved in cell cycle 
regulation, proliferation and differentiation (Karamboulas et al., 2006). The HDAC 
inhibitors interrupt the cell cycle and induce growth arrest and apoptosis (Ornoy, 
2009). 
In this study sodium valproate was used as a reference drug because of its known 
effects in both the systems (Ahir & Pratten, 2011). VPA has been used for many 
years for its anticonvulsant and mood stabilizing properties (Gurvich & Klein, 2002). 
In the past few decades its therapeutic profile has enormously extended with a new 
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addition of anticancer effects due to its HDAC inhibition properties (Gotfryd et al., 
2011). In utero exposure to VPA in humans results in neural, craniofacial, 
cardiovascular and skeletal malformation (Bennett et al., 2000). These malformation 
significantly increase during first trimester administration of the drug (Gurvich & 
Klein, 2002).  
VPA effects on the contractile activity of chick cardiomyocytes in vitro and 
cardiomyocytes derived from stem cells do not show a big variation when the doses 
were compared. The effects observed in both the systems were comparable with 
previous studies (Ahir & Pratten, 2011; Murabe et al., 2007a). VPA at 800µM is a 
KLJKGRVHFRPSDUHGWRWKHGUXJ¶VVHUXPWKHUDSHXWLFOHYHOVEXWGXHWRWKHSUHVHQFH
of high levels of VPA in umbilical cord this dose may correspond to the embryo/fetal 
in vivo effects (Ornoy, 2009). The mechanism of teratogenicity by HDAC inhibition 
(Blaheta & Cinatl, 2002) does not seem to be the case in the MM system, because 
the cardiomyocytes viability and proliferation remains unaffected, while the inhibition 
of HDAC results in altered cell proliferation and induction of apoptosis  
(Chateauvieux et al., 2010; Gurvich et al., 2004). VPA through HDAC inhibition also 
triggers DNA demethylation which inhibits maintenance of cell cycle (Chateauvieux 
et al., 2010). Cell cycle arrest in G1 phase has already been observed with VPA 
derivatives in other cell lines (Gotfryd et al., 2011). This kind of inhibitory effect was 
observed with ESDC, where decreased differentiation into contracting 
cardiomyocytes and cell viability was observed. Murabe in 2007b using R1 ES cell 
line has already proved that VPA inhibits mesodermal differentiation of embryonic 
stem cells. In another study it was observed that VPA at high doses inhibits ES cells 
differentiation into cardiomyocytes as a result of oxidative damage (Na et al., 2003). 
The highly reactive epoxide intermediate produced during bioactivation may trigger 
the formation of free radical species, which affects normal development by binding 
to various macromolecules (Defoort et al., 2006). When the reactive oxygen species 
production is compared in the two systems the MM cardiomyocytes do not seem to 
increase ROS production to significantly high levels after VPA treatment, while with 
EBs the ROS levels were found to be significantly increased compared to control. 
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This may because the cardiomyocytes in MM system were differentiated and have 
acquired the detoxifying mechanism against oxidative stress, while the EBs cells, 
which correspond to very early embryonic developmental stages have low levels of 
cellular antioxidants that neutralize ROS produced (Defoort et al., 2006). The MM 
system may behave differently with ROS production if the drug dose was increased 
to high levels which would not be therapeutically relevant. The effects on contractile 
activity may be the result of disturbances in establishing the contractile system 
either by gap junctions or some other mechanism. Beside these, VPA also disturbs 
the FA cycle (Chateauvieux et al., 2010) along with a number of signalling molecules 
that may affect cell differentiation (Gurvich et al., 2004). Folic acid supplements, 
free radical scavengers and antioxidant enzymes were found to counteract VPA-
induced teratogenic effects (Defoort et al., 2006; Na et al., 2003; Ornoy, 2009; 
Zhang et al., 2010).  
Pregnant epileptic women on CBZ therapy may have a normal outcome, because 
they may be less susceptible to CBZ teratogenicity either by altered epoxide 
hydrolase enzyme levels or polymorphisms in folate metabolism associated genes 
(Nicolai et al., 2008; van Gelder et al., 2010), but generally a higher rate of 
cardiovascular malformations and NTDs are experienced with CBZ treated mothers 
compared to control groups (Hansen et al., 1996; Murabe et al., 2007b). The 
teratogenic mechanisms of CBZ can be either by inhibition of FA absorption (van 
Gelder et al., 2010), epoxide intermediates (Lindhout et al., 1984), HDAC inhibition 
(Beutler et al., 2005) or increased free radical production. As it is believed that the 
in vitro system lacks drug metabolising systems, the extent of epoxide intermediate 
production is unknown. HDAC inhibitory effects are already established, as with 
valproic acid (Beutler et al., 2005; Murabe et al., 2007b). The remaining two 
mechanism of teratogenicity were counteracted in this study by direct addition of FA 
and AA or the antioxidant enzyme superoxide dismutase to cardiomyocytes in 
culture. 
CBZ at 200µM-400µM caused statistically significant inhibitory effects on 
cardiomyocyte contractile activity in primary culture. The results clearly show that 
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the drug does not inhibit cardiomyocyte proliferation nor cause growth arrest at 
higher doses, but only interferes with the process that involves the cardiomyocytes 
re-establishing the beating process. In ESDC, at higher doses, CBZ inhibitory effects 
were observed for all end points. Beating was completely stopped at 200µM, which 
LQGLFDWHV WKH GUXJ¶V WHUDWRJHQLF HIIHFWV RQ FDUGLRP\RF\WH GLIIHUHQWLDWLRQ DW KLJKHU
doses. The CBZ IC50 value for cell viability (0.31mM) observed by Murabe in ESDC 
using the R1 cell line is well below that observed here (Murabe et al., 2007b). The 
antiproliferative activity of CBZ increased with increased dose. According to Peres 
Martin, at higher doses (400µM), CBZ arrests cell division from metaphase to 
anaphase, by forming monopolar spindles and impaired centrosome separation 
(Perez Martin et al., 2008). These results were consistent with the findings of 
decreased cell number by total protein content estimation and reduced EBs size, 
which indicated decreased cell division. The other mechanism of toxicity could be 
oxidation of DNA by hydroxyl free radicals to form 8-oxoguanine, which is involved in 
producing mutation and teratogenesis (Wells et al., 2009). It may be that CBZ use 
before the start of organogenesis is more toxic to cardiogenesis than its use at the 
later stages of gestation. The HDAC inhibitory effects of CBZ cannot be ruled out in 
case of ESDC due to decreased cell proliferation (Karamboulas et al., 2006).  
FA and AA were used in an attempt to counteract the embryotoxic effects of CBZ at 
200-400µM. In MM, the addition of FA and AA showed no signs of improvement in 
the contractile ability of the cardiomyocytes. This could be because homocysteine is 
not involved in the inhibitory mechanism or these molecules were not sufficient to 
prevent damage to the contractile activity mechanism. Alternatively, it may involve 
some other pathways or some disturbance in gap junction communications. 
However, the addition of SOD in MM improved the contractile ability of the 
cardiomyocytes even in the CBZ 400µM treated group. This may suggest that 
superoxide free radicals produced by oxidative stress were involved in the inhibitory 
mechanism of contraction and these were detoxified by SOD, or the increased 
production of peroxide by SOD promotes cardiogenesis (Crespo et al., 2010) or 
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increases Ca2+ release, which ultimately led to increased contractile activity (Xi et al., 
1999).  
FA (100µM) and AA (100µM) addition to the CBZ treated groups in ESDC showed a 
different result compared to MM system. The stem cells, especially when treated 
with AA, showed very fast beating foci compared to control, which totally supports 
the idea that AA addition could increase cardiogenesis in vitro. This, on the other 
hand, deviates from the previously reported antioxidant inhibitory effects on 
cardiogenesis (Takahashi et al., 2003). AA acts as pro-oxidant in the presence of 
transition metals, AA increases the levels of peroxides which is found to be 
cardiogenic in stem cells differentiation (Crespo et al., 2010). The addition of the 
DQWLR[LGDQW$$ WR WKH0&%= WUHDWHG JURXS¶V LQGXFHG FRQWUDFWLOH DFWLYLW\ DQG
improved cell viability, protein content and size of EBs. In the 400µM CBZ treated 
groups there was not much improvement compared to control and it may be that the 
AA antioxidant effect, or induction of cardiogenesis, was not sufficient to reverse the 
growth arrest of cardiomyocytes. The addition of SOD to CBZ groups showed no 
improvement signs in contractile activity but the cell viability and the size of EBs 
improved on day 3 and 5 of treatment. In both the case of MM and ESDC the 
production of peroxide was critical for the initiation of cardiogenesis signalling or 
induction of contractile activity either by direct conversion of superoxide anions by 
SOD or the increased production of peroxide by some extrinsic factors like Ascorbic 
acid (fig 4.14). FA in ESDC showed some protective effects on cell viability and 
protein content, especially with CBZ 200µM treated group. The CBZ impairment of 
FA transfer inside the rapidly dividing cells might have affected their growth. 
When the reactive oxygen species production was measured in both the systems, 
the CBZ treated chick cardiomyocytes showed no significant increase. However, the 
increase ROS observed in ESDC with CBZ treatment indicates that ROS production is 
the mechanism that inhibits cardiogenesis and induces teratogenesis. As stated 
earlier the early stage cells exhibit low levels of antioxidant enzymes and a weak 
defence system (Defoort et al., 2006; van Gelder et al., 2010), which was not 
sufficient in the case of ESDC to neutralize the excessive ROS produced. In the case 
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of ESDC the ROS production in the presence of AA was below the control level, but 
the AA treated ESDC contracts with full pace at all days of scoring (fig 4.8D and 
4.9D). With ESDC AA showed protective effects on CBZ produced ROS which was 
evident with the results observed after ES differentiation. The CBZ 200µM treated 
ESDC were rescued by AA antioxidant effects, while the ROS level after AA treatment 
did not look different in either dose. It may be that CBZ 400µM along with ROS 
production also induces growth arrest from metaphase to anaphase, by forming 
monopolar spindles and impaired centrosome separation (Perez Martin et al., 2008). 
The difference in effects of AA in the MM system may be due to different stages of 
development or the low level of H2O2 produced has a role in cardiogenesis induction. 
As it is observed that undifferentiated ES cell do not sense ROS production 
mechanism even with H2O2 (data not shown here). In MM system the SOD protected 
WKH GUXJ¶V HIIHFWV RQ FRQWUDFWLOH DFWLYLW\ WKDWPLJKW EH LWV HIIHFWV RQ GHWR[LILFDWLRQ
DQG FRQYHUVLRQ RI VXSHUR[LGH¶V LQWR SHUR[LGHV ZKLFK LQGLUHFWO\ protects the other 
mechanism interfering contractile activity. But in ESDC SOD failed to recover lost 
contractile compare to AA which has cardiogenic induction properties.  
Putting it together it is concluded that CBZ teratogenic effects are dose and 
developmental stage dependent. The CBZ teratogenic mechanism is mainly due to 
induction of oxidative stress through increased ROS production in both the systems. 
The ESDC were affected directly by high levels of ROS production while low levels of 
ROS increase might have affected gap junctional communication or some other 
mechanism indirectly in MM system. This indicates that inhibition of cardiogenesis at 
low doses involves a mechanism that can be improved by production of peroxide by 
the addition of AA, but for the induction of contractile activity in MM the 
detoxification of the superoxide anion is important. The antioxidant enzyme SOD can 
rescue the later stage oxidative stress, which might be because of the differentiated 
FHOOV¶ DELOLW\ WR UHVSRQG62'HIIHFWs. The AA induced cardiomyocyte differentiation 
does not depend on its antioxidant properties solely but its ability to promote cardiac 
differentiation through peroxide mediated pathways which cannot protect growth 
arrest at higher doses.  
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Fig 4.14 Biochemical pathways for carbamazepine metabolism to free radical 
intermediates and detoxification by antioxidants. PHS=prostaglandin H synthase,  
LPO=lipoxygenase, P450=cytochrome P450, SOD=superoxide dismutase, 
O¯2=superoxide anion, H2O2=hydrogen peroxide, Fe=iron, HO¯=hydroxyl anion, 
(modified from wells et al (Wells et al., 2009)). 
 
The third anticonvulsant molecule tested in this study was a hydantoin derivative 
(Tiboni et al., 2003), the diphenylhydantoin or commonly known as phenytoin. PHT 
has been used as an antiepileptic drug nearly for half a century (Temiz et al., 2009). 
The drug mainly acts by affecting sodium depolarization (Tunnicliff, 1996). Previous 
studies confirmed the structural and behavioural teratogenic properties of PHT in 
both human and animals. Like other AEDs, PHT also crosses the placenta and 
produces the specific fetal hydantoin syndrome (Tiboni et al., 2003). Phenytoin 
affects the developing heart at a sensitive stage by inducing hypoxia/ischemia, 
which relates to PHT induced teratogenic effects (Okruhlicová et al., 2003). 
PHT in both the systems inhibited the cardiomyocytes contractile activity. In the MM 
system the same effects were observed at 4 times higher dose compared to the 
ESDC system. Earlier studies confirm PHT dose-dependent induced bradycardia and 
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arrhythmias in the mouse (Danielsson et al., 1997). Danielson in 2007 also reported 
that PHT caused irregular embryonic heart rhythm by blocking special K+ channels at 
100µM and above. Therefore, it may be hypothesized that PHT inhibits the 
contractile activity by blocking the potassium channel (IKr) in the ESDC and chick 
heart MM culture system (Danielsson et al., 2007). 
The PHT toxic mechanism is mainly attributed to its reactive intermediate metabolite 
production and folic acid inhibition (Ozolins et al., 1995; Temiz et al., 2009; Winn & 
Wells, 1996). If the electrophilic arene oxide intermediates are not detoxified by 
epoxide hydrolase or by glutathione S-transferases they may lead to the formation 
of ROS thereby initiating teratogenesis (Ozolins et al., 1995). The epoxide can be 
bioactive-reactive chemically with nucleophilic centres in nucleic acid (DNA, RNA), 
lipids, or proteins-resulting in a variety of toxic effects including necrosis, 
mutagenesis, carcinogenesis, or teratogenesis. Formation of a trans-dihydrodiol by 
microsomal epoxide hydrolase catalysed hydrolysis of an electrophilic epoxide may 
deactivate the metabolite and decrease the risk of cellular damage (Hartsfield et al., 
1995). When the highly reactive arene oxide intermediates are detoxified the 
oxidative balance is not disturbed and cells function normally. But there are some 
reports of receptor-mediated effects of unmetabolized phenytoin (Ozolins et al., 
1995). Several studies confirm increased ROS production by PHT through the 
production of intermediate metabolites which are responsible for initiating 
teratogenesis (Parman et al., 1998). The in vitro system lacks the drug bioactivation 
system which results in no production of arene oxide intermediates but studies 
confirm the increased ROS production with PHT treatment in the in vitro system 
(Abramov & Wells, 2011; Gallagher & Sheehy, 2001; Parman et al., 1998). The 
effects on cardiac development may be the result of increased ROS production, 
which impairs macromolecules like proteins and DNA by irreversible binding (Parman 
et al., 1998). In this study the PHT effects on cell viability and protein content 
observed in the MM and ESDC system were not very different from control. The 
ESDC with 200µM dose showed some reduced cell viability and some insignificant 
trend of reduced cell proliferation. These altered effects were expected at high doses 
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(Okruhlicová et al., 2003) but in differentiated cells of MM system the PHT at these 
high doses failed to produce toxic effects on cell viability and proliferation. Some in 
vitro studies confirm these results of reduced ES differentiation into cardiomyocytes 
without affecting cell activity (zur Nieden et al., 2001). Using the CHO cell line Winn 
observed no significant effects on cell viability at 240µM but the effects became 
significant at 800µM and inversely increased oxidation of DNA (Winn et al., 2003). 
The other proposed mechanism of folic acid inhibition of intestinal absorption by PHT 
(Ariel et al., 1982) would not be relevant in the in vitro system. This is confirmed by 
the use of FA with PHT resulting in no change to the protective effects or 
enhancement in teratogenicity (Azarbayjani et al., 2006). 
The species and strain differences with PHT induced teratogenesis is mainly the 
results of different enzyme levels which detoxifies the toxic intermediates 
(Danielsson et al., 2007). The possibly of multiple teratogenic mechanisms in case of 
PHT, which depends on gestational age, tissue type and drug dose (Ozolins et al., 
1995), seems likely. The extent of the embryotoxic effect of PHT at similar doses in 
vivo and in vitro was not comparable, which may be explained by differences in 
exposure characteristics (Beekhuijzen et al., 2000)  
The fourth anticonvulsant molecule in this study was primidone. In the body it is 
metabolized to PEMA and phenobarbital. The phenobarbital is thought to be 
responsible for its activity (Pizzi et al., 1998). In both systems PRM inhibited 
contractile activity. The inhibition in contractile activity observed in MM system was 
very much dependent on the time of exposure with the drug dose. The contractile 
activity at 200-800µM PRM, which is a very high dose, showed the same values of 
contractile activity at 144h of cell culture. This means the dose increase after 200µM 
showed the same toxic effects on chronic exposures. But in vivo studies showed 
toxic effects even at non-toxic doses (McElhattn et al., 1977) which is not observed 
in case of MM system. When the effect on contractile activity was recorded in ESDC 
the results were dose dependent the contractile activity drops down with increased 
dose. But the inhibitory effects were observed at very low doses compares to MM 
system. The contractile activity inhibition results in ESDC resemble in vivo toxic 
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doses (McElhattn et al., 1977). The viability and cell proliferation remain unaltered in 
both systems. The common mechanism for most AEDs of folic acid interference and 
ROS production (van Gelder et al., 2010) might be not be responsible for the 
contractile activity inhibition. Since folic acid inhibition affects cell proliferation, 
which does not show any trend in either the system. Nor does oxidative stress look 
to be a likely candidate for cell viability and proliferation effects. Maybe the low 
levels of ROS produced disturb the oxidative balance after prolonged exposure and 
affects cell contractile activity by some molecular mechanism or disturbance in gap 
junction communication. As stated earlier in the in vivo system PRM effects are 
mainly due to its metabolite phenobarbital (Pizzi et al., 1998) but here in the in vitro 
system there is no PRM bioactivation, so the results are effects of PRM itself. The 
PRM compound itself showed anticonvulsant effects, while its metabolite 
phenobarbital along with anticonvulsant effects showed decreased cardiomyocytes 
contractile activity in MM and ESDC systems (Ahir, 2009). 
The complexity of epilepsy and AEDs induced teratogenic effects remains 
unresolved. From the results observed in study it can be concluded that antiepileptic 
drugs affect the cardiomyocyte differentiation at an early stage more pronouncedly 
compared to late developmental stage cells. The potential teratogenic mechanism 
differs between drugs but mostly involves disturbance in cellular oxidative state or 
FA acid pathway. These toxic mechanisms can be counteracted by adding protective 
molecules to the culture system. 
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Chapter 5 
Evaluation and comparison of antidepressant 
teratogenic effects in chick cardiomyocyte 
micromass system and embryonic stem cell 
derived cardiomyocyte 
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5.1 Depression and Antidepressants in Gestation 
Statistically, women have a higher life time risk of developing major depression (10-
25%), with a peak prevalence during childbearing age (Alwan et al., 2007; Bonari et 
al., 2004a). 1 in 5 pregnant women experience depression but fewer are treated 
(Bonari et al., 2004b). Major depression significantly increases the morbidity rate in 
mothers and shows adverse effects on the developing fetus (Bellantuono et al., 
2007). The fetuses and neonates of depressed mothers differ biochemically, 
physiologically and behaviourally (Field et al., 2004). These psychopathologic 
symptoms during pregnancy may have physiological effects on the developing fetus 
LQGLUHFWO\ E\ WKH PRWKHU¶V DEQRUPDOO\ GHSUHVVHG EHKDYLRXU FDXVLQJ DQ LQFUHDsed 
consumption of cigarettes and alcohol during pregnancy or even a suicide attempt 
(Bonari et al., 2004b). These may confound the pregnancy outcome. Untreated 
maternal depression may lead to spontaneous abortions, low birth weight, small 
head circumference, increased uterine resistance, low Apgar score, preterm delivery, 
neonatal retardation and high cholesterol levels in the new born, as well as 
hypertension and preeclampsia in the pregnant woman (Bonari et al., 2004a; Bonari 
et al., 2004b; Field et al., 2004). The use of antidepressants (ADP) is necessary to 
avoid these maternal and fetal life complications due to depression. Investigations 
over the last several decades on the use of ADPs during the first trimester of 
pregnancy suggest the absence of major congenital malformation risk, but the 
Swedish medical registry data concluded that Paroxetine (a SSRI) use increases 
major congenital malformation incidence 1.5 to 2 fold (Cohen et al., 2006). ADP use 
during pregnancy may cause pre-term delivery. The use of tricyclic ADPs may cause 
a reduction in limb size (Ericson et al., 1999). Increased cardiovascular defects were 
found in new born whose mothers were treated with ADPs during pregnancy, the 
malformation differing with the type of ADP used. Strongest effects on the 
cardiovascular system were on ventricular and atrial septa. Other random effects on 
the cardiovascular system include hypoplastic left heart or aortic atresia, 
transposition of large vessels, tetralogy of Fallot and abnormal pulmonary vein 
return (Kallen et al., 2006). 
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5.1.1 Bupropion 
Bupropion is an aminoketone class drug, chemically and structurally unrelated to 
classical ADPs. It was first marketed as an oral antidepressant agent in the mid 
¶V WKHQ UHPRYHG IURP WKHPDUNHWGXH WRVHL]XUHVLGHHIIHFWV ,Q LWZDV
reintroduced at a low dose with necessary contraindications and precautions (Alwan 
et al., 2010; Shepherd et al., 2004). Bupropion shows antidepressant properties and 
is used as non-nicotinic aid in smoking cessation (Alwan et al., 2010; Chun-Fai-Chan 
et al., 2005; Cole et al., 2007)7KHGUXJ¶VSKDUPDFRORJLFDODFWLYLW\ LVSULPDULO\E\
strong inhibition of dopamine reuptake and nicotinic receptor antagonist activity, as 
well as a weak blockage of norepinephrine and serotonin reuptake (Shepherd et al., 
2004; Slemmer et al., 2000). The mechanism of the ability of bupropion to help the 
patient abstain from smoking remains unknown, but appears to be pharmacologically 
mediated by its effects on the noradrenergic and dopaminergic systems (Chun-Fai-
Chan et al., 2005). These indirect sympathomimetic effects might be explained by 
the close resemblance of its molecular structure with phenylethylamine (Cremers et 
al., 2003).  
Bupropion is extensively metabolized in the body, mainly into 4-hydroxybupropion. 
4-hydroxybupropion blood levels are ten times higher than peak levels of the parent 
drug, and this is thought to be involved in WKHGUXJ¶VWR[LFHIIHFWV(Cremers et al., 
2003; Shepherd et al., 2004). The therapeutic blood plasma level for bupropion 
ranges from 10-100ng/ml, while for seizures, a plasma concentration above 
170ng/ml was found (Hill et al., 2007). The major adverse effects of bupropion 
resemble those of amphetamines, with some conduction disturbances (Cremers et 
al., 2003). Like cocaine it exerts biphasic effects on myocardial contractile activity; 
the positive inotropic effect is mediated by catecholamine release due to its indirect 
sympathomimetic properties, while these effects are reversed (negative inotropic) 
ZKHQFDUGLDFǃ-adrenoceptors are EORFNHG7KHODWWHUPD\EHWKHUHVXOWRIWKHGUXJ¶V
toxic effects, or like cocaine it may block calcium release and influx (Cremers et al., 
2003). 
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Presently there are no control studies concerning bupropion safety in pregnancy 
(Chun-Fai-Chan et al., 2005). The results do not provide a clear picture of its 
teratogenic profile. Studies in animals show no signs of teratogenicity with bupropion 
use, nor is it found to be involved in increasing congenital malformations above the 
normal. Only increased abortion rates were found in bupropion treated mothers 
(Chun-Fai-Chan et al., 2005), but Cole et al, 2007 have observed that in rabbits it 
slightly increased malformations and skeletal abnormalities, with decreased fetal 
weight. The GSk pregnancy registry data shows 2.5% major malformations, most 
with cardiovascular defects, from bupropion use in humans (Cole et al., 2007). A 
statistically significant number of congenital heart defects were observed in infants 
with bupropion maternal exposure, specially increased cases of left outflow tract 
defects (Alwan et al., 2010). For these uncertain effects of bupropion and the lack of 
control studies during pregnancy, the United States Food and Drug Administration 
)'$SODFHGEXSURSLRQLQWKHSUHJQDQF\FDWHJRU\³&´(Cole et al., 2007).  
5.1.2 Lithium carbonate 
Lithium carbonate (Li2CO3) is widely prescribed for the treatment of acute manic 
depression (Gralla & McIlhenny, 1972). During the last few decades, the clinical 
profile for Li2CO3 has extended beyond manic depression, to also include 
management of alcoholic patients (Messiha, 1986). The serum therapeutic 
concentration of Lithium in humans ranges from 0.6-1.2mM (Ikonomov et al., 2000), 
with a small therapeutic to toxic ratio (0.7), which on chronic exposure, even at 
therapeutic doses, produces malformations (Giles & Bannigan, 1997). In humans 
Li2CO3 crosses the placenta (Nokhbatolfoghahai & Parivar, 2008) and perturbs 
normal development (Klein & Melton, 1996). Earlier investigations show lithium use 
during pregnancy reduces litter size, and causes infertility in males by inhibition of 
testicular glycolysis and reduced spermatozoa motility. Since the discovery that 
lithium salts produce embryos with profound exgastrulation in sea urchins, it became 
evident that lithium may induce morphological deviations in primitive development 
(Gralla & McIlhenny, 1972). At serum therapeutic levels lithium is shown to induce 
FDUGLRYDVFXODU PDOIRUPDWLRQV VSHFLDOO\ WKH (EVWHLQ¶V DQRPDO\ GLVWXUEDQFH LQ
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embryonic vascular development, yolk sac vessels vascular stasis and vascular 
dilation in the cranial region of the embryo. These effects were reversed by 
treatment with myo-inositol (Giles & Bannigan, 1999). Treatment of mouse embryos 
with lithium at the neurulation stage causes discrete ruptures in certain cranial blood 
vessels (Giles & Bannigan, 1999). In Xenopus embryos, lithium treatment induces 
the formation of a second dorsal axis, but these teratogenic effects were reported to 
be preventable by a co-injection of myo-inositol (Hedgepeth et al., 1997). Lithium 
affects DNA by competing with Mg2+ in binding and may impair DNA synthesis and 
repair (Léonard & Gerber, 1997). Lithium also enhances granulopoiesis and thereby 
induces neutrophilia (Barr & Galbraith, 1983; Nokhbatolfoghahai & Parivar, 2008).  
Therapeutic and teratogenic mechanisms of Li2CO3 remain to be fully elucidated. 
However, its interference with the phosphatidylinositol (PI) cycle is thought to be the 
major factor in mood stabilizing and in teratogenic properties (Giles & Bannigan, 
1999; Klug et al., 1992; Segal, 2004). More recently the toxic mechanism for lithium 
has been associated with inactivation of glycogen synthase kinase-ǃ *6.-ǃ
which mimics the canonical Wnt signalling pathway (Ikonomov et al., 2000; 
Manisastry et al., 2006; Martin et al., 2011).  
In the phosphatidylinositol cycle, phospholipase C (activated by G protein receptors) 
metabolizes the plasma membrane phosphatidylinositol into two second messengers, 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 regulates the release 
of Ca2+ from the non-mitochondrial pool (mostly ER). The Ca2+ activates the calcium 
and calmodulin dependent kinases and promotes extracellular Ca2+ influx, While DAG 
activates PKC (De Jonge et al., 1995; Papaleo et al., 2009; Segal, 2004). The IP3 is 
then dephosphorylated by a number of steps; finally inositol monophosphate is 
hydrolysed into free inositol by the enzyme inositol monophosphatase (IMPase). The 
free inositol is recycled back for the regeneration of phosphatidylinositol (Klug et al., 
1992). In the cardiovascular system IP3 plays a key role in vascular smooth muscle 
mechanical coupling, thereby regulating peripheral resistance and blood pressure. In 
the developing heart IP3 initiates the pacemaker activity, promotes cardiogenesis 
and regulates cardiomyocyte contraction by promoting calcium release and influx 
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(Kockskämper et al., 2008). Inhibition of the PI cycle affects early developmental 
events, especially the development of the heart and vessel formation (Giles & 
Bannigan, 1999; Kockskämper et al., 2008; Méry et al., 2005).  
 
Fig 5.1 PI cycle and effects of lithium on IMPase inhibition. Phospholipase C (PLC), 
phosphosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), inositol 1,4,5 
triphospahte (InsP3), diacyl glycerol (DAG), inositol monophosphatase (IMPase), 
phosphatidylinositol (PI). Modified from Conway (Conway & Miller, 2007). 
Lithium targets the enzymes IMPase in the PI cycle (King et al., 2010; Segal, 2004), 
thereby inhibiting the formation of free inositol. Inositol depletion consequently 
results in failure of PI to reconstitute at the cell membrane (Giles & Bannigan, 1999). 
When exogenous inositol is not readily available, the cells do not respond to PI 
dependent extracellular signal transduction. IP3 production is reduced and the 
regulation of Ca2+ is affected (Giles & Bannigan, 1999; King et al., 2010). These 
effects can be negated by the addition of myo-inositol (Klug et al., 1992).  
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In another mechanism of teratogenicity, lithium mimics Wnt signalling and produces 
a hyperdorsalized embryo (Klein & Melton, 1996). Wnt signalling has an important 
role in development, axis formation, cancer, stem cell biology and neural function. 
Wnt inactivates GSK3-ǃZKLFKUHVXOWVLQǃ-FDWHQLQFHOOXODUDFFXPXODWLRQ,QWXUQǃ-
catenin forms a transcriptional enhancer complex and upregulates expression of 
selected target genes (Eisenberg & Eisenberg, 2007; Martin et al., 2011). In the 
absence of  Wnt signals, GSK3-ǃ SKRVSKRU\ODWHV ǃ-catenin leading to its 
ubiquitination and proteosomal degradation (Eisenberg & Eisenberg, 2007). Lithium 
mimics the Wnt pathway by inhibiting phosphorylation of GSK-ǃ UHVXOWLQJ LQ ǃ-
catenin accumulation in the cell (Manisastry et al., 2006). Wnt signalling inhibits 
early cardiac specification and the proper orchestration of cardiac development by 
acting via its major transducer ǃ-catenin (Eldad, 2007; Manisastry et al., 2006).  
 
 
 
A)     B)  C) 
 
 
 
 
      Degradation     
Fig 5.2 :QWǃ-Catenin Pathway. A) TKH SKRVSKRU\ODWLRQ RI ǃ-catenin by GSK3-ǃ
OHDGV WR ǃ-catenin degradation. B) and C) the inactivation of GSK3-ǃ E\:QW DQG
Li2CO3, ZKLFKDOORZVǃ-catenin accumulation in the cells and entry into the nucleus.  
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5.1.2.1 Myo-inositol 
Myo-inositol belongs to the vitamin B complex group. It is one of the nine possible 
stereoisomers of C6 sugar alcohol (Papaleo et al., 2009). Humans consume 1g of 
inositol per day (Papaleo et al., 2009). Myo-inositol is fairly ubiquitous, and is 
extensively studied, particularly myo-inositol containing phospholipids in biological 
membranes. It has an essential role in cell growth, cell morphogenesis, lipid 
synthesis, cell membrane structure and especially phosphatidylinositol (PtdIns) 
signal transduction which controls diverse cell processes including proliferation 
(Holub, 1986; Papaleo et al., 2009). Providing the requisite amount of inositol to 
continue PtdIns signalling in the cells can reverse the lithium effects (Giles & 
Bannigan, 1999; Klug et al., 1992).  
 
5.2 Methodology 
5.2.1 Materials and Methods 
The materials utilized are discussed in detail in appendix 1. The antidepressant drugs 
bupropion hydrochloride and lithium carbonate at various doses were investigated 
for toxic effects in the chick embryonic cardiomyocyte micromass (see section 2.4.1) 
and ESDC systems (see section 2.4.2). 
5.2.2 Preparation of test chemicals 
Both bupropion HCl and lithium carbonate are water soluble, thus their stock 
solutions were prepared using the culture medium. The lithium carbonate doses with 
myo-inositol (water soluble) were prepared in complete culture medium using the 
stock solutions. 
5.2.3 End points 
The cardiomyocyte contractile activity at pre and post drug exposure were recorded 
in the MM system, while in ESDC it was recorded on day10, 11 and 12 of 
differentiation (see section 2.5.1). The cell viability (resazurin assay) (see section 
2.5.2) and total protein content (kenacid blue assay) (see section 2.5.3) were 
measured at the end of the culture period. 
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5.2.4 Statistical analysis 
The results of three independent repeats were statistically analysed using Prism 5 
software. All the drugs doses results were compared with control using one way 
$129$ZLWK'XQQHW¶V SRVW KRF WHVW )RU QRQ-parametric scoring the Kruskal wallis 
test was used. P<0.05 was considered as a significant difference.  
5.3 Results 
5.3.1 Bupropion hydrochloride 
5.3.1.1 Bupropion effects on cardiomyocytes in the Micromass system 
The first antidepressant molecule bupropion when tested in the MM system, showed 
more pronounced cytotoxic effects on cardiomyocytes, compared to the known 
anticonvulsant teratogens tested. Cardiomyocyte contractile activity declined with 
increase in drug dose. The length of exposure did not seem to significantly vary the 
results (fig 5.3A), except for BPN 75µM. This showed some chronic exposure 
inhibitory effects compared to 100 and 200µM. BPN 200µM dose at 144h of MM, 
significantly reduced the contractile activity compared to control (P<0.05). The cell 
viability estimation using resazurin assay followed the same inhibitory trend with 
increased dose. The BPN dose 50-200µM significantly (P<0.05) decreased 
cardiomyocyte viability compared to control (fig 5.3B). The total protein content also 
decreased with increase in drug dose (fig 5.3C), 25-200µM drug dose showed 
significant inhibitory effects (P<0.05). The cultured cardiomyocytes do not resemble 
the control at high doses tested. Increased floating cells and decreased proliferation 
were observed compared to the control. The foci size decreases and the spaces 
between the contracting foci increases with increased dose, especially observed at 
BPN 200µM (fig 5.4). To find out if the effects on cell viability were either a direct 
effect of the drug or due to decreased cellular number, the ratio of cell viability to 
total protein was calculated, which suggests the effects on cell viability might be the 
result of decreased proliferation rather than a direct effect of BPN on cell viability (fig 
5.4F). 
 
     
116 
 
5.3.1.2 Bupropion effects on ES derived cardiomyocytes 
When the ESDC were treated with bupropion, the drug showed inhibitory effects on 
differentiated cardiomyocyte contractile activity. The declining trend started at 5µM 
and continued up to the highest dose used (200µM). The scoring recorded on day 
10, 11 and 12 did not show a big variation except 75µM, which became significant 
on day11 and 12 (P<0.05). The BPN dose 100 and 200µM continued to significantly 
differ from the control on all days (P<0.05) (fig 5.3D). The other end point of cell 
viability showed some variation but not a particular trend. Even the BPN 200µM 
failed to differ significantly from control (P>0.05) (fig 5.3E). The cellular protein 
content was reduced with increased BPN dose. The drug dose from 50µM showed 
decreased protein, with significant values at 75-200µM (P<0.05) (fig 5.3F). The EBs 
resemble the control when observed under the microscope. Unlike MM, cellular 
proliferation was even with no void spaces between contracting foci, but EB 
proliferation to spread on the surface after attachment looked slightly reduced in size 
compared to control.  
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Fig 5.3 The effects of BPN on MM and ESDC systems. A) Effects of BPN on contractile 
activity in MM system, B) effects of BPN on cell viability (resazurin assay) in MM 
system, C) effects of BPN on total protein content (kenacid blue assay) in MM system, 
D) effects of BPN on contractile activity in ESDC, E) effects of BPN on cell viability 
(resazurin assay) in ESDC, F) effects of BPN on total protein content (kenacid blue 
assay) in ESDC. * represents a significant difference from control (C=Control). 
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Fig 5.4 Effects of control and BPN doses on cardiomyocytes proliferation in MM 
system. Fig 5.4F Ratio of cell viability to cell numbers (total protein) in BPN treated 
cardiomyocytes using MM system. 
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5.3.2 Lithium carbonate 
5.3.2.1 Lithium carbonate effects on cardiomyocytes in the Micromass  
            system  
Lithium carbonate, when at a concentration ranging from 50-2000µM in the MM 
system, showed no significant inhibitory signs on cell viability and total cellular 
protein content (fig 5.5B and C). The cardiomyocyte contractile activity remained 
unaffected at low doses tested. At higher doses 1200-2000µM some decrease in 
contractile activity was observed which was not statistically significant (fig 5.5A). 
The drug exposure for a short period of time and chronic exposure did not affect the 
values to a great extent. The cardiomyocytes looked healthy, well attached and 
formed large beating foci comparable to the control.  
5.3.2.2 Lithium carbonate effects on ES derived cardiomyocytes 
The results with lithium carbonate in ES derived cardiomyocytes were completely 
different from those with MM system. The cardiomyocyte contractile activity started 
to decreases below the therapeutic serum levels (>0.6mM) of drug and became 
significant at around 800µM on all scoring days recorded. The drug dose 1500µM 
showed no cell contraction at all, only some dull beating was observed at day 10 in 
very few repeats. The increased dose of 2000µM caused the contractile activity in 
(6'& WR FHDVH FRPSOHWHO\ ILJ ' 7KH GUXJ¶V HIIHFWV RQ FHOO YLDELOLW\ ZHUH QRW
different to those observed in the MM system (fig 5.5E). The drug showed some 
increased levels of resorufin production but failed to attain significant difference from 
control. But interestingly the total protein contents of ESDC increased with increased 
drug dose (fig 5.5F). The 1500 and 2000µM Li2CO3 increased the cellular protein 
contents to significant levels (P<0.05). At 2000µM the EBs after attachment 
expanded and covered a large area compared to the control.  
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Fig 5.5 The effects of Li2CO3 on MM and ESDC systems. A) Effects of Li2CO3 on 
contractile activity in the MM system, B) effects of Li2CO3 on cell viability (resazurin 
assay) in the MM system, C) effects of Li2CO3 on total protein content (kenacid blue 
assay) in the MM system, D) effects of Li2CO3 on contractile activity in ESDC, E) 
effects of Li2CO3 on cell viability (resazurin assay) in ESDC, F) effects of Li2CO3 on total 
protein content (kenacid blue assay) in ESDC. * represents a significant difference 
from control (C=Control). 
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5.3.3 Evaluation of myo-inositol non-toxic dose in ESDC 
Myo-inositol doses ranging from 100-2000µM were tested on ESDC for evaluation 
and identification of the non-toxic dose. Differentiating cells exposed to this dose 
range did not show any strong cytotoxic effects. The cardiomyocytes continued 
contraction at all doses tested, but the 2000 µM showed some inhibition compared to 
low doses (fig 5.6A). Besides this, for 2000 µM treated cardiomyocytes (fig 5.6B), 
compared to other doses and the control, the viability was relatively low, but failed 
to attain a significant difference (P>0.05). Cellular protein content remained 
unaffected at all doses tested (fig 5.6C). 1000 µM was found to be the highest non-
toxic dose in ESDC.  
5.3.4 Protective effects of myo-inositol on Lithium carbonate treated ESDC 
Attempts were made to counteract the inhibitory effects of lithium carbonate, as 
observed earlier, using myo-inositol 1000µM. The cells were exposed to Li2CO3 doses 
of 800, 1500 and 2000 µM along with myo-inositol. The contractile activity at Li2CO3 
800µM, which previously was reduced to significantly lower score compared to the 
control in ESDC, showed improvement. The contraction was still not identical to the 
control but rose to a level not significantly different. At Li2CO3 1500µM the ESDC 
were not contracting but with the addition of myo-inositol the cells started to 
contract. The contraction was very slow but easily recognisable. However, the 
1500µM Li2CO3 treated cells still showed a significant difference to control (P<0.05). 
With 2000µM Li2CO3 dose no contraction was observed after supplementing the cells 
with myo-inositol (fig 5.6D). The cell viability remained unaffected after myo-inositol 
addition (fig 5.6E). The total protein content dropped down at all doses especially 
with Li2CO3 2000µM, which had shown a significant increase in protein content. After 
myo-inositol addition it reduces and was not significant compared to the control (fig 
5.6F).  
 
 
     
122 
 
Contractile Activity
Myo-Inositol concentration in PM
C
e
ll
 s
c
o
ri
n
g
(
c
o
n
tr
a
c
ti
le
a
c
ti
v
it
y
 o
f 
c
a
rd
io
m
y
o
c
y
te
s
)
C 10
0
50
0
10
00
20
00
 
0
1
2
3
Day10Day11Day12
A) Contractile Activity
C
e
ll
 s
c
o
ri
n
g
(
c
o
n
tr
a
c
ti
le
a
c
ti
v
it
y
 o
f 
c
a
rd
io
m
y
o
c
y
te
s
)
C
Lic
 80
0
Lic
15
00
Lic
20
00
My
o1
00
0
Lic
80
0+
My
o
Lic
15
00
+M
yo
Lic
20
00
+M
yo
0
1
2
3
Day10 Day11 Day12
*
*
D)
Resazurin Assay
C
10
0 50
0
10
00
20
00
0
100
200
300
400
Myo-Inositol concentration in PM
R
e
s
o
ru
fi
n
 p
ro
d
u
c
ti
o
n
 n
g
/
m
l
B) Resazurin Assay
R
e
s
o
ru
fi
n
 p
ro
d
u
c
ti
o
n
 n
g
/
m
l
C
Lic
 80
0
Lic
15
00
Lic
20
00
My
o1
00
0
Lic
80
0+
My
o
Lic
15
00
+M
yo
Lic
20
00
+M
yo
0
200
400
600
E)
Kenacid Blue Assay
Myo-Inositol concentration in PM
P
ro
te
in
 p
ro
d
u
c
ti
o
n
 (
Pg
/
m
l)
C 10
0
50
0
10
00
20
00
 
0
20
40
60
80
100
C) Kenacid Blue Assay
P
ro
te
in
 p
ro
d
u
c
ti
o
n
 (
Pg
/
m
l)
C
Lic
 
80
0
Lic
15
00
Lic
20
00
My
o1
00
0
Lic
80
0+
My
o
Lic
15
00
+M
yo
Lic
20
00
+M
yo
0
20
40
60
80
100
*
F)
Fig 5.6 The effects of myo-inositol and Li2CO3 on ESDC. A) Effects of myo-inositol on 
contractile activity, B) effects of myo-inositol on cell viability (resazurin assay), C) 
effects of myo-inositol on total protein contents (kenacid blue assay), D) protective 
effects of myo-inositol on contractile activity, E) protective effects of myo-inositol on 
cell viability (resazurin assay), F) protective effects of myo-inositol on protein contents 
(kenacid blue assay). * represents a significant difference from control (C=Control). 
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5.3.5 Antidepressant effects on Reactive oxygen species production 
When the antidepressant drugs bupropion hydrochloride and lithium carbonate were 
evaluated for the production of ROS, neither showed any significant effect on ROS 
production in the MM or the ESDC system (fig 5.7 and 5.8). The positive control H2O2 
10µM in both of the systems produced significant ROS levels compared to control.   
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Fig 5.7 Effects of BPN on ROS production. A) BPN effects in MM system, B) BPN 
effects in ESDC. * represents a significant difference from control.  
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Fig 5.8 Effects of Li2CO3 on ROS production. A) Li2CO3 effects in MM system B) 
Li2CO3 effects in ESDC. * represents a significant difference from control.  
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5.3.6 Blind trials  
To make the experimental outcome more reliable and to avoid any biased scoring 
with contractile activity a blind study was performed in both the systems. Toxic, 
moderately toxic and non-toxic drugs doses were selected, primarily on basis of the 
results of contractile activity three repeats as observed earlier. The drugs doses were 
prepared and with the help of colleague the falcon flasks were coded. The MM and 
ESDC experiments were performed as described in chapter 2, using coded drug 
solutions and endpoints were recorded. After the three repeats the doses were 
decoded, analysed and results of this blind study was compared with the results 
observed earlier. For MM system the codes were A=PRM 800µM, B=VPA 400µM, 
C=Li2CO3 2000µM, D=Control and E=BPN 25µM. While for ESDC A=VPA 400µM, 
B=Li2CO3 2000µM, C=PRM 800µM, D=Control and E=BPN 25µM. When the results of 
the MM system blind trials were compared with the previously obtained results, the 
results were comparable. The controls with a beating score of 3, with no significant 
effects with BPN and Li2CO3 treated cells. The VPA and PRM continued to reduce the 
contractile activity in more or less the same fashion. In ESDC Li2CO3 2000µM 
stopped the cells beating, with VPA and PRM showing some significantly decreased 
effects, as observed earlier. The results for cell viability and protein content were 
also comparable. The effects observed on contractile activity in both the systems 
were comparable with no huge difference. The results of this study eliminate the 
fragility of the contractile activity recording procedure due to manual scoring. This 
further supports the study and the validity of system adopted. 
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Fig 5.9 Blind trial study of different drug doses in MM and ESDC systems. A) Effects 
on contractile activity in the MM system, B) effects on cell viability (resazurin assay) 
in MM system, C) effects on total protein content (kenacid blue assay) in MM system, 
D) effects on contractile activity in ESDC, E) effects on cell viability (resazurin assay) 
in ESDC, F) effects on total protein contents (kenacid blue assay) in ESDC.              
* represents a significant difference from control (C=Control). 
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5.4 Discussion 
Depression affects 10-25% of women (Field et al., 2004). Depression in pregnancy 
complicates normal embryonic development, including that of the placenta, as well 
as causing preeclampsia, spontaneous abortions or premature deliveries (Field et al., 
2004). The affected neonates experience elevated fetal activity, growth retardation, 
and altered behavioural, biochemical and physiological states (Field et al., 2004). 
Women being most hit by depression, especially during the child bearing years and 
disturbed hormones level during pregnancy further added a natural elevating factor. 
Prenatal depression increases in the second trimester compared to the first and 
negatively regulates fetal development and pregnancy outcome (Field et al., 2004). 
It may affect pregnancy by influencing the maternal mental state and the 
consumption of substances of abuse during pregnancy and due to depressed 
behaviour may weave a web of complications for prenatal and postnatal 
environments (Bonari et al., 2004b). The use of antidepressants during pregnancy 
confounds the pregnancy outcome. But untreated depression leads to severe 
complications (Bonari et al., 2004a). In this study using in vitro systems ADP effects 
were evaluated with particular reference to cardiac development. 
The first antidepressant molecule bupropion HCl was tested in both the systems. 
This molecule has been used for depression, and most recently as a non-nicotinic aid 
in smoking cessation (Alwan et al., 2010). The antidepressant mode of action is by 
indirectly acting as a sympathomimetic amine, but it can also act with nicotinic 
receptor antagonist activity (Cremers et al., 2003; Shepherd et al., 2004; Slemmer 
et al., 2000). In the body bupropion is principally metabolized by the CYP2B6 
isoenzyme to hydroxybupropion, threohydrobupropion and erythrohydrobupropion. 
Hydroxybupropion is the pharmacologically active metabolite, its plasma levels are 
higher than the parent drug and it is thought to be LQYROYHG LQ WKH GUXJ¶V WR[LF
effects (Cremers et al., 2003; Hesse et al., 2000; Shepherd et al., 2004). A number 
of congenital heart defects were associated with bupropion use during pregnancy, 
especially anatomically malformed hearts, which is not observed with other 
antidepressants like SSRIs (Alwan et al., 2010).  
     
128 
 
The use of the MM and ESDC systems may elucidate the mechanism of suspected 
bupropion toxic effects, for which it comes under FDA pregnancy category C (Cole et 
al., 2007). In the MM system bupropion affects the cardiomyocyte ability to re-
establish the beating system with increasing dose; cardiomyocyte proliferation in 
particular is mostly affected by the drug. The cells divide but their ability to form flat 
sheets with beating foci is suppressed. The foci connect with each other with thin 
longs strands. Contractile activity was present, even at 200µM BPN and the 
synchronised contraction of foci was not decreased drastically by the decreased size 
and connections between the foci. From the results it is observed that bupropion 
with increase in dose affects cells proliferation either by arresting cell division by 
senescence or by inducing apoptosis. Jang et al, 2011 in a study using the human 
neuroblastoma SH-SY5Y cell line confirms the activation of the caspase 3, 8 and 9 
pathways after BPN treatment, with caspase 3 having particularly noticeable 
increased levels compared to the others. The induction of apoptotic pathways might 
have caused reduced cell proliferation. The same cardiomyocytes, when subjected to 
viability testing, showed decreased oxidoreductase levels as the drug dose 
increased. This might be explained as the consequence of decreased proliferation, 
which results in a decreased number of cells. The effects on cell viability were purely 
the result of decreased cell numbers. 
When it comes to bupropion effects on differentiating cardiomyocytes using 
embryonic stem cells, the effects were more pronounced on contraction compared to 
the MM system. The higher doses lower the contractile activity more compared to 
the MM system. The effects may be the result of decreased cell proliferation making 
it impossible to form beating foci, but in ESDC the EBs are plated in 24 well plates, 
not as a single cell suspension like the MM system. The space between foci is 
therefore not so apparent. The EBs have already formed a compact system which 
show toxic effects on cell proliferation or maybe the ES cells do not sense the 
mechanism of bupropion toxicity compared to differentiated MM cardiomyocytes. 
Interestingly in ESDC any effects on cell viability do not decline to significant 
difference levels. The EBs size on day three and five was not very different compared 
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to the control, but when the EBs were plated a slight decrease in expansion was 
observed at the higher BPN doses tested.  
Conduction disturbances, delay and worsening of angina and myocardial infarction 
have already been reported with bupropion use (Cremers et al., 2003). Bupropion 
exerts biphasic effects in human myocardium in a similar way to cocaine. Increased 
contractile activity is not observed with BPN use. The negative inotropic effect at 
higher doses could be by the inhibition of calcium release from sarcoplasmic 
reticulum or calcium influx across the sarcolemma, as with cocaine (Cremers et al., 
2003). This may be the cause of reduced contractile activity in both the systems but 
it requires proper elucidation before making any conclusion. BPN may have effects 
on cellular oxidative state, but when analysed, ROS levels were not altered after 
treating the cardiomyocytes in either system. This is in accordance with the results 
of Jang et al, 2011 using a neuroblastoma cell line (Jang et al., 2011). When 
bupropion treated cells were supplemented with ascorbic acid and superoxide 
dismutase to see the protective effects, no improvement in any end point was found 
in either of the systems (data not shown). There may be some other unidentified 
toxic mechanism or cardiac induction by ascorbic acid may occur (Takahashi et al., 
2003). 
The second antidepressant molecule, lithium carbonate, was tested for teratogenic 
effects, in particular with cardiogenesis. The therapeutic prolife of the lithium ion has 
enormously expanded during the last few decades (Messiha, 1986). The therapeutic 
and toxic effects are mediated either by interference with the PI cycle or GSK3-ǃ
inactivation (Giles & Bannigan, 1999; Ikonomov et al., 2000). Teratogenic effects of 
lithium are well established. It perturbs normal embryonic development in diverse 
organisms, producing a secondary dorsal axis (Hedgepeth et al., 1997) and CVS 
defects (Giles & Bannigan, 1999).  
In this study micromass and ESCD showed stage dependent effects of lithium on 
cardiogenesis. In the MM system, cardiomyocytes are differentiated and have 
already acquired contractile ability before isolation, but anatomically they are still 
under development to orchestrate the heart (Bellairs & Osmond, 1998). However, 
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contractile activity is established before drug addition (Memon & Pratten, 2009). In 
comparison, the ES cells were undifferentiated and have not even acquired or 
expressed lineage commitment (Davila et al., 2004; Friel et al., 2005). The lithium 
dose range used was well below the therapeutic level up to serum toxic levels 
(Ikonomov et al., 2000). In the micromass system any toxic effects were not 
statistically significant. The cardiomyocytes contractile activity does not seem to be 
much affected by a therapeutic dose. This may be because the cells are well 
differentiated and they can withstand lithium carbonate inhibition of IMPase in the PI 
cycle, or the cells have become tolerant to these conditions. The other mechanism of 
toxicity associated with lithium is that of mimicking Wnt pathways (Klein & Melton, 
1996). Wnt controls heart development but is also modulated during adult heart 
remodelling, but Wnt has a limited role in the developed heart compared to during 
organogenesis (Bergmann, 2010). That is perhaps why it did not affect differentiated 
cardiomyocytes in the MM system to any extent. Cell viability and cell proliferation 
was not affected at all, even at toxic doses. It may be that these pathways do not 
trigger a toxic mechanism that inhibits cells division or formation of the contractile 
system in differentiated cardiomyocytes.  
When ES were differentiated to cardiomyocytes in the presence of lithium the results 
were completely different in comparison to the MM system. The ESDC showed a 
decreased contractile activity with increased dose. The effects were observed at 
therapeutically relevant doses. ESDC treated with the serum toxic concentration of 
2000µM had no beating areas. The lithium inhibition of IMPase in the PI cycle 
reduces the production of IP3, which eventually results in decreased Ca
2+ release 
(Hedgepeth et al., 1997) and this might have shown the inhibitory effects on 
contractile activity. Beside calcium being a major ion in cardiomyocyte contractile 
activity, it also has an important role in development and signalling (Whitaker & 
Smith, 2008). IP3 initiates pace maker activity and promotes  cardiogenesis 
(Kockskämper et al., 2008), and lithium reduces the endogenous production of IP3 
(King et al., 2010) which affects the cells¶ ability to initiate the beating mechanism. 
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Lithium treatment in Xenopus decreases cardiac gene and protein expression (Martin 
et al., 2011). 
In ESDC the lithium effects on cell viability remained insignificant compared to 
control, rather like in the MM system, but the total protein content was increased, 
especially with toxic dose treatment. This may be the result of IMPase inhibition by 
lithium, but IMPase inhibitors do not produce embryo dorsalization. Thus the 
inhibition of IMPase was not sufficient for dorsalization of Xenopus embryo 
(Hedgepeth et al., 1997) but could affect the contractile mechanism. Lithium 
activation of Wnt signalling might initiate the mechanism of increased cell 
proliferation, because Wnt is found to be associated with producing hyperdorsalized 
embryos. Myo-inositol could block dorsal axis induction by lithium through a more 
indirect mechanism that is independent of IMPase inhibition. Inhibition of GSK3-ǃ is 
a general mechanism for lithium action. It is difficult to see why co injection of myo-
inositol reverses the effects when this does not affect the Wnt pathway and IP cycle 
and does not produce embryo dorsalization. Depletion of inositol is necessary, but 
not sufficient for the teratogenic effects of lithium. The mechanism of myo-inositol 
rescue is uncertain. There may be some relation between inositol depletion and 
GSK3-ǃ (Hedgepeth et al., 1997). The increased ROS production observed with 
lithium is in accordance with the results observed by Shu-Huei Kao et al at high 
concentration (20mM) using a different cell type (Shu-Huei Kao et al., 2008). 
Addition of myo-inositol reversed the lithium inhibition of contractile activity. There 
is some evidence of myo-inositol and derivatives having antioxidant effects (Jiang et 
al., 2011; Rao et al., 1991), but ROS production in this study was not significantly 
different to the control. This might be different at high doses of lithium carbonate. 
It can be concluded that bupropion effects may be mediated through activation of 
apoptotic pathways, while effects on contractile activity could be the results of the 
GUXJ¶V QHJDWLYH LQRWURSLF Hffects at toxic doses. The formation of EBs due to 
gravitational force using the hanging drop method might make the cells behave 
differently compared to some other methods of EB formation. It would be interesting 
to see how these cells come together to form EBs in the presence of BPN using some 
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other method for differentiation into cardiomyocytes. While the lithium effects were 
the results of PI cycle inhibition and GSK3-ǃ LQDFWLYDWLRQ DV H[SHFWHG $GGLWLRQ RI
myo-inositol to the cells compensates for the depleted inositol. If the PI cycle 
continues, IP3 is formed, which promotes cardiogenesis and pace maker initiation of 
contractile activity. This rescue was observed in ESDC. From the results it can be 
concluded that lithium carbonate effects on ESDC contractile activity are due to 
IMPase inhibition of the PI cycle, which plays a pivotal role in ES derived 
cardiogenesis and pacemaker induction unlike that which is observed in the 
differentiated cardiomyocytes of the MM system. While the increased protein content 
might be attributed to lithium, Wnt pathway activation shows cardiac stage 
dependent effects (Bergmann, 2010).  
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Chapter 06 
Effects of the active constituents of the herbal 
DQWLGHSUHVVDQW6W-RKQ¶V:RUWRQFKLFN
cardiomyocyte in the micromass system 
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6.1 Depression, herbal medicines and pregnancy 
Depression is a commonly prevailing mental disorder in our society (Morelli, 2003). 
Many women of child bearing age, especially between 25 and 44 years of age suffer 
from major depression. The estimated life time risk during pregnancy of these 
psychopathological symptoms may vary between 10-25%. Untreated depression 
during pregnancy may have direct physiological effects on the developing fetus, or 
indirectly by the abnormally depressed behaviour of the mother (Bonari et al., 
2004a). The possible side effects of synthetic antidepressant drugs directed the need 
for alternative medicines. The use of herbal medicines may provide the solution for 
this problem (Rodríguez-Landa & Contreras, 2003). Herbal medicines are officially 
classified as dietary supplements and are readily available (Klepser et al., 2000). It 
is a general belief that herbal medicines are harmless, although statistical data do 
not confirm this (Kober et al., 2008). The use of herbal medicines in expectant 
mothers varies from 7-55%. The pregnant woman often fails to appreciate the 
chemicals in herbal medicines may have the power to trigger abnormal 
embryonic/fetal development through toxic mechanisms. The lack of adequate safety 
data for the use of natural medicines during pregnancy, mostly because of the 
number of pharmacologically active compounds present, further affects safety 
precautions (Denise, 2003). 
6.2 Hypericum Perforatum 6W-RKQ¶V:RUW 
+\SHULFXPSHUIRUDWXPFRPPRQO\NQRZQDV6W -RKQ¶V:RUW 6-: LVD WRSVHOOLQJ
over the counter herbal antidepressant drug (Chan et al., 2001; Wurglics & 
Schubert-Zsilavecz, 2006). SJW has been used for nearly 2000 years to treat 
diarrhoea, wound healing, urine and bladder problems and mostly frequently for mild 
to moderate depression (da Conceição et al., 2010; Walker et al., 2002; Wurglics & 
Schubert-Zsilavecz, 2006). It was the Swiss physician Paracelsus (ca. 1493-1541) 
who first used it to treat depression (Dugoua et al., 2006). The SJW extract contains 
a number of pharmacologically active constituents including flavonoids, 
napthodianthrones, phloroglucinol, proanthocyanidins, xanthones, and essential oils 
(Hostanska et al., 2003; Wurglics & Schubert-Zsilavecz, 2006). However, with the 
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presence of a number of pharmacologically active compounds, the idea of one plant, 
one active compound and one mechanism seems incorrect. It is more like that 
multiple active compounds contribute in a more complex antidepressant mechanism 
(Butterweck & Schmidt, 2007). SJW is found to be a more effective antidepressant 
than placebo, while its effects are comparable to synthetic tricyclic antidepressants 
and selective serotonin reuptake inhibitors (SSRIs) (Hammerness et al., 2003; Kober 
et al., 2008). The antidepressant effects of SJW were previously attributed to 
phloroglucinol, napthodianthrones and several flavonoids by MAO inhibition, but in 
vitro studies suggested these effects are achieved only at very high concentrations, 
which cannot be achieved by the recommended 300mg dose of SJW (Butterweck & 
Schmidt, 2007). The antidepressant effects are more likely the result of the 
inhibition of a number of neurotransmitters, especially involving serotonin reuptake 
(Denise, 2003; Moretti et al., 2009). 
The SJW extract, beside its therapeutic effects, also is known to interfere with 
calcium transport, G protein coupled receptors, ion channels, phosphodiesterase and 
DNA (da Conceição et al., 2010; Khan et al., 2011). SJW use is not generally 
associated with serious side effects, with some reports of mild GIT disturbances, 
anxiety, fatigue, palpitation, restlessness, dry mouth and photosensitivity (an 
average of 2.4% of patients) (Lawvere & Mahoney, 2005). Beside these effects SJW 
induces the cytochrome P-450 system, which affects a number of drug metabolisms 
and may results in altered effectiveness (Chan et al., 2001; Lawvere & Mahoney, 
2005) 6-:¶V FRQVXPSWLRQ GXULQJ SUegnancy may result in decreased offspring 
weight, while its emmenagogue (stimulation of pelvic blood flow), uterine stimulant 
and abortifacient properties were confirmed in animal studies and some cases of 
spontaneous abortions in humans (Chan et al., 2001; Dugoua et al., 2006; Moretti 
et al., 2009).  
Two pharmacologically active compounds, Hypericin (0.3%) a napthodianthrone, and 
Hyperforin (3%) a phloroglucinol (Mennini & Gobbi, 2004; Vitiello, 1999), are used 
to standardize SJW extracts and are the most widely studied compounds in its 
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extract because of their possible antidepressant activity (da Conceição et al., 2010; 
Lawvere & Mahoney, 2005; Moretti et al., 2009). 
6.2.1 Hypericin usually constitutes 0.3% of the total SJW extract, and produces 
antidepressant effects by inhibiting MAO-A (IC50 68µmol/L), MAO-B (IC50 
420µmol/L) (Eckert et al., 2004; Kubin et al., 2005; Wurglics & Schubert-Zsilavecz, 
2006) and serotonin reuptake (Gregoretti et al., 2004). It also has affinity for 
dopamine D3 receptors (Mennini & Gobbi, 2004). The 50% MAO inhibition activity is 
100-1000 fold higher than normal Cmax values after oral administration of SJW 
extract, which cannot be achieved without the severe phototoxic effects of hypericin 
(Kubin et al., 2005; Wurglics & Schubert-Zsilavecz, 2006). In humans its therapeutic 
plasma concentration ranges from 1.3-91ng/ml with poor absorption and 
bioavailability and a half-life of 6-48.2h (da Conceição et al., 2010). Hypericin may 
cause infertility by denaturing the DNA of sperm and affecting its penetration into 
the ovum. Hypericin treatment decreases morphological score, yolk sac diameter 
and somite number in whole embryo culture (Chan et al., 2001). Hypericin enters 
the cell by diffusion and a membrane associated translocation process. It interacts 
with human serum albumin (HSA), low density lipoprotein (LDL) and high density 
lipoprotein (HDL), which facilitates its solubility and dissolution in aqueous solution. 
Due to its lipophilic properties it incorporates into phospholipid bilayers, enters the 
cell and is localized in the Golgi apparatus and endoplasmic reticulum. Only at 
increased exposure time is it found in the nuclear membrane or inside the nucleus 
(Kober et al., 2008; Sauviat et al., 2007). Hypericin interacts with purine in DNA by 
forming a hydrogen bond with the OH group at N7 (Kober et al., 2008). Hypericin at 
higher doses is phototoxic. It may produce skin irritation on exposure to UV light by 
generating singlet oxygen and other ROS, which may lead to cell death and necrosis. 
This photodynamic property is used for cancer treatment (photodynamic therapy) 
(Karioti & Bilia, 2010; Theodossiou et al., 2004; Wurglics & Schubert-Zsilavecz, 
2006), but these effects are associated with interference in calcium mobilization 
which limits its use (da Conceição et al., 2010). These light dependant toxic 
properties were confirmed by Stupakova et al, since when HUVEC, U-87 MG and U-
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373 MG cells were exposed to nM and µM concentrations of hypericin they showed 
no effect, but on photo activation the cell viability was significantly affected 
(Stupáková et al., 2009). An increased hypericin concentration 150-250µgml-1 
decreases the cell viability with cell vacuolization, tumefaction and cell death (da 
Conceição et al., 2010). Beside this hypericin antiviral activity has already been 
established (Lopez-Bazzocchi et al., 1991).  
Hypericin interacts with a number of enzymes like PKA (IC50 >80µmol/L), PKC (IC50 
3.37µmol/L), tyrosine kinase (epidermal growth factor kinase or insulin receptor 
tyrosine kinase), glutathione reductase (IC50 2nmol/L) and phosphatidylinositol-3-
kinase or dopamine-beta-hydrolase that plays a critical role in cell signalling. But 
these interactions are mostly light dependent (Kober et al., 2008; Kubin et al., 
2005; Sauviat et al., 2007).  
                          
            Hypericin             Hyperforin 
Fig 6.1 Hypericin and Hyperforin chemical structures (Hostanska et al., 2003). 
6.2.2 Hyperforin is considered mainly responsible for the antidepressant effects in 
SJW because of its comparable effects with commercially available synthetic 
antidepressant drugs (Wurglics & Schubert-Zsilavecz, 2006). It acts by affecting 
synaptosomal uptake of serotonin, dopamine, glutamine, GABA and noradrenaline 
neurotransmitters (Medina et al., 2006). These effects are probably due to an 
alteration in sodium conductive pathways or modified neurotransmitter storage 
(Wurglics & Schubert-Zsilavecz, 2006). The mean plasma concentration of hyperforin 
after 3h of oral administration of 300-600mg dose reaches 150-370ng/ml (Wurglics 
& Schubert-Zsilavecz, 2006). Which is in the range of its IC50 value (120-3.300nM) 
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for synaptosomal uptake inhibition of serotonin (Butterweck & Schmidt, 2007). The 
pure compound is poorly susceptible to light and oxidation (Beerhues & Beerhues, 
2006). Hyperforin inhibits leukotriene biosynthesis by inhibiting the enzyme 5-
lipoxygenase (Feißt et al., 2009). Hyperforin triggers apoptosis by initiating caspase 
dependent pathways. Hyperforin and hypericin synergistically can produce light 
independent antiproliferative effects (Hostanska et al., 2003). Hyperforin is secreted 
at quantifiable levels in breast milk, which is reported to result in a higher incidence 
of lethargy and drowsiness in breast feeding infants (Chan et al., 2001; Hammerness 
et al., 2003). 
6.3 Materials and Methods 
The micromass culture system materials (Appendix 1) and methods are discussed in 
GHWDLOLQFKDSWHU,QEULHIGD\¶VROGFKLFNFDUGLRP\RF\WHVZHUHVHHGHGLQDO
droplet in 24 wells plate at a cellular density 3×106 cellsml-1. After 2h of cell 
attachment the wells were flooded with 500µl of complete culture medium.   
6.3.1 Preparation of test chemicals 
The four concentrations doses of hypericin (50, 100, 200 and 400ngml-1) and 
hyperforin (100, 200, 400 and 800ngml-1) were prepared by diluting a stock solution 
(see section 2.6) and this was protected from light. Both the drugs, either alone or in 
combination, were used with increasing concentrations. 500µl of medium with 
double the drug concentration required was added 24h after cell seeding.  
6.3.2 End Points 
For cardiomyocytes contractile activity the culture was morphologically inspected 
using the microscope and the score was recorded at 24h, 48h and 144h of cell 
culture (see section 2.5.1). For estimation of drug cytotoxic effects on cell viability, 
the resazurin reduction assay was performed at 144h of cell culture (see section 
2.5.2), followed by kenacid blue total protein content estimation (see section 2.5.3). 
6.3.3 Statistical analysis 
The results of three independent repeats were statistically analysed using Prism 5 
software. All the drugs doses results were compared with the control using one way 
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$129$ZLWK'XQQHW¶VSRVWKRFWHVW)RUQRQ-parametric data the Kruskal Wallis test 
with 'XQQ¶V SRVW KRF WHVW was used. The P<0.05 was considered as a significant 
difference.  
6.4 Results 
The active coQVWLWXHQWVRI6W-RKQ¶V:RUWK\SHULFLQDQGK\SHUIRULQZHUHWHVWHGDW
and above blood serum therapeutic concentrations. Both the drugs appeared to 
inhibit contractile activity at a dose above serum levels, but hypericin, even at the 
higher doses tested (400ng/ml) failed to achieve statistical significance from the 
control (P>0.05), while hyperforin showed some significant difference at 144h of cell 
culture with 800ng/ml dose (P<0.05). The drug combination follows more or less the 
same pattern of contractile activity inhibition as hyperforin alone. The combination of 
50 and 100ng/ml hypericin with 100 and 200ng/ml hyperforin receptively showed no 
significant inhibitory effects on contractile activity, while higher dose combinations 
above serum levels 200ng/ml HP+400ng/ml HF at 48h and 400ng/ml HP+800ng/ml 
HF at 48 and 144h showed a statistically significant difference from control 
(P<0.05). Cardiomyocyte cell viability, using the resazurin assay, showed no 
significant pattern of variation from control with 50-400ng/ml hypericin or, 
hyperforin. When both the drugs were combined, up to 200ng/ml HP with 400ng/ml 
HF, the drugs also showed no significant effect on cell viability, while the drug 
combination above the serum level (400ng/ml HP and 800ng/ml HF) showed a 
statistically significant decreased conversion of resazurin to resorufin compared to 
control. The third end point of effect on total cellular protein content more or less 
showed the same pattern of results as the resazurin assay. HP at all doses does not 
significantly alter the cellular protein content compared to control. HF appeared to 
inhibit cell proliferation at 400 and 800ng/ml compared to control but it failed to 
achieve statistical significance, while the drug combination of 400ng/ml HP and 
800ng/ml HF showed significantly decreased protein level compared to control 
(P<0.05).  
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Fig 6.2 The effects of HP and HF on cardiomyocytes in the MM system. A) Effects of 
HP 50ng/ml and HF 100ng/ml on contractile activity, B) effects of HP 50ng/ml and HF 
100ng/ml on cell viability (resazurin assay), C) effects of HP 50ng/ml and HF 
100ng/ml on total protein content (kenacid blue assay), D) effects of HP 100ng/ml 
and HF 200ng/ml on contractile activity, E) effects of HP 100ng/ml and HF 200ng/ml 
on cell viability (resazurin assay), F) effects of HP 100ng/ml and HF 200ng/ml on total 
protein content (kenacid blue assay).  
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Fig 6.3 The effects of HP and HF on cardiomyocytes in the MM system. A) Effects of 
HP 200ng/ml and HF 400ng/ml on contractile activity, B) effects of HP 200ng/ml and 
HF 400ng/ml on cell viability (resazurin assay), C) effects of HP 200ng/ml and HF 
400ng/ml on total protein content (kenacid blue assay), D) effects of HP 400ng/ml 
and HF 800ng/ml on contractile activity, E) effects of HP 400ng/ml and HF 800ng/ml 
on cell viability (resazurin assay), F) effects of HP 400ng/ml and HF 800ng/ml on 
total protein content (kenacid blue assay). * represents a significant difference from 
control. 
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6.5 Discussion 
Increased depression during pregnancy complicates the pregnancy by altered 
behaviour and increased morbidity rates in the developing embryo (Bellantuono et 
al., 2007). These increased psychopathological symptoms during pregnancy may 
directly affect development or the effect may be indirectly mediated by increased 
cigarette and alcohol consumption due to abnormally depressed behaviour (Bonari et 
al., 2004a). Untreated depression during pregnancy leads to spontaneous abortion, 
low birth weights, small head circumference, low Apgar score, neonatal retardation, 
and may lead to hypertension (Bonari et al., 2004a) and preeclampsia which may 
develop into eclampsia (Kurki et al., 2000).  
Complementary or alternative medicine use has increased markedly during the 
¶V7KHHDVHRIDYDLODELOLW\DQGWKHJHQHUDOSHUFHSWLRQRIWKHLUKDUPOHVVQDWXUH
due to natural ingredients, have played a critical role in the increased popularity 
(Klepser et al., 2000; Kober et al., 2008). Unfortunately patients often do not 
disclose the use of herbal medicines or practitioners do not give it importance while 
recording the medical history (Klepser et al., 2000). Due to a lack of comprehensive 
studies on SJW effects in pregnancy, and the complication produced by depression, 
it is difficult to define whether any effects are the results of drug toxicity or 
depression itself. Further, this dilema is augmented by the presence of a number of 
pharmacologically active compounds in SJW, which makes it difficult to identify the 
particular toxic compound.  
In this study the active antidepressant constitutents of SJW extract, hypercin and 
hyperforin, were evaluated separately and in combination for their synergistic 
contribution using the chick embryonic in vitro micromass cardiomyocyte system. 
Contractile activity, which is a cardiomyocyte intrinsic property, when evaluated with 
hypericin, showed no significant effect at all doses, although the hypericin 400ng/ml 
dose was much higher than serum therapeutic levels. The same observation of no 
altered trends compared to control was found with cell viability and cellular protein 
content which reflects the effect on cellular proliferation. Antiproliferative effects and 
decreased cell survival were expected with hypericin (da Conceição et al., 2010). 
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However, at low doses the toxic effects of hypericin are mainly dependent on light 
activation and in this experiment the hypericin was protected from light. This 
confirms the toxic effects of hypericin are probably due to the production of singlet 
oxygen or ROS, which may disturb different cellular processes by binding to proteins 
and DNA (Karioti & Bilia, 2010; Theodossiou et al., 2004; Wurglics & Schubert-
Zsilavecz, 2006). Low ROS production leads to apoptosis even cell survival, but at 
high doses it induces necrosis (Kober et al., 2008).  The other drug hyperforin at 
higher doses significantly decreases the cardiomyocytes contractile activity at 400 
and 800ng/ml, with some small effects on cell viability and cell proliferation, but 
these differences were not significant compared to the control. The effect on 
contractile activity at higher doses may involve some interference with the 
contraction mechanism or related proteins with no effects on cellular proliferation 
and viability. Cellular proliferation in the HF treated group does not look very 
different from the control and this may indicate antiproliferative signalling was not 
triggered at this dose or in cardiomyocytes compared to the other cell line observed 
by Hostanka et al, 2003. The synergistic effects of hypericin and hyperforin on cell 
proliferation were already shown by Hostanka et al., 2003, and a similar decrease in 
cell protein and cell viability was also observed in these experiments. The 
combination of drugs, hypericin with ROS production properties (Theodossiou et al., 
2004; Wurglics & Schubert-Zsilavecz, 2006) and hyperforin caspase activation 
(Hostanska et al., 2003) may contribute to the toxic mechanism. The combined 
drugs effects on contractile activity were more likely caused by hyperforin alone. It 
may be that inhibitory effects on contractile activity are purely from hyperforin but 
antiproliferative effects are due to some synergistic antiproliferative mechanism. In 
view of above results it can be concluded that the active constituents of SJW, 
hypericin and hypericin, neither alone nor in combination, at serum therapeutics 
levels do not produce severe toxic effects on embryonic cardiomyocytes in cell 
culture. But the drug dose above serum therapeutic level may produce some toxic 
effects even in the absence of light.  
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7.1 Intercellular communication 
The complex events underlying development and homeostatic balance require a flow 
of information between cells and tissue systems (Levin, 2002; Vinken et al., 2006). 
The cells exchange information either by release of chemicals or signalling molecules 
through extracellular spaces or intercellularly between contiguous cells via 
specialized cell membrane nexus aggregates (gap junctional plaques) (Dhein, 1998; 
John et al., 2003). 
7.2 Intercellular communication via gap junctions  
Intercellular communication via gap junctions mediates important regulatory 
mechanisms in embryonic development, cellular growth control, differentiation, 
apoptosis, electrical coupling, tissue homeostasis and metabolic transport (Dhein, 
1998; Leithe & Rivedal, 2004a; Solan & Lampe, 2005). Gap junctions are specialized 
cell membrane spanning conduits (channels), which allows the direct exchange of 
small molecules (<1KDa) including second messengers, nucleotides, ions and other 
metabolites between adjacent cell cytoplasm (Leithe & Rivedal, 2004a; Ruch et al., 
2001; Solan & Lampe, 2005). This extremely versatile system allows rapid 
synchronized spread of action potentials in excitable cells by ion diffusion (electrical 
coupling) and of small molecules and second messengers in non-excitable cells 
(metabolic coupling) (Goodenough & Paul, 2003; Michael, 2007; van Veen et al., 
2001). Mutation in gap junction genes or disturbance in gap junction intercellular 
communication (GJIC) results in a number of diseases including tumour growth 
(Ruch et al., 2001). 
In vertebrates, gap junctions are encoded by the connexin gene family, while in 
invertebrates it is innexins (Lo, 2000; Michael, 2007; Wei et al., 2004). To date, 20 
connexin genes in the mouse genome and 21 in the human genome have been 
identified (Söhl & Willecke, 2004; Wei et al., 2004). Two nomenclature systems are 
used to designate connexins; one based on molecular mass, for example 43KDa 
connexin protein is Connexin43 or Cx43; the second system divides the connexins 
into suEFODVVHV Į ǃ Ǆ RU į DFFRUGLQJ WR VHTXHQFH VLPLODULW\ DQG F\WRSODVPLF
domains (Vinken et al., 2006; Wei et al., 2004). Connexins are fairly ubiquitous, 
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with Cx43 the most widespread (Laird, 2005). The connexins are cotranslationally 
integrated in the endoplasmic reticulum (ER), assembled into connexons in the trans 
Golgi network (TGN), then trafficked and docked head to head in the plasma 
membrane (PM) to form a junction with another connexon supplied by the adjacent 
cell or they connect the cell with extracellular milieu (non-junctional) (Solan & 
Lampe, 2005).  
7.3 *DSMXQFWLRQ¶VFRPSRVLWLRQ7RSRORJ\ 
Gap junctions are dodecameric bipartite structures, composed of one hexameric 
subunit (connexon) from each communicating cell (Dhein, 1998; Vinken et al., 
2006), which bridge a 2nm gap between the plasma membrane of adjacent cells 
(Dhein, 1998). Each connexon is an assembly of six connexin proteins and the 
overall gene and protein structure among various connexins isoforms is largely 
conserved (van Veen et al., 2001). Each connexin protein has 9 principal domains: 
the four transmembrane domains (TM1-TM4), two extracellular loops (E1 and E2), 
the C-terminus (CT), the N-terminus (NT) and the cytoplasmic loop (fig 7.01A) 
(Dhein, 1998; van Veen et al., 2001; Vinken et al., 2006). The C-terminus amino 
acids sequence length determines the molecular mass of the particular connexin, 
while the extracellular loops and four transmembrane domains are highly conserved 
among species and connexins isoforms (Dhein, 1998; van Veen et al., 2001). The 
four transmembrane domains (M1-0 H[KLELWV DQ Į-helical structure, while the 
extracellular domains form a tight seal to prohibit substance leakage between the 
channel lumen and the extracellular milieu (Wei et al., 2004). Three conserved 
cysteine residues in extracellular loops E1 and E2 help in connexon head-to-head 
docking by forming a disulphide bond with the opposing hemichannels. (Dhein, 
1998; van Veen et al., 2001). Connexins may express different isoforms (Martin & 
Evans, 2004) by forming homomeric (six identical connexins) or heteromeric (more 
than one connexins isotype) connexons, which in turn may bond with either the 
same (homotypic) or different (heterotypic) connexons from the adjacent cell (fig 
7.01B) (Dhein, 1998; Wei et al., 2004).  
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diagram representing the six connexin protein assembly to form homo or hetero 
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7.4 Gap junction regulation and phosphorylation  
Regulation of GJIC from gene transcription to degradation makes a substantial 
contribution in number of physiological and pathological situations (Laing et al., 
1997; Vinken et al., 2006). Gap junctions have a half-life of 2-5h; therefore 
continuous turnover is critical for GJIC (Solan & Lampe, 2005). Investigations have 
shown that connexin protein biogenesis mainly occurs in ER membrane bound 
ribosomes, and they oligomerize into hexameric connexons as they are transported 
through the TGN, followed by their trafficking along the secretory pathways to fuse 
into the PM (Lauf et al., 2002; Martin & Evans, 2004). In the PM the randomly 
dispersed connexons cluster at new or pre-existing gap junction plaques for 
functional coupling (Chipman et al., 2003; Lampe & Lau, 2004). A number of studies 
confirm the presence of non-junctional connexins in PM that connect cells to the 
extracellular milieu (Lauf et al., 2002). Molecular chaperones assist in stable protein 
folding in ER, and upon exit the properly folded proteins pass through the ERGIC 
prior to entering TGN (Laird, 2006), while misfolded proteins are subjected to 
degradation (Berthoud et al., 2000). The precise location for oligomerization is 
unclear, it differs with connexin and cell type but the disruption of the Golgi 
apparatus and microtubule network prevents Cx43 trafficking (Martin & Evans, 
2004). An exception is Cx26 which oligomerizes before reaching the Golgi apparatus 
and is transported via Golgi independent pathways (Laird, 2006; Thomas et al., 
2005). Therefore it is slightly affected by Golgi disturbance, while highly sensitive to 
microtubule inhibitors (Martin & Evans, 2004). Closed connexons are delivered to the 
PM to prevent uncontrolled exchange (Laird, 2006), where cadherin based adherens 
junctions may act as a prerequisite for gap junction formation and cell-cell coupling 
(Wei et al., 2004). The Cx43 independent binding domains in CT interacts with cell 
junction proteins like ZO-1 (which links connexin to the cytoskeleton actin) thereby 
generating scaffolds for recruiting other regulatory proteins in gap junctions 
(Chipman et al., 2003; Martin & Evans, 2004). Beside this a number of Cx43 protein 
ELQGLQJ SDUWQHUV LQFOXGLQJ Įǃ-catenin, p120-catenin, ZO-2, caveolin-1, cadherins, 
Į-actinin and microtubules participate in signalling pathways that regulate cell 
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adhesion, cell motility, and the actin cytoskeleton. (Laird, 2006; Wei et al., 2004). 
Gap junction gating is regulated by a number of mechanisms including Ca2+, pH, free 
radicals, transjunctional and transmembrane voltage and phosphorylation (Chipman 
et al., 2003; Vinken et al., 2006; Wei et al., 2004).  
Both ubiquitin-proteasomal and lysosomal pathways are involved in connexin 
degradation. The proteasome degrades most cytosolic and nuclear proteins and 
removes misfiled and disaggregated proteins from the ER, while the lysosome 
degrades integral membrane proteins and receptor mediated internalized proteins 
(Berthoud et al., 2000; Laing et al., 1997; Qin et al., 2003). Gap junction 
internalization occurs via the formation of an annular junction, which is internalized 
into one of the two cells and degraded (Jordan et al., 2001). 
Transient changes in the GJIC signalling cascade appear necessary for normal cell 
cycling (Solan et al., 2003). The connexin gap junctions undergo various biochemical 
and post translation modifications, but among these phosphorylation has acquired 
the most attention (Solan & Lampe, 2007). Connexin phosphorylation regulates or 
alters the normal functioning of gap junctions. Altered phosphorylation induces 
changes in the connexin protein structure, which translocate the protein to the 
cytoplasm instead of forming GJ within the cell membrane (Musil & Goodenough, 
1990). Connexin phosphorylation is apparently not required for functional channel 
formation, but appears to efficiently regulate channel gating, assembly and turnover 
(Martin & Evans, 2004; Solan et al., 2003).  
The majority of connexin proteins are phosphoproteins (Solan & Lampe, 2005), with 
the exception of Cx26, which is probably due to a short CT (Lampe & Lau, 2000; 
Musil & Goodenough, 1991). Phosphorylation mostly occurs on the CT of the protein, 
while NT phosphorylation has not been reported (Solan & Lampe, 2005). Connexin 
phosphorylation predominantly occurs on serine residues, but has been reported also 
on threonine and tyrosine residues of CT (van Veen et al., 2001). Cx43 CT is 
involved in channel voltage gating and phosphorylation and dephosphorylation of CT 
may affect this (Moreno & Lau, 2007). Difference in unitary conductance of the 
channel has been attributed to the phosphorylation state (Moreno, 2004). 
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Several kinases are known to phosphorylate connexins, including MAPK, PKC, PKA, 
PKG, CK1, v-Src, p130gag-fps (Lampe & Lau, 2000; Musil & Goodenough, 1991; van 
Veen et al., 2001; Vinken et al., 2006). Little is known about connexin 
dephosphorylation that maintains the equilibrium (Vinken et al., 2006). 
Cx43 upon phosphorylation showed reduced migration on polyacrylamide gel 
electrophoresis (SDS-PAGE) (Solan et al., 2003). Western blot analysis of Cx43 
indicates three bands ranging from 41-46KDa molecular weight: Po the non-
phosphorylated state, the P1 phosphorylated state and the P2 the highly 
phosphorylated state (van Veen et al., 2001). These phosphorylated species are 
sensitive to phosphoserine specific phosphatases (Qin et al., 2003).  
Reagents that activate PKC inhibit GJIC (Lampe & Lau, 2000). The phorbol ester TPA 
was the first tumour promoter identified as a GJ inhibitor (Loch-Caruso et al., 2004). 
TPA hyperphosphorylates the Cx43 on serine368 by direct stimulation of PKC, which 
down regulates Cx43 trafficking, intercellular coupling and GJIC (Cruciani & Mikalsen, 
2002; Solan et al., 2003; van Veen et al., 2001). Cx43 assembly is blocked and the 
half-life is shortened on TPA exposure (Lampe, 1994). During key stages of the cell 
cycle where gap junctional assembly is reduced, increased Ser368 phosphorylation 
was observed (Solan et al., 2003). Phosphorylation at Ser255 accelerates 
internalization and degradation, while tyrosine phosphorylation reduces GJ. Growth 
factors like EGF PDGF, IGF and FGF decrease GJ by phosphorylation of Cx43 (van 
Veen et al., 2001).   
The PKC activator TPA promotes tumorigenesis, increases gap junction 
phosphorylation and decreases GJIC in a number of cell types (Lampe & Lau, 2000; 
Ruch et al., 2001). TPA mimics diacylglycerol. DAG is produced along with IP3 via 
PLC mediated cleavage of PIP2. The IP3 induces calcium release while DAG activates 
PKC (Leithe & Rivedal, 2004b; Nishizuka Y, 1986 ). TPA mimics DAG structure and 
activates PKC. The TPA phosphorylates Cx43 at Ser368 via PKC activation and 
inhibits gap junction assembly and modifies the channel properties (Lampe & Lau, 
2000; Ruch et al., 2001). After prolonged exposure to TPA the cells become 
refractory to the inhibitory effects, as had been frequently observed in other cells. 
     
151 
 
This may be due to down regulation of PKC, a major cellular target for TPA (Oh et 
al., 1991). 
cAMP has been found to increase GJIC (Lampe & Lau, 2000) and several studies 
have indicated that activation of the PKA pathway via dibutryl-cAMP increases 
serine364 (Ser364) phosphorylation, which leads to an increase in GJIC and the 
number of Cx43 positive plaques (TenBroek et al., 2001). However some cell types 
do not alter the phosphorylation status of Cx43 in response to cAMP. Recent 
evidence indicated that the cAMP dependent PKA pathways did not phosphorylate 
Cx43 directly, but enhanced assembly of Cx43 GJIC and was totally dependent upon 
the basal phosphorylation of Ser364 by unknown kinases (TenBroek et al., 2001). 
 
Fig 7.2 Schematic diagram representing connexin biogenesis in the ER and 
assembly at TGN to form connexon hemichannels. The black misfolded proteins are 
degraded by the lysosome. The Connexin migrates to PM to form gap junction. The 
junctional plaque is internalized and degraded via proteasomal pathways. 
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7.5 Gap junctions in the cardiovascular system  
Connexins are not only structural precursors of gap junctions (Vinken et al., 2006), 
but also they play a critical role in development by forming morphogen gradient 
compartments, which regulate cell growth, patterning and differentiation (Wei et al., 
2004). In the heart, connexins are involved in electrical impulse propagation, 
development and cardiomyocyte volume regulation (Gros et al., 2005). The non-
junctional channels control NAD and ATP release in the extracellular spaces, which 
are involved in Ca2+ wave propagation between cells. These channels remain closed 
most of the time and are tightly regulated, otherwise they may cause cell death 
(Vinken et al., 2006).  
Cardiac tissues are arranged phenotypically, in different compartments, and the gap 
junction channels connect and electrically synchronize these compartments (Levin, 
2002; Vink et al., 2004). Gap junctions in the heart typically co-exist with adhesion 
junctions at ingeniously orchestrated intercalated discs, which facilitate the 
propagation of low resistance electrical impulses and mechanical attachment 
between cardiomyocytes (Gourdie, 1995; Martin & Evans, 2004). Cx43 is the 
predominant isoform expressed in the heart, others include Cx40, Cx45, Cx37 and 
Cx50 (Vink et al., 2004). Cx43 is widely expressed in all atrial and ventricular 
myocardium cells at all stages of development and is principally responsible for 
electrical synchrony in the heart (Martin & Evans, 2004; van Veen et al., 2001; Wei 
et al., 2004). Cx45 is in the SA and AV node, Cx40 is coexpressed with Cx43 in atrial 
myocardium (Martin & Evans, 2004; van Veen et al., 2001), Cx37 is confined to 
endothelial tissue and Cx50 is only in cardiac valves (Vink et al., 2004). Cx40 
generates channels with high conductance and Cx45 forms voltage-sensitive 
channels with very low conductance (Wei et al., 2004). This compartmentalized 
connexin expression pattern in the heart is expected to provide for the orderly 
sequential spread of activation potential from the atrial to ventricular chambers (Wei 
et al., 2004). An increase in Cx43 expression is observed immediately prior to labour 
(Lampe & Lau, 2000; Solan & Lampe, 2005). The gene targeting studies have 
further explored the specific role of connexin channels in heart conduction and 
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morphogenesis. Cx43 disturbance interferes with the working myocardium, and slow 
conduction and partial AV block is observed in Cx40 knockout, while Cx45 knockout 
mice exhibit conduction block and endocardial cushion defects in gestation (Wei et 
al., 2004). Cx40 knockout mice die during gestation with AV septation defects or 
outflow tract malformations, while Cx45 is required for endocardial cushion 
development. Cx43 plays an essential role in development of the coronary arteries 
and outflow tract morphogenesis (Wei et al., 2004) and mice with Cx43 disruption 
exhibit right ventricular outflow tract obstruction, causing cyanosis and death at 
birth (Vinken et al., 2006). Despite this abnormality, however, the hearts of these 
Cx43 deficient animals still beat rather rhythmically, though not synchronously 
throughout the tissue, suggesting that gap junction proteins in addition to Cx43 may 
partially compensate for the loss of intercellular connections (Vink et al., 2004). In 
Cx43 knockout mice, dysregulation of neural crest cell migration during embryonic 
development results in heart malformation (Giepmans, 2004). In Cx40-/- mice, the 
most common abnormalities are double outlet right ventricle, bifid atrial 
appendages, tetralogy of Fallot, ventricular septal defects, aortic arch abnormalities 
and partial endocardial cushion defects. These results indicate that Cx40 role in the 
septation process (Gros et al., 2005). 
7.6 Gap junctions in disease and teratogenicity 
The GJIC is regarded as an important mechanism in coordinating growth and 
development and tissue compartmentalization during embryogenesis (Goodenough 
et al., 1996). Communication between cells is very important during development; 
small morphogens can pass through the channels and may control or affect normal 
functioning. Abnormal connexin expression is involved in cancer, cardiac ischemia 
and cardiac myopathy (Kumar & Gilula, 1996). The processes of mitotic cell division 
and apoptosis exhibit high levels of GJIC at the start which decreases as the event 
progress, this correlates the GJIC and cellular growth (Vinken et al., 2006). Tumour 
cells have dysfunctional GJIC, which may be due to post-translational modification or 
decreased degradation (Leithe & Rivedal, 2004a). Connexin overexpression in 
tumour cells act as a tumour suppressor, which decreases cell proliferation and 
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increases cell death (Vinken et al., 2006).Mutation in connexin proteins results in 
µFKDQQHORSDWKLHV¶ZKLFKQHJDWLYHO\UHJXODWHYDULRXVSURFHVVHVDW FHOOXODU OHYHOVDQG
may affect development (Levin, 2002; Solan & Lampe, 2005). The connexin C-
terminus tails possess multiple sites for phosphorylation and this regulates channel 
assembly, trafficking, gating and turnover (Lampe & Lau, 2000). Cx43 is 
ubiquitously expressed during embryo development in various tissues. In Cx43 
knockout mice, dysregulation of neural crest cell migration during embryonic 
development results in heart malformation (Giepmans, 2004). Cx43 knockout mice 
die due to malformation of the conotruncal region of the right ventricle (Lampe & 
Lau, 2000). Mutation in Cx43 from serine to proline at Ser364 results in visceral 
atrial heteroataxia in humans and Xenopus (Levin, 2002; Solan & Lampe, 2005). 
Cx43 pharmacological inhibitors, blocking GJC, affect cellular proliferation 
(Giepmans, 2004). C-terminus tail lacking mutants of Cx43 and Cx32 result in 
inhibition of cell proliferation (Giepmans, 2004), while Cx43 mutation results in 
developmental abnormalities of the face, eyes, limbs and dentition called 
oculodentodigital dysplasia (ODDD) (Laird, 2006; Wei et al., 2004). Mutation in 
Cx26, Cx30 and Cx31.1 genes result in non-syndromic deafness and skin disorders 
(Martin & Evans, 2004), Cx32 results in demyelinated Schwann cells causing 
Charcot-Marie-Tooth syndrome (CTMX), Cx26 and Cx45 knockout mice die in utero, 
Cx37 female mice are infertile (Lampe & Lau, 2000). Cx50 and Cx46 mutation is 
implicated in cataract formation (Lampe & Lau, 2000; Martin & Evans, 2004). 
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7.7 Material and Methods: 
The immunohistochemistry and Western blot analysis materials (Appendix 1) and 
methods are discussed in detailed in chapter 2. 
7.7.1 Statistical analysis 
For Western blot analysis three repeat results were statistically analysed using one 
way ANOVA followed by post hoc test. 
7.8 Controls 
7.8.1 Positive Control 
Day 9 chick hearts were used as a positive control for Cx43 protein 
immunolocalization and Western blot analysis. Heart tissue has been shown to 
express Cx43 with increased intensity with development (Kirchhoff et al., 2000; 
Wiens et al., 1995). 
7.8.2 Negative Control-TPA   
The PKC activator TPA (12-O-tetradecacanoylphorbol-13-acetate) was used as a 
negative control. TPA decreases the Cx43 gap junction communication by 
hyperphosphorylation in a number of cell types (Lampe & Lau, 2000). TPA increases 
the phosphorylation of Cx43 at Ser368 in the C-terminus tail. Increased 
phosphorylation results in decreased communication between cells by decreasing GJ 
assembly (Lampe & Lau, 2000; Ruch et al., 2001). The TPA was diluted in DMSO to 
a stock solution of 50µM; the stock solution was further diluted to 100nM in culture 
medium and exposed to the cells for 2h.  
7.8.3 Loading control for Western blot 
Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis and 
catalyzes the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate. It 
has also been implicated in several non-metabolic cell processes (Tarze et al., 2006). 
The GAPDH gene is stable and constitutively expressed at high levels in almost all 
tissues and considered as a housekeeping gene. The housekeeping genes are used 
as a loading control to normalize the protein in molecular assays (Barber et al., 
2005). The Western blot analysis exhibits the GAPDH band at approximately 36-
40KD. 
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7.9 Results  
The connexin43 Western blot analysis exhibits multiple bands (Green color bands). 
Indicating a lower non-phosphorylated P0 and higher phosphorylated P1 band 
between the molecular weight 40-50KDa. The non-phosphorylated isoform showed 
increased migration on gel compared to the high molecular weight phosphorylated 
isoform of Cx43. The phosphorylated isoform of Cx43 at Ser368 was labelled (red 
band) by the phospho-Ser368 Cx43 specific antibody between the Cx43 bands. With 
Cx43 WB a number of non-specific band were observed on the blot that may 
represent some fluorescent proteins labelled by primary or secondary antibodies (Fig 
7.3A). In immunolocalization the Cx43 protein was found appositionally at the cell 
membrane or the intracellularly in the cytoplasm (Fig 7.3B).  
  
80kDa
50kDa
40kDa
25kDa
Cx43
P1
P0
80kDa
50kDa
40kDa
25kDa
PCx43
 
Fig 7.3A Cx43 and PCx43 western blot analysis. Exhibiting the Cx43 P0 and P1 
isoforms and PCx43 bands.  
  
Cx43 appositional
presence at the cell
membrane
Cx43 intracellular
presence
Cx43 Cx43with DAPI nuclear stain
a b
Fig 7.3B Cx43 immunolocalization intracellularly and at the cell membrane.           
a) The line indicates the Cx43 protein presence intracellularly and at the cell 
membrane, b) Cx43 protein with DAPI nuclear stain. 6FDOHEDUǋP 
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7.9.1 Evaluation of Cx43 antibody 
The connexin 43 immunolocalization was studied in both systems and day 9 chick 
hearts. The control showed no non-specific binding with secondary antibody only 
with the cardiomyocytes (fig 7.5A). The cryosectioned day 9 chick heart staining 
with monoclonal anti-connexin 43 showed the presence of Cx43 protein (fig 7.5B). In 
the micromass system the cultured embryonic cardiomyocytes exhibit appositional 
(cell membrane) and intracellular (cytoplasm) presence of Cx43 (fig 7.5C). The ES 
derived contractile cardiomyocytes also exhibit the presence of Cx43 in the cell 
cytoplasm and at the membrane connecting with other cells (fig 7.5D).  
Western blot analysis for the quantification of Cx43 and PCx43 in culture 
cardiomyocytes and day 9 hearts exhibits a protein band between molecular weight 
marker 40 and 50kDa (fig 7.4A). The green bands of Cx43 represent different 
phosphorylated states of the protein with different migration potential on the gel (fig 
7.4A). The red band at or above Cx43 represent the CT Ser368 phosphorylated 
isoform of Cx43 tagged with Phospho-Cx43 (PCx43) antibody (fig 7.4A). The house 
keeping gene GAPDH band was observed on the blot below the 40KDa molecular 
marker and was used to normalize the protein (fig 7.4B).   
 
A)          B) 
      
     Day9        MM       ESDC                        Day9        MM       ESDC 
Fig 7.4 Western blot analysis of Cx43 and phospho-Cx43 proteins. A) Represents 
Cx43  and PCx43 bands, B) the red band below 40KDa marker represents GAPDH. 
 
50KDa 
40KDa 
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A
A B C D
B C D
Negative Control Day 9 chick heart MM cardiomyocytes ES derived cardiomyocytes
Fig 7.5 Cx43 immunolocalization in day 9 chick heart, MM and ES derived cardiomyocytes. A) Negative control, B) Day 9 chick heart,      
C) micromass cardiomyocytes and D) ES cell derived cardiomyocytes (Green color represents Cx43 while Blue is DAPI nuclear staining). 
6FDOHEDUǋP.  
                                                                                                                                                                                                                  
Cx43 
Cx43 
with DAPI 
nuclear 
stain 
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7.9.2 Effects of VPA on Cx43 immunolocalization in the MM and ESDC 
systems 
In the MM system, the Cx43 monoclonal antibody tagged with green fluorescent 
Fluo488 secondary antibody, showed the presence of Cx43 proteins intracellularly 
and at the cell membrane in the cultured cardiomyocytes (fig 7.6A). The negative 
control of TPA (100nM) treatment for 2h reduced the protein expression compared to 
the control (fig 7.6B). When Cx43 immunolocalization in VPA treated cardiomyocytes 
was compared with the control, increasing drug dose resulted in an overall decrease 
in protein expression (fig 7.6). At VPA 200µM, the effect on total protein expression 
was not very obvious (fig 7.6C). When the drug dose was doubled, Cx43 expression 
decreased with some disturbance in protein localization compared to control (fig 
7.6D). These effects continued at higher doses and reduced protein expression was 
observed in cardiomyocytes after VPA 800µM treatment (fig 7.6E). 
In the ESDC no treatment group, anti-Cx43 antibody showed the protein presence 
inside the cell and at the cell membrane, connecting with other cell gap junctions (fig 
7.7A). With TPA treatment in ES cells, a clear decrease in protein expression was 
recorded with some intracellular disturbed localization (fig 7.7B). VPA treatment with 
same doses reduced the Cx43 protein overall expression in cardiomyocytes. At 
200µM the VPA treated cells exhibited protein expression at the cell boundary, which 
was found to be disturbed in the 400µM treated group and was further affected with 
800µM VPA treatment (fig 7.7C, D and E). 
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7.9.3 Western blot analysis of VPA treated cardiomyocytes in MM and ESDC 
system 
The Western blot analysis of Connexin43 and the form of Connexin Phosphorylated 
at Ser368 in the cytoplasmic tail showed the positive presence of protein at its 
specific molecular weight of 43KDa. In the micromass system the VPA and negative 
control TPA treated cardiomyocytes results were compared with the control. The TPA 
showed a decrease in overall Cx43 protein expression and an increase in Cx43 
phosphorylation when normalized using the housekeeping gene GAPDH. When the 
VPA results were compared with the control a significant decrease in Cx43 protein 
expression was observed with increased dose (fig 7.8B). Increased Cx43 
phosphorylation was detected which was elevated to significant levels at the 800µM 
drug dose (fig 7.8C). 
In the ESDC the results were more or less similar to the MM system. The TPA 
treatment showed some increase in the cellular phosphorylated isoform of Cx43 and 
decrease in total Cx43 compared to control. When the VPA treated ESDC were 
subjected for the quantification of cellular Cx43 and PCx43 levels the cells showed an 
effect on protein expression with increased VPA dose. A significant decrease in Cx43 
level was observed with VPA treatment compared to control (fig 7.8E), while the 
Cx43 phosphorylation was increased after VPA treatment compared to the control 
(fig 7.8).  
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A
A
B
B
C
C
D
D
E
E
   Control                TPA 100nM               VPA 200µM                         VPA 400µM                      VPA 800µM 
 
Fig 7.6 Cx43 expression in VPA treated chick cardiomyocytes in MM system. A) Control, B) TPA 100nM, C) VPA 200µM, D) VPA 
400µM and E) VPA 800µM (Green color represents Cx43 while Blue is DAPI nuclear staining). (Scale bar 33ǋP 
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A
A
B C D E
B C D E
          Control                TPA 100nM                VPA 200µM                        VPA 400µM                       VPA 800µM 
 
Fig 7.7 Cx43 expression in VPA treated ES derived cardiomyocytes. A) Control, B) TPA 100nM, C) VPA 200µM, D) VPA 400µM                  
and E) VPA 800µM (Green color represents Cx43 while Blue is DAPI nuclear staining). 6FDOHEDUǋP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Fig 7.8 Western blot analysis of VPA effects on Cx43 and PCx43 in the MM and 
ESDC systems A) Cx43, PCx43 and GAPDH blot in the MM system (A=Control, 
% 73$Q0& 93$ǋ0' 93$ǋ0DQG( 93$ǋ0%93$HIIHFWVRQ
Cx43 in the MM system, C) VPA effects on PCx43 in the MM system (A=Control, 
% 73$Q0 & 93$ǋ0 ' 93$ǋ0 DQG ( 93$ǋ0 ' &[ 3&[
and GAPDH, blot in the ESDC system E) VPA effects on Cx43 in the ESDC system 
and  F) VPA effects on PCx43 in the ESDC system. * represents the significant 
difference from control.   
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7.9.4 Effects of CBZ on Cx43 immunolocalization in the MM and ESDC  
           systems 
As before, control groups in the MM system showed Cx43 positive staining in 
cardiomyocytes expressing green color (fig 7.9A). The negative control TPA showed 
decreased cellular Cx43 levels after 2hr of treatment (fig 7.9B). When the cultured 
cardiomyocytes in the MM system were treated with CBZ for 5 days, the drug 
affected the Cx43 protein. The 100 and 200µM treated groups showed decreased 
and disturbed Cx43 localization compared to the control (fig 7.9C and D). With an 
increased dose of 400µM the decreased protein expression continued with disturbed 
assembly compared to control (fig 7.9E). 
In the ESDC the control and negative control groups continued to produce the 
expected results (fig 7.10A and B). In CBZ 100 and 200µM treated ESDC the Cx43 
expression was not very much affected (fig 7.10C and D). The cells showed weak 
protein expression but the cellular localization was like the control. ES cell 
differentiation in the presence of 400µM CBZ resulted in reduced cell proliferation 
and the ability to spread on the surface after attachment (see section 4.4.2.3). The 
cells did not form connections between them and reduced assembly of Cx43 at the 
cell membrane was observed (fig 7.10E).  
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7.9.5 Western blot analysis of CBZ treated cardiomyocytes in MM and ESDC  
           system 
In the MM system, CBZ affects Cx43 protein as observed using western blot analysis, 
showing reduced levels of Cx43 protein with increased drug dose (fig 7.11B). After 5 
days of treDWPHQWZLWK&%=DWDQGǋ0WKHFKLFNHPEU\RQLFFDUGLRP\RF\WHV
showed reduced levels of CX43 protein, which became significant compared to the 
FRQWURODWǋ0&%=GRVH7KHQHJDWLYHFRQWURO73$FRQWLQXHGWRDIIHFWWKHFHOOXODU
levels of Cx43 after 2h treatment. With PCx43 antibody the results showed a 
different picture; the cellular levels with CBZ treatment were unaffected even at high 
dose, while TPA increased the overall phosphorylation of connexin43 at Ser368 (fig 
7.11C).  
With the ESDC the results after CBZ treatment were like the MM system. Increase in 
CBZ dose resulted in a decrease in CX43 levels in the differentiating cells. With 100 
DQGǋ0&%=GRVHWKH&[SURWHLQGRHVQRWGURSGRZQPXFKFRPSDUHGWRWKH
FRQWUROEXWZLWK&%=ǋ0WKHFDUdiomyocytes exhibited a significantly low level of 
Cx43 protein (fig 7.11E). The effects on Cx43 phosphorylation showed a reduced 
protein phosphorylation at the Ser368 cytoplasmic tail residue compared to the 
FRQWURO$WDQGǋ0WKHYDOXHVDSSHDUHGWo be decreased compared to control 
JURXS EXW IDLOHG WR DWWDLQ VWDWLVWLFDOO\ VLJQLILFDQW OHYHOV :KLOH DW ǋ0 WKH FHOOV
exhibited significantly reduced protein phosphorylation compared to the control (fig 
7.11F).  
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Fig 7.9 Cx43 expression in CBZ treated chick cardiomyocytes in the MM system. A) Control, B) TPA 100nM, C) CBZ 100µM,            
D) CBZ 200µM and E) CBZ 400µM (Green color represents Cx43 while Blue is DAPI nuclear staining). (Scale bar 33ǋP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Fig 7.10 Cx43 expression in CBZ treated ES derived cardiomyocytes. A) Control, B) TPA 100nM, C) CBZ 100µM, D) CBZ 200µM and 
E) CBZ 400µM (Green color represents Cx43 while Blue is DAPI nuclear staining). (SFDOHEDUǋP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Fig 7.11 Western blot analysis of CBZ effects on Cx43 and PCx43 in the MM and 
ESDC systems. A) Cx43, PCx43 and GAPDH blot in the MM system (A=Control, 
B=TPA 100nM, C=CBZ100µM, D=CBZ200µM and E=CBZ 400µM), B) CBZ effects on 
Cx43 in the MM system, C) CBZ effects on PCx43 in the MM system, D) Cx43, PCx43 
and GAPDH blot in the ESDC system (A=Control, B=TPA100nM, C=CBZ100µM, 
D=CBZ200µM and E=CBZ 400µM), E) CBZ effects on Cx43 in the ESDC system and  
F) CBZ effects on PCx43 in the ESDC system. * represents the significant difference 
from control. 
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7.9.6 Effects of BPN on Cx43 immunolocalization in the MM and ESDC  
         systems  
BPN doses in the MM system decrease and disturb Cx43 protein expression. With an 
increase in drug dose from 50 to 200µM a gradual decrease in protein level was 
observed (fig 7.12). In the BPN 50µM treated (fig 7.12C) group the cardiomyocytes 
exhibit disturb protein localization compared to the untreated group. At higher doses 
this continues with reduced expression. At 200µM BPN the Cx43 expression further 
declined and protein distribution and assembly as seen in the control was hardly 
observed (fig 7.12E).  
When the BPN effects on ESDC were compared, the drug showed reduced expression 
but no significant disturbance in protein distribution (fig 7.13). As the dose of BPN 
increased from 50-200µM effects of reduced Cx43 expression were observed but 
they did not drastically change. The protein localization looked very much unaffected 
when compared to the results with TPA treated group.  
7.9.7 Western blot analysis of BPN treated cardiomyocytes in ES and ESDC 
           system 
With increasing doses of BPN a gradual decrease in Cx43 protein levels in the 
micromass system was seen compared to the control. The low dose (BPN 50µM) 
analyzed with Western blotting showed a Cx43 protein level close to control, while at 
100µM the Cx43 protein dropped down and continued further with 200 µM (fig 
7.14C). The phosphorylated Cx43 isoform showed no variation after BPN treatment 
in the MM system (fig 7.14D), while TPA treatment exhibited high levels of PCx43. In 
ESDC the BPN showed no significant variation in Cx43 levels after treatment. The 
high doses of 100 and 200µM BPN after 12 days of treatment appeared to reduce 
the Cx43 levels to some extent but this failed to attain the statistical significance (fig 
7.14E). The phosphorylated protein exhibited reduced expression with increase in 
dose but again the variation was not enough to induce a statistically significant 
reduction (fig 7.14F).  
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Fig 7.12 Cx43 expression in BPN treated chick cardiomyocytes in the MM system. A) Control, B) TPA 100nM, C) BPN 50µM,             
D) BPN 100µM and E) BPN 200µM (Green color represents Cx43 while Blue is DAPI nuclear staining). (Scale bar 33ǋm). 
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Fig 7.13 Cx43 expression in BPN treated ES derived cardiomyocytes. A) Control, B) TPA 100nM, C) BPN 50µM, D) BPN 100µM                   
and E) BPN 200µM (Green color represents Cx43 while Blue is DAPI nuclear staining). 6FDOHEDUǋP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Fig 7.14 Western blot analysis of BPN effects on Cx43 and PCx43 in the MM and 
ESDC systems. A) Cx43, PCx43 and GAPDH blot in MM system (A=Control, 
B=TPA100nM, C=BPN50µM, D=BPN100µM and E=BPN200µM), B) BPN effects on 
Cx43 in MM system, C) BPN effects on PCx43 in MM system, D) Cx43, PCx43 and 
GAPDH blot in ESDC system (A=Control, B=TPA100nM, C=BPN50µM, D=BPN100µM 
and E=BPN200µM), E) BPN effects on Cx43 in ESDC system and F) BPN effects on 
PCx43 in ESDC system. * represents the significant difference from control. 
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7.9.8 Effects of Li2CO3 on Cx43 immunolocalization in the MM and ESDC 
           systems 
In the MM system Li2CO3 at therapeutic serum levels showed effects on cardiac Cx43 
expression, which further became prominent with increase in drug dose (fig 7.15). 
Li2CO3 800µM effects on Cx43 protein localization and turn over were comparable to 
control (fig 7.15C). As the drug dose was increased to 1500µM, disturbed gap 
junction assembly was observed (fig 7.15D). The Li2CO3 2000uM dose further 
reduced the overall expression of Cx43 protein. (fig 7.15E). 
In ESDC, the 800µM treated group exhibited no effect on Cx43 protein expression 
compared to higher doses (7.16C). At 1500µM (fig 7.16D) the drug slightly reduced 
the protein expression with low amount of fluorescent green color localization. With 
2000µM the Cx43 expression was not much affected compared to TPA (fig 7.16E).  
7.9.9 Western blot analysis of Li2CO3 treated cardiomyocytes in ES and  
          ESDC system 
In Western blot analysis lithium carbonate treatment at 800-ǋ0 VKRZHG
UHGXFHG OHYHO RI &[ SURWHLQ LQ WKH 00 V\VWHP ILJ % 7KH GRVH RI ǋ0
reduced the protein expression near to those observed with TPA. The significantly 
reduced protein levels continued with increase in drug dose. In ESDC treatment with 
lithium carbonate failed to produce any effects on cellular Cx43 levels (fig 7.17E). 
The drug effects on phosphorylated Cx43 in the MM system showed an apparent 
reduced cellular level at all doses analyzed, but only at 2000µM reached a 
statistically significant difference (fig 7.17C), while in ESDC no alteration or variation 
in PCx43 levels was observed compared to the control (fig 7.17F).   
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Fig 7.15 Cx43 expression in Li2CO3 treated chick cardiomyocytes in the MM system. A) Control, B) TPA 100nM, C) Li2CO3 800µM,                
D) Li2CO3 1500µM and E) Li2CO3 2000µM (Green color represents Cx43 while Blue is DAPI nuclear staining). (Scale bar 33ǋP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Fig 7.16 Cx43 expression in Li2CO3 treated chick cardiomyocytes in the ES system. A) Control, B) TPA 100nM, C) Li2CO3 800µM,                
D) Li2CO3 1500µM and E) Li2CO3 2000µM (Green color represents Cx43 while Blue is DAPI nuclear staining). 6FDOHEDUǋP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Fig 7.17 Western blot analysis of Li2CO3 effects on Cx43 and PCx43 in the MM and 
ESDC systems. A) Cx43, PCx43 and GAPDH blot in MM system (A=Control, 
B=TPA100nM, C=Li2CO3800µM, D= Li2CO31500µM and E=Li2CO3 2000µM), B) Li2CO3 
effects on Cx43 in MM system, C) Li2CO3 effects on PCx43 in MM system, D) Cx43, 
PCx43 and GAPDH blot in ESDC system (A=Control, B=TPA100nM, C=Li2CO3800µM, 
D= Li2CO31500µM and E=Li2CO3 2000µM),  E) Li2CO3 effects on Cx43 in ESDC 
system and F) Li2CO3 effects on PCx43 in ESDC system. * represents the significant 
difference from control. 
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7.10 Discussion 
This chapter aims to evaluate the possible role of connexin 43 in the etiology of drug 
induced effects on differentiation and contractile activity of cardiomyocytes. The 
developing embryo exhibits highly orchestrated molecular and cellular events 
involving cell signaling, transcription and the flow of information between cells 
(Lanza, 2006; Lanza, 2004) that first differentiates the embryonic stem cells into 
germ layers (Lanza, 2006; Lanza, 2004). With further development the mesodermal 
germ layer predominates in the EBs and differentiates it towards a cardiac lineage 
with synchronized rhythmical phases of relaxation and contraction. The continuous 
flow of information between differentiating cells is important for development, 
growth and regulation (Levin, 2002; Vinken et al., 2006). Small molecules can flow 
directly through gap junction channels between adjacent cells (Leithe & Rivedal, 
2004a). This phenomenon is important, especially in tissue compartmentalization 
and electrical coupling of individual myocytes which mediate rapid synchronized 
contraction (Coppen et al., 2003; Levin, 2002; Vink et al., 2004; Wei et al., 2004). 
In vertebrates, gap junctions are encoded by the connexin gene family (Lo, 2000; 
Michael, 2007; Wei et al., 2004), with Cx43 ubiquitously expressed in almost all cells 
(Laird, 2005) and essential for the normal development and function of the heart 
(Zhaowei et al., 2000 ). The connexin protein, from gene transcription to 
degradation, contributes substantially in a number of physiological and pathological 
processes (Laing et al., 1997; Vinken et al., 2006). Connexin turnover and 
regulation is very important for the formation of functional channels and due to its 
short half-life a continuous regulation of protein synthesis, assembly, trafficking, 
formation of functional channels and degradation is required (Solan & Lampe, 2005). 
Any disturbance in connexin regulation or mutation results in a loss of 
communication between cells (Ruch et al., 2001), but there are reports that different 
connexins in the heart may compensate for loss of function of other connexins (Vink 
et al., 2004). In the heart, mutation or disturbance in Cx43 exhibits various cardiac 
developmental defects with fetal deaths in some cases (Vinken et al., 2006). The 
connexins undergo various biochemical and post translational modifications, with 
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phosphorylation regulating various gap junction functions. (Martin & Evans, 2004; 
Solan et al., 2003). Phosphorylation at the Cx43 Ser368 cytoplasmic tail has been 
shown to be involved in trafficking and channel gating (Lampe et al., 2000). Any 
disturbances in phosphorylation affects connexin regulation (Solan et al., 2003) as 
altered phosphorylation induces changes in connexin structure, which translocate it 
to the cytoplasm instead of forming GJ within the cell membrane (Musil & 
Goodenough, 1990). 
The control group cardiomyocytes in both the MM and ESDC systems tagged with 
anti-connexin43 exhibit intracellular and appositional localization of protein. The 
positive control, the growing chick heart on day 9 of development, as expected 
exhibits high levels of protein, which was further confirmed by imunoblot analysis of 
the protein. No information regarding the use of phospho-Cx43 antibody for 
immunohistochemical analysis was provided by the supplier and when tested the 
antibody produced only non-specific binding (data not shown). Cx43 migration on 
gels exhibits different bands as observed in earlier studies. The unphosphorylated 
band due to its low molecular weight compared to its phosphorylated isoform 
showed increased migration on the gel (Loch-Caruso et al., 2004; Ruch et al., 2001), 
while the red PCx43 band was found in between the green Cx43 band. TPA showed 
reduced Cx43 expression after 100nM treatment for 2hours, at the lower dose of 
50nM the TPA effects were not prominent in immunolocalization and immunoblot 
(data not shown here). TPA acts by hyper phosphorylating the Cx43 at Ser368 
through PKC stimulation, which results in gap junction closure and internalization 
(Loch-Caruso et al., 2004; Ruch et al., 2001), which was evident in immunoblot 
analysis, when low levels of Cx43 were detected with increased phosphorylation of 
the total connexin present at Ser368.  
The sodium valproate treatment of cardiomyocytes reduced the Cx43 level in both 
the systems, which was further confirmed by immunohistochemical analysis of VPA 
treated cardiomyocytes. From the results of Western blotting it can be concluded 
that VPA increases the phosphorylation of Cx43 at Ser368 and affects protein 
regulation. As stated earlier Ser368 phosphorylation regulates some important 
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events in connexin turnover (Lampe & Lau, 2000) and translocates the protein into 
the cytoplasm with increased internalization, which was evident from the results of 
Cx43 immuno analysis (Loch-Caruso et al., 2004; Musil & Goodenough, 1990; Ruch 
et al., 2001). When the results of Cx43 staining were compared for the VPA treated 
cardiomyocytes they clearly show that increased drug dose results in Cx43 
hyperphosphorylation, which affects Cx43 regulation. In turn this interferes with the 
passage of ions, which is necessary to establish contractile activity. The potential 
mechanism for the altered effects could be HDAC inhibition (Phiel et al., 2001) or 
increased ROS production (Na et al., 2003) as observed earlier with VPA treatment 
which may affect the protein. The VPA effects on PKC and Erk1/2 (Gotfryd et al., 
2011; Gurvich et al., 2004) could be another source of inducing disturbance in Cx43 
protein regulation. 
The FDA category C teratogenic drug carbamazepine (Ornoy, 2006), induces 
anomalies in the developing heart (Murabe et al., 2007b). Immunohistochemistry of 
the CBZ treated group in the MM system showed effects on the Cx43 cellular 
distribution. The results of Western blot analysis confirm the reduced turnover of 
Cx43 protein with increase in CBZ dose. These CBZ effects completely support the 
idea that reduced cell contractions observed in the MM system are the result of drug 
effects on Cx43. The decreased Cx43 expression observed with TPA treatment due to 
hyperphosphorylation at Ser368 affects the protein turnover (Cruciani et al., 2002; 
Solan et al., 2003; van Veen et al., 2001). But Western blot analysis of CBZ treated 
chick cardiomyocytes do not support this idea in the MM system, and the PCx43 
levels after CBZ treatment were comparable to the control. It may involve some 
mechanism other than phosphorylation at Ser368 (TenBroek et al., 2001; van Veen 
et al., 2001). In ESDC the cellular expression of Cx43 proteiQDWDQGǋ0&%=
was comparable to control. The cellular Cx43 distribution was unaffected but in 
(6'&LQKLELWHGFRQWUDFWLRQZDVREVHUYHGZLWKǋ0WUHDWPHQWDQGQRFRQWUDFWLRQ
DWWKHǋ0GRVH:HVWHUQEORWDQDO\VLVVXSSRUWVWKHLPPXQRKLVWRFKHPLVWUy result, 
ZLWK XQDIIHFWHG &[ OHYHOV ZLWK  DQG ǋ0 &%= WUHDWPHQW DOWKRXJK VRPH
apparent low levels of PCx43 were observed after these dose treatments. The 
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decreased contraction might have been attributed to altered phosphorylation at 
Ser368, which is involved in many connexin regulation processes, especially in 
channel gating (Lampe & Lau, 2000). It is possible that carbamazepine affects 
channel gating by decreasing phosphorylation, which results in the formation of non-
functional channels. With ǋ0 &%= &[ H[SUHVVLRQ DV VKRZQ E\
immunohistochemistry exhibited reduced levels and GJs ability to form connections 
between cells. That might be the result of reduced cell proliferation due to formation 
RIPRQRSRODU VSLQGOHVZLWKǋ0&%= WUHDWPHQW (Perez Martin et al., 2008). The 
LPPXQREORW DQDO\VLV VKRZHG UHGXFHG&[ZLWK&%=ǋ0 WUHDWPHQWZKLFKPD\
affect cell proliferation and differentiation because connexins plays an important role 
during these processes (Dhein, 1998; Leithe & Rivedal, 2004a; Solan & Lampe, 
2005). The other mechanism could be HDAC inhibition by CBZ which may alter the 
protein expression at the gene level (Beutler et al., 2005; Ornoy, 2009). However, 
Khan found HADC inhibition increased Cx43 levels in neural progenitors with 
decreased phosphorylation of Cx43 (Khan et al., 2007), while in hepatocytes HDAC 
inhibitors negatively affect the Cx43 protein levels (Vinken et al., 2007). These 
effects in part agree with the result observed in our lab. Increased ROS production 
with CBZ treatment may affect protein regulation, especially in case of the MM 
system where disturbed regulation was observed with increased dose compared to 
the control. Treatment with antioxidants may protect the Cx43 protein from ROS 
induced damage.  
7KHDQWLGHSUHVVDQWPROHFXOH%XSURSLRQLQWKH00V\VWHPFRQILUPVWKHGUXJ¶VDELOLW\
to affect the Cx43 protein levels in cultured chick cardiomyocytes. The Western blot 
and immunohistochemistry results with anti-Cx43 indicate reduced protein 
expression. Increase in drug dose seems to affect both the protein levels and cellular 
GLVWULEXWLRQ7KHǋ0%31WUHDWHGFDUGLRP\RF\WHVVKRZHGGLVWXUEHG&[FHOOXODU
organization and assembly at the cell membrane compared to the control. In the MM 
system the BPN affects the cardiomyocyte contractile activity but the effects are only 
REVHUYHGDWǋ0DIWHUGD\VRIH[SRVXUH7KLVPD\PHDQWKDW%31DIIHFWV&[
levels after chronic exposure at high doses but at low doses although some 
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disturbance in protein localization is recorded, other connexins may compensate for 
the effects on Cx43 and so the cells continue to contract (Vink et al., 2004). At high 
doses the significant decrease in Cx43 may cause effects on contractile activity and 
cell proliferation, which involves some mechanism other than Ser368 
hyperphosphorylation in the MM system. In ES cells the BPN does not affect the 
cellular Cx43 protein levels after 12 days of exposure, but the cardiomyocytes 
contraction was affected after BPN treatment. The other parameter of connexin43 
phosphorylation showed reduced levels compared to the control which may affect 
different processes regulated by connexin phosphorylation and in turn may alter 
channel properties and affect contraction. The biphasic property of BPN produces 
inhibition of calcium release which may have the possibility of reducing contractile 
activity (Cremers et al., 2003). 
With the antidepressant drug lithium carbonate, the chick cardiomyocytes exhibit 
low levels of Cx43 which was observed in immunolocalization and Western blot 
analysis of the protein. Increased drug doses showed an effect on protein turnover 
but in the MM system the cardiomyocytes contractile activity was not significantly 
UHGXFHGDWǋ0:KHQWKHGUXJHIIHFWVRQSKRVSKRU\ODWLRQVWDWXVZDVanalyzed 
through immunoblots, a reduced Cx43 phosphorylation at Ser368 residue was 
observed. The disturbed PCx43 may have affected multiple processes in Cx43 
regulation which might have affected the cellular turnover of Cx43. Blood serum 
FRQFHQWUDWLRQV RI DURXQG ǋ0 /L2CO3 are considered toxic. In the MM system 
Cx43 levels and distribution are altered at this dose, but the possibility of 
compensation by other connexins may mean no effect on the contractile activity. In 
the ES cells the effects on Cx43 were less prominent in immunostaining at the same 
dose. The drug showed no effect on protein level after 12 days of treatment. Cx43 
waVQRW DIIHFWHGE\ WKH WR[LFGRVH RIǋ07KHSURWHLQSKRVSKRU\ODWLRQ VWDWXV
also showed no variation compared to control. When the result of immuno analysis 
ZDVFRPSDUHGZLWKFRQWUDFWLOHDFWLYLW\DWDQGǋ0OLWKLXPWUHDWHG(6FHOOV
do not exhibit contractile activity. The decreased contractile activity might be the 
result of drug effects on inositol recycling in the cells (Giles & Bannigan, 1999). 
     
182 
 
Earlier studies confirm that Li+ E\DFFXPXODWLQJǃ-catenin induces Cx43 mRNA and 
protein expression. Also Wnt signaling is an important modulator of Cx43 dependent 
intracellular coupling in the heart and lithium mimics Wnt signaling (Zhaowei et al., 
2000 ).  
The effects of various drugs on Cx43 levels and distribution confirm the role of Cx43 
in contractile activity and cell differentiation. The regulation of Ser368 
phosphorylation in the formation of GJ is also likely. Beside this, the drugs do not 
rely solely on hyperphosphorylation as a potential mechanism to interfere with GJ 
regulation.  
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Chapter 8 
Chick Neural Stem Cell isolation, 
characterization, differentiation and effects of 
teratogens on neuronal differentiation 
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8.1 Introduction 
The central nervous system is a complex organ of the body comprising of the brain 
and spinal cord. CNS cells - neurons, astrocytes and oligodendrocytes - form 
intricate connections to facilitate electro-chemical signalling. These cells form trillions 
of connections, which are made more complex by neuronal types with distinct 
morphology, connectivity and neurotransmission (Ahmed et al., 2009). During 
neurogenesis, neurotoxin exposure may result in neural dysfunction and abnormal 
neural development. In humans the brain continues to develop beyond the second 
trimester of pregnancy, with postnatal maturation continuing through adolescence. 
Neurotoxins have many opportunities to interfere with brain development and 
function during pregnancy and postnatally. The developing brain is much more 
susceptible to toxic insult compared to the adult brain and therefore neurotoxin 
exposure during pregnancy provides a potential threat to induce malformation. 
Neurodevelopmental defects in humans are usually recognised after large scale 
prospective epidemiological studies (Suñol, 2010). With the advent of in vitro 
teratogenicity testing, neurotoxins can be identified at an early stage of screening 
and the related risk may be avoided or rectified. 
8.1.2 Neural Stem cells 
Stem cells are primitive cells that have the ability to proliferate and self-renew, with 
differentiation into major cell lineages. The stem cell property of self-renewal with 
regeneration is an important phenomenon in development and tissue homeostasis 
(Ahmed et al., 2009; Taupin et al., 2000). During neurogenesis CNS cells are 
derived from neural tube cells. These mitotically active cells are neural progenitors, 
precursors or stem cells (Reh, 2002). Neural stem cells (NSC) are relatively 
quiescent and are present in specific regions in the developing and adult nervous 
system. Like all stem cells NSCs have the ability to proliferate, self-renew and 
generate the primary phenotype of the nervous system (Kashem et al., 2009; Ma et 
al., 2006; Wang et al., 2006). The NSC culture system for the isolation, expansion 
and differentiation into CNS progeny provides a unique and powerful in vitro model 
to study and elucidate the molecular mechanisms involved in nervous system 
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development, plasticity and regeneration (Louis & Reynolds, 2005) and may help to 
ameliorate neurodegenerative diseases (Bez et al., 2003; Price & Williams, 2001). 
8.1.3 Neurogenesis 
The CNS is composed of four major types of cell: neurons, oligodendrocytes, 
astrocytes and the ependymal lining of the central lumen. These cells arise from 
common neuroepithelial cells in the neural tube that produce neurons first then glial 
cells at later stages (Kintner, 2002). Neurogenesis was first thought to be limited to 
during prenatal development, however it occurs throughout adulthood in various 
region of brain such as the subventricular zone (SVZ) and subgranular zone (SGZ) of 
the dentate gyrus (Taupin et al., 2000). After fertilization, the epiblast cells in the 
blastocyst differentiate into three germ layers. The primitive streak elongates with 
the formation of the anterior and posterior axis and embryo regionalization and 
differentiation starts. These highly orchestrated processes are controlled by cyclic 
expression of various signalling molecules, growth factors and an extracellular 
matrix gradient (Bottenstein, 2003). The early neural tube formed at the anterior 
end of primitive streak is composed of homogenous proliferating cells known as 
neuroepithelial cells (Sommer & Rao, 2002). These cells proliferate and elongate in 
response to the mitogen Fibroblast growth factor-2 (FGF2) to form the neural plate 
and undergo a series of morphological changes with the formation of a closed neural 
tube. Posterior mesenchymal cells canalize and extend the spinal cord into the 
lumbosacral region (secondary neurulation). The number of neuroepithelial cells 
reduces during development as they transform into neural and glial precursors. 
These precursors start to express appropriate receptors for additional growth and 
differentiation, notably EGF receptors, which increase the NSC population in the 
neuroepithelial cells (Bottenstein, 2003). These neural stem cells differentiate in 
response to specific signals and migrate to target regions to contribute to brain 
development (Sommer & Rao, 2002). Mitogens like FGF and EGF promote NSC and 
progenitor cell proliferation in vivo and in vitro (Taupin et al., 2000).   
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8.1.4 Control of Stem cell behaviour and differentiation: Growth factors and 
signalling molecules 
Neurogenesis involves first the generation of lineage committed progenitors followed 
by their terminal differentiation into brain cell types (Ahmed et al., 2009). The stem 
cell microenvironment regulates progenitor self-renewal and differentiation, via 
several intrinsic and extrinsic determinants in vitro and in vivo including Wnt, Notch 
and, Sonic hedgehog (SHH) (Scott et al., 2010; Shi et al., 2008). These trigger 
pathways are mediated through various growth factors and molecules which act at 
different stages of stem cell development and differentiation and sculpt the whole 
brain. The early NSC respond to FGF which acts as a mitogen and increases the pool 
of NSC - decrease in FGF receptors results in decreased NSC proliferation (Sommer 
& Rao, 2002). Later-stage NSC respond to EGF along with FGF (Bottenstein, 2003; 
Sommer & Rao, 2002). Therefore the mitogens FGF and EGF play an important role 
in neural stem cells proliferation and self-renewal. These growth factors modulate 
extracellular matrix component secretion and composition such as laminin B1 and B2 
chains, which up-regulate the NSC proliferation. Along with these mitogens and 
adhesion molecules the NSC express various integrins, extracellular components and 
neurotransmitters which may regulate NSC numbers (Sommer & Rao, 2002). 
Various signalling pathways like cAMP, PKA and calcium may also regulate NSC 
proliferation. Despite continued exposure to proliferative signals the cells respond to 
signalling molecules for a specific period of time only and undergo differentiation, 
apoptosis or senescence (Sommer & Rao, 2002). 'XULQJ QHXURJHQHVLV WKH :QWǃ-
catenin pathway plays an important role in NSC proliferation and self-renewal by 
acting on cyclin D1 (Ahmed et al., 2009; Shi et al., 2008). It controls progenitor 
expansion and differentiation balance, and depending upon the stage of 
GHYHORSPHQWLWPD\SURPRWH16&SUROLIHUDWLRQRUQHXURQDOGLIIHUHQWLDWLRQǃ-catenin 
has been shown to promote neural differentiation, but in the presence of FGF-2 it 
inhibits neuronal differentaition0XWDWLRQ LQǃ-catenin results in midbrain boundary 
cell elimination while overexpression results in hyper-cellularity of the brain (Ahmed 
et al., 2009). Besides this, notch and sonic hedgehog signalling have been implicated 
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in regulating key pathways in the balance between neural progenitor expansion and 
differentiation balance. It can be concluded that Wnt, Notch and Shh signalling 
appears to be essential for NSC maintenance and differentiation (Ahmed et al., 
2009). FGF-2 has both mitogenic and neurotrophic action (Vescovi et al., 1993). Low 
levels of FGF promote neuronal differentiation, while higher levels promotes glial 
differentiation (Bottenstein, 2003). In vitro FGF-2 is used in the presence of heparin, 
which is shown to enhance FGF-2 induced NSC proliferation, while also reducing the 
number of astrocytes differentiating. Insulin has also been found to enhance the 
proliferative effects of FGF-2 (Kelly et al., 2003). Neurotrophins like NGF, BDNF and 
NT3 receptors are expressed early in neural progenitor cell formation. Addition of 
BDNF to the culture of neurospheres obtained from E-15 mouse brain promotes 
differentiation of multipolar neurons. In vitro BDNF increased the hippocampal stem 
cells survival and differentiation. While NT3 promotes NSCs differentiation by 
increasing the length of G1 phase of cell division and decreasing cyclin D2. 
Intraventricular infusion of NT3, like BDNF, increased the number of neurons in the 
cortical plate, and both NT3 and NT4 increased neuronal survival rather than 
neuronal commitment in human neurospheres (Bottenstein, 2003). Addition of B27 
and N2 supplements to the medium promotes NSC survival and differentiation 
(Svendsen et al., 1995). Recently it has been demonstrated that BDNF promotes the 
differentiation of neural crest cells along a sensory neuron lineage, and that BDNF 
and NT-3 promote the maturation of embryonic chick sensory neurons in vitro 
(Ghosh & Greenberg, 1995).  
8.1.5 Neural stem cells in vitro isolation and differentiation 
The earlier evidence of adult neurogenesis was presented by Joseph Altaman and 
*RSDO 'DV LQ WKH ¶V (Altman, 1962; Altman & Das, 1965 ), which totally 
contradicts the long held dogma of no new neurons after birth proposed originally by 
Cajal (Ming & Song, 2005). In a landmark paper Reylond and Weiss in 1992 further 
disapproved the earlier belief that neurogenesis in adults CNS does not occur and 
first isolated the adult mouse NSC and established the in vitro method of 
neurosphere formation (Reynolds & Weiss, 1992). The embryonic brain contains a 
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large population of NSC which are restricted to certain regions in the adult brain 
(Taupin et al., 2000). The neurosphere formation assay has been applied to both 
embryonic and adult tissues (Ahmed, 2009). The isolated NSCs are grown in vitro in 
a serum free medium, where these cells form aggregates or neurospheres. These 
neurospheres are mostly round shaped consisting of 3D aggregates of cells, 
containing a heterogeneous population of progenitor cells along with neuronal and 
glial lineage cells at different stages of differentiation (Ahmed, 2009; Wang et al., 
2006). The cells in the neurosphere  are multipotent and differentiate into major 
CNS lineages (Lim et al., 2007). The idea of the neurosphere-formation assay was 
based on the fact that the cells which form neurospheres are NSC, and these cells 
proliferate, self-renew and differentiate in vitro upon provision of appropriate 
microenvironmental cues (Ahmed, 2009; Gobbel et al., 2003). In vitro these NSCs 
are maintained in the presence of mitogens FGF and EGF with serum replacement 
supplements like N2 and B27 which expands their number without the loss of 
differentiation potential (Gobbel et al., 2003). These neurospheres enlarge and 
become darker at the centre representing increased apoptotic and necrotic events 
due to an insufficiently nourished inner core and hypoxic conditions (Bez et al., 
2003). These neurospheres are enriched in integrin, cadherin and EGF receptors. 
NSC survival in neurospheres critically depends on the growth conditions and 
supplements in the in vitro system. High density cultures of NSC exhibit neurosphere 
aggregation. To date there are no definite markers for NSC; the formation of 
neurospheres in vitro is still considered the indicator of NSC presence (Ahmed, 
2009). However, the intermediate filament protein nestin (Storch et al., 2003), 
transcription factor SOX2 and transmembrane glycoprotein CD133 are used to 
identify NSC presence (Ahmed et al., 2009). When the mitogens are removed the 
NSC differentiate in vitro on a PDL coated substrate (which promotes neurite growth 
and cell viability) (Ahmed, 2009; Gobbel et al., 2003). In the presence of 
serum/laminin these cells differentiate into predominantly astrocytes followed by 
neurons and then oligodendrocytes. The addition of growth and neurotrophic factors 
such as BDNF, NT3, NT4, bFGF, IGF-1 and retinoic acid significantly increases 
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neuronal differentiation, while PDGF promotes oligodendrocytes and NGF peripheral 
neurons and astrocytes. Thus from the earlier studies it is observed that 
neurosphere derived cells are multipotent and the media composition and growth 
factors regulates their differentiation into specific lineage cells (Ahmed et al., 2009; 
Gobbel et al., 2003; Ren et al., 2009).  
8.1.6 Neural stem cells characterization 
The neural stem cell has the ability to proliferate, self-renew and differentiate into 
nervous system progeny. Various markers have been used in vivo and in vitro to 
characterize the stem cells including transcription factors that maintain neural 
progenitor cells (Graham et al., 2003). The NSC ability to form neurospheres in vitro 
is frequently used to identify stem cells (Ahmed, 2009). The intermediate filament 
nestin is used as a marker of NSC but it is also expressed in immature neurons 
(Brazel et al., 2005; Miyagi et al., 2006). Beside this Notch1, Sox2 and c-Myc are 
also used to characterize NSC presence (Kerosuo et al., 2008; Miyagi et al., 2006; 
Wang et al., 2004). The transcription factor SOX2 is expressed in epiblast cells as 
well as embryonic, neural and trophoblast stem cells but not in the differentiated 
cells (Miyagi et al., 2006; Scott et al., 2010). In NSC SOX2 is expressed both in 
adult and embryonic progenitor cells (Ahmed et al., 2009). SOX2 appears to be a 
common marker for all cells within these heterogeneous population in neurospheres 
(Miyagi et al., 2006). SOX2 along with Nanong and Oct4 through co-operative 
interaction maintain the stem cell phenotype (Ahmed et al., 2009; Rodda et al., 
2005). Its down regulation results in neural progenitor pool depletion with induction 
of neuronal differentiation (Ahmed et al., 2009; Graham et al., 2003). In mature 
neurons SOX2 expression is absent (Komitova & Eriksson, 2004). SOX2 knockout 
mouse die at around the implantation stage (Miyagi et al., 2006; Uchikawa et al., 
2011).  
8.1.7 Neuronal marker-Neurofilament 
Neurofilaments (NF), along with various other cytoskeleton proteins, form the basic 
neuronal structure. NFs are most abundant, ubiquitous neuron specific filaments and 
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are used as marker of neurons (Grant & Pant, 2000; Schwartz et al., 1992). NF are 
composed of three major subunits NF-L (68KDa), NF-M (120KDa) and NF-H 
(200KDa) (Bottenstein, 2003). They are distributed in neuronal axons, dendrites and 
perikaryons (Hashimoto et al., 2000). NF mediates radial growth and determines 
axonal diameter, which directly regulates the rate of nerve conduction velocity. NF-L 
loss results in axonal diameter reduction, While its accumulation results in disturbed 
transport and neurodegenerative diseases (Bottenstein, 2003; Dale & Garcia, 2012). 
Neurofilament-L was chosen in this work because it is abundant in neurons 
compared to its  high molecular weight subunits (Bottenstein, 2003; Jung, 2007).  
8.2 Methodology   
8.2.1 Chick NSC Isolation 
For the isolation of chick neural stem cells, eggs were incubated at 37C, 100% 
humidity for the required days. On the day of explantation, embryos were dissected 
in 2% glucose solution in cold PBS (Ca2+ and Mg2+ free) under the dissecting 
microscope (Nikon, UK). The embryos were decapitated first then the brain was 
removed using fine sterilized forceps and micro scissors. The meninges were 
removed carefully and the brain tissues were transferred into a 15ml universal tube 
containing cold PBS with 2% glucose on ice. The brain was allowed to settle down 
and the glucose solution was removed after centrifuging at 400rpm for 5 minutes. 
Tissues were suspended in 1ml (for 12 brains) complete NSC culture medium and 
dissociated manually by pipetting up and down, first using a 1ml pipette tip then 
200µl tip until a single cell suspension was obtained. The tissues were allowed to 
settle down and the supernatant was removed. The undissociated tissues were 
suspended again in 1ml medium and gently triturated to obtain a single cell 
suspension. The cell density and cell viability was determined using a 
haemocytometer with a 0.4% Trypan blue solution (see appendix 5). Viable cells at 
a 0.3-0.5×106 cellsml-1 density were suspended in 10ml NSC culture medium in a 
low attachment T-25 flask. The cells start to form floating neurospheres within 2-3 
days, frequent shaking helps the neurospheres to detach from the surface. On day 4 
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the medium was changed by centrifuging the culture flask at low speed 400rpm for 5 
min and removing the supernatant containing dead floating cells. The neurospheres 
were re-suspended in 10ml NSC culture medium. 
8.2.2 Sub culturing the Neurospheres 
When the neurospheres were grown to considerable size (more than 100µm) they 
were passaged to avoid cell necrosis. The culture medium containing the 
neurospheres was collected in a universal flask. The T-25 flasks were washed with 
warm PBS (Ca2+ and Mg2+ free) to detach the attached neurospheres. The 
neurospheres were centrifuged at 900-1000rpm for 5 min and the supernatant was 
removed. The neurospheres were washed in PBS followed by centrifugation at the 
same speed. The collected neurospheres were dissociated using 1ml 0.1% trypsin 
solution in Ca2+ and Mg2+ free PBS and incubated for 5 min at 37oC. After 5 min the 
neurospheres were dissociated again by gentle trituration (50 times) using a 200µl 
pipette tip and incubated again for 3 min. 5ml culture medium was added to the 
trypsinized cells and centrifuged at 900-1000rpm for 5 min. The pellet was 
suspended in 2ml medium, and cell density and cell viability was determined using a 
haemocytometer (see appendix 5). 0.3-0.5×106 viable cellsml-1 were suspended 
again in culture medium in a T-25 flask and labelled with passage number and date.  
8.2.3 NSC differentiation 
8.2.3.1 PDL coating  
 
ǋJPO-1 poly-D-Lysine (PDL) solution was prepared in distilled water. The 96-well 
SODWHVZHUHFRDWHGRYHUQLJKWZLWKǋOZHOO-1 PDL solution at room temperature. The 
solution was aspirated and wells were rinsed with sterile distilled water to remove 
the excess PDL. The plates were dried at room temperature and stored at 4-8oC for 
future use. In the case of coverslip coating, the coverslips were first washed in 
alcohol followed by 3 washes in distilled water and then autoclaved. Overnight PDL 
coating was followed by a rinse and drying. The coverslips were transferred to 24-
well plates using sterile forceps.  
 
     
192 
 
8.2.3.2 NSC differentiation into neurons 
After preparing a single suspension of neurospheres (see section 8.2.2), the cells 
were either passaged or differentiated into neurons. For differentiation the cells were 
suspended in a complete differentiating medium (see appendix 2.4) and cell density 
and cell viability was determined (see appendix 5). $ ǋO DOLTXRW RI î6 
cellsml-1 was placed at the centre of the PDL coated 96-ZHOOSODWHVDQGǋODOLTXRW
containing 104 cells on the PDL coated coverslips. The cell were allowed to attach for 
4h and flooded with more differentiating medium. In the case of drug effects 
evaluation, the medium containing the required drug dose was added after 4h of cell 
seeding (control cultures received carrier medium only). The cell viability was 
determined using LDH (see section 8.3.2) and resazurin assays (see section 2.5.2.1) 
on day 6 of differentiation followed by Kenacid blue total protein content estimation 
(see section 2.5.3.1). 
8.3 End Points 
Three end points were used in this study to estimate the effects of drugs on NSC 
differentiation into neurons. 
8.3.1 Resazurin and Kenacid blue assay   
For the resazurin (see section 2.5.2.1) and kenacid blue assay (see section 2.5.3.1) 
the same methods were applied as stated in section 2.5. In the resazurin assay the 
time of dye incubation was reduced to 45 min as it was found that NSC are fast 
growing cells and they readily reduced the dye to resorufin.  
8.3.2 Lactic dehydrogenase (LDH) assay 
Measurement of the release of LDH into the media is used as a marker of dead cells. 
For measurement of LDH in the medium a Sigma-Aldrich, UK LDH detection kit was 
used. In brief the cells were grown as described in section 8.2.4.2. On the 6th day of 
NSC differentiation the culture medium from the 96-well plate was transferred to 
another 96-well plate in a laminar flow hood. The plate containing the medium was 
centrifuged at 250×g for 4 min and then used for enzymatic analysis. The LDH assay 
mixture was prepared prior to use by mixing an equal volume of LDH assay 
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substrate solution, LDH assay dye solution and 1× LDH assay cofactor preparation. 
ǋOFHQWULIXJHGFXOWXUHPHGLXPZDVWUDQVIHULQWRDIODWERWWRPHG-well plate and 
WZLFHWKHDPRXQWRI/'+DVVD\PL[WXUHǋOZDVDGGHG7KHSODWHZDVSURWHFWHG
from light and incubated at RT for 20-PLQǋORI1+&OZDVDGGHGWRHDFKZHOO 
to terminate the reaction. The absorbance was recorded at wavelength 490nm with 
690nm background. The background absorbance wavelength was subtracted from 
dye absorbance and the results were expressed as the percentage of controls.  
8.3.3 Material and method for Western blot and Immunohistochemistry  
The materials (appendix 1) and methods for Western blot (WB) (see section 2.8) and 
immunohistochemistry (IHC) (see section 2.7) are discussed in detail in chapter 2. 
8.3.4 In cell Western blot 
For the neurofilament-/ SURWHLQ DQDO\VLV LQ GLIIHUHQWLDWHG QHXURQV WKH µ,Q FHOO¶
Western blot method was used. 0.1×106 cellswell-1 were grown in black walled clear 
bottomed 96-wells plates. On the 6th day of differentiation the cells were washed in 
PBS first followed by 20 min fixation in 4% PFA (see appendix 3). The cells were 
washed again and permeabilized for 30 min using 0.15% triton solution in TBST (see 
appendix 3). Using 3% Fish skin gelatin (FSG) solution in TBST the cell were blocked 
for 30 min and incubated overnight with mouse monoclonal Neurofilament-L primary 
antibody (1:300) and rabbit GAPDH (1:3000) prepared in 3% FSG solution. The next 
day cells were washed three times with PBS and incubated with secondary antibodies 
(green mouse 1:3000 and red rabbit 1:3000 (see appendix 4.3)) for 1h at 37oC. The 
cells were washed again with PBS and plate was scanned using an Odyssey scanner 
DWUHVROXWLRQǋPNHHSLQJWKHRIIVHWDW 
8.4 Results 
8.4.1 Determination of chick NSC isolation day 
The exact chick NSC isolation day was determined using the NSC marker SOX2 
(Sigma-Aldrich, UK). The undifferentiated mouse embryonic stem cells were used as 
a positive control because of their ability to exhibit cellular SOX2 presence 
(Yamanaka et al., 2008). 4-8 day old chick brains were isolated (see section 8.2.1) 
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and Western blot (WB) samples were prepared as described earlier in section 
2.8.4.2. The SOX2 antibody band, according to supplied information is observed 
between 34-37kDa. The results of SOX2 WB indicate a green band below 40KDa 
molecular weight marker, while the housekeeping gene GAPDH (red band) with a 
molecular weight 37KDa was observed above it (fig 8.1B). When the results were 
analysed (fig 8.1A), the SOX2 ratio to GPADH clearly shows the positive presence of 
SOX2 at days 4-8 of chick brain development along with ES cells as a positive 
control. At day 4 the expression was low which increased with further development 
on day 5 and remained more or less constant up to day 7 and started to decline 
after day 7 (fig 8.1A). The day 5 chick embryo brains were selected for the neural 
stem cell isolation assay because of the early stage of development and high levels 
of SOX2 which represent a NSCs pool.  
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Fig 8.1A The graphical representation of Western blot analysis of SOX2 
expression in positive control embryonic stem cells (ES cells) and in embryonic 
day 4-8 chick brains. The graph shows the presence of the stem cell marker SOX2 
in ES cells, while the SOX2 expression increased after day 4 of development in 
chick brain and was maintained until day 7. The day 8 brain showed some 
decreased SOX2 values compared to earlier days. The embryonic day 5 brain was 
selected for NSC assay because of increased SOX2 expression at earlier days of 
development. 
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Fig 8.1B Western blot picture of anti-SOX2 staining of fig 8.1A. The SOX2 (mol.wt 
34-37KDa) protein band is seen below GAPDH (mol.wt 37KDa). The SOX2 protein 
was normalized using GAPDH to calculate the amount of SOX2 present in total 
number of cells. 
 
 
8.4.2 NSC characterization 
The chick neurospheres were characterized either using the NSC marker SOX2, or by 
their intrinsic property to form floating neurospheres (Ahmed, 2009), resembling the 
D3 ES cell embryoid bodies (see section 2.4.2.4). The cells when cultured formed 
floating neurospheres after 3 days (see section 8.2.2), the size and number of 
spheres formed depended upon the initial cell seeding density (fig 8.2A and B). 
When the neurospheres become considerably enlarged the central region becomes 
dark (fig 8.2C) and neurospheres start clumping together (fig 8.2D). 
 
40KDa 
25KDa 
GAPDH 
SOX2 
ESCs    Day4    Day5     Day6    Day7    Day8 
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C D
Fig 8.2 NSC neurospheres formation in an in vitro system. (A) On day 1 the cells 
start to come close and communicate with each other to form neurospheres, (B) on 
day 3 these small cell aggregates (neurospheres) further increase in size (C) black 
coloured necrotic areas can be seen in enlarged neurospheres (magnification ×25), 
and D) large neurospheres shows clumping and increased dark areas (magnification 
×20). 
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The neurospheres were stained with the NSC marker SOX2 using IHC techniques 
(see section 2.7.2) to confirm the presence of neural stem cells. Under the 
fluorescent microscope the neurospheres showed the positive presence of SOX2 
protein in the neurosphere cells (fig 8.3A).  
        
                                            
A B
C
Fig 8. 3 NSC characterization with SOX2 immunostaining of neurospheres. A) SOX2 
staining indicating the NSC presence in the neurosphere, B) DAPI nuclear staining 
of cells present in the neurospheres and C) SOX2 and DAPI merge. 
 
8.4.3 NSC differentiation into neurons 
For the NSC differentiation into neurons two approaches were applied. Firstly 
neuronal differentiation with addition of low doses of FGF-2 (5ngml-1) compared to 
no FGF-2; secondly the use of different concentrations of chicken serum. The extent 
RI QHXURQDO GLIIHUHQWLDWLRQ ZDV DQDO\VHG XVLQJ WKH ǃ-Tubulin III (1:1000) marker 
which is expressed in differentiating neuronal cells (Bottenstein, 2003), while Glial 
fibrillary acidic protein (GFAP) (1:15000) was used for astrocytes  (Bottenstein, 
2003). The Western blotting (WB) procedure is described earlier in section 2.8.3. 
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The :%EORWUHVXOWVFOHDUO\LQGLFDWHWKHSUHVHQFHRIǃ-Tubulin III and GFAP proteins 
with all different combinations (fig 8.4C), but the presence of serum promoted GFAP 
expression (astrocytes) (fig 8.4B), while low concentration of FGF- SURPRWHG ǃ-
Tubulin III (neuronal differentiation) particularly in the absence of chicken serum (fig 
8.4A). NSC differentiation in the absence of chicken serum with low concentration of 
FGF-2 (5ngml-1) was selected for the neuronal differentiation and estimation of drug 
effects.  
E-tubulin III
R
a
ti
o
 
o
f
E-
tu
b
u
li
n
 
II
I 
to
 
G
A
P
D
H
No
 
F+
No
 S
No
 
F+
1%
S
No
 
F+
5%
S
F+
No
S
F+
1%
S
F+
5%
S
Ad
ult
 m
ou
se
 
br
ain
0.00
0.01
0.02
0.03
0.04
0.05
A) GFAP
R
a
ti
o
 
o
f 
G
F
A
P
 
to
 
G
A
P
D
H
No
 
F+
No
 S
No
 
F+
1%
S
No
 
F+
5%
S
F+
No
S
F+
1%
S
F+
5%
S
Ad
ult
 m
ou
se
 
br
ain
0.0
0.5
1.0
1.5
B)
Fig 8.4A and B Result of Western blot analysis of NSC differentiation into neurons 
in the presence and absence of FGF-2 (F) and chicken serum (S). The adult mouse 
EUDLQ ZDV XVHG DV FRQWURO $ 7KH EDU JUDSK LQGLFDWHV ǃ-tubulin III protein 
expression in the presence of FGF-2 and absence of chicken serum increases, B) 
NSC differentiation into astrocytes (GFAP) is promoted by the increase in serum 
concentration.      
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C)
D)
40KDa GAPDH
50KDa
60KDa
E-Tubulin III
 GFAP
5ng/ml FGF        - - - + + + - 
Serum - 1% 5% - 1% 5% - 
Adult mouse  
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- - - - - - + 
 
Fig 8.4C The Western blot picture of ǃ-tubulin III and GFAP protein expression in 
in differentiating NSC in the presence and absence of FGF-2 and chicken serum. The 
blot indicates an increase in expression of GFAP with increased serum concentration 
while NSC differentiation into neurons (ǃ-tubulin III) was found to increase in the 
presence of FGF-2 with no serum supplements. Fig 8.4D Represents the house 
keeping gene GAPDH ZKLFK ZDV XVHG WR QRUPDOL]H WKH ǃ-tubulin III and GFAP 
proteins. 
 
 
 
Differentiated neurons in the presence of FGF-2 (5ngml-1) and absence of serum 
were immunostained (see section 2.7.2) with the neuronal marker neurofilament-L 
(NF-L) (see appendix 4.1.1) to confirm the presence of neurons on day 6 of NSC 
differentiation. The stained cells, when observed under the fluorescent microscope, 
exhibited the positive presence of neurofilament-L on day 6 of differentiation (fig 
8.5C and D). 
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Fig 8.5 Neural stem cell differentiation into neurons in the presence of low FGF-2 
concentration (5ngml-1) and absence of serum. Fig 8.5A and B shows differentiated 
neurons on experimental day 6 (magnification ×20). Fig 8.5C represents the NF-L 
staining of neurons while fig 8.5D represents NF-L staining merged with DAPI 
nuclear stain. 
 
8.4.4 Effects of known drugs on NSC derived neurons  
NSC differentiation into neurons was tested using known drugs, whose toxic nature 
is already recorded in the literature. Penicillin G (PG) is a non-teratogenic drug 
(Anneelieke et al., 2007) which exhibits comparable LDH release in the medium to 
the control (fig 8.6A). No significant effect on cell viability or protein was observed 
on neuronal differentiation after 6 days treatment with PG (fig 8.6B and C). The non-
teratogenic analogue of 5-Fluorouracil (5-Fu), 6-Methyluracil (6-Mu) (Cumberland et 
al., 1994) showed some increased percentage of LDH release in the medium 
compared to control (fig 8.6A), but cell viability and total protein content remained 
not significantly different to the control (fig 8.6B and C). The teratogenic drug 5-Fu 
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(Anneelieke et al., 2007) showed a decreased percentage of LDH release in the 
medium compared to the control (fig 8.6A), and cell proliferation and viability were 
also significantly reduced after 5-Fu treatment compared to the control (fig 8.6B and 
C).  
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8.4.5 Effects of selected teratogens on NSC derived neurons 
8.4.5.1 Sodium valproate 
The chick NSC derived neurons were treated with 3 doses of VPA ranging from blood 
VHUXP OHYHOV ǋ0 WR D YHU\ KLJK GRVH ǋ0 ILJ $ B and C). After six 
days of treatment the VPA treated neurons were subjected to LDH release and 
resazurin cell viability assays. Using the resazurin assay the 5-Fu (which is used as 
negative control because of its known effects on NSC differentiation (fig 8.6)) 
affected the neuronal viability to significantly low levels compared to the control 
(P<0.05), while the cell viability of VPA treated neurons remained as in the control 
even at the 800µM dose (fig 8.7B). At lower doses, VPA100uM treated cells exhibited 
an apparent increased release of LDH into the medium compared to high doses 
ǋ0H[SUHVVHGDVDSHUFHQWDJHRIWKHFRQWUROYDOXHVILJ$:KHQWKHVDPH
cells were subjected to total protein content estimation the results were comparable 
with those from resazurin cell viability assay (fig 8.7B and C). The 5-Fu significantly 
affected the cell proliferation while VPA showed no significant difference from the 
control (fig 8.7C).  
8.4.5.2 Carbamazepine 
The second antiepileptic drug (AED) carbamazepine was tested on differentiating 
neurons at a dose ranging from 50-400µM. The toxic effects on resazurin cell 
viability were evident with increased dose (fig 8.7E). The 400µM CBZ dose exhibited 
some significantly reduced cell viability compared to the control. The declining trend 
was obvious with increased dose, at low doses (50µM) the neurons showed apparent 
improved cell viability in comparison to the control (fig 8.7E). Using the cell 
proliferation Kenacid blue assay similar effects were observed showing a decreased 
proliferation with increased dose, but the control and 50µM CBZ treatment showed 
FRPSDUDEOHSURWHLQFRQFHQWUDWLRQVILJ)ZKLOHDWǋ0LWEHFDPHVLJQLILFDQWO\
different to control (fig 8.7F) (fig 8.7E). When the drug effects on LDH release were 
FRPSDUHGDVDSHUFHQWDJHRIWKHFRQWUROWKHDQGǋ0&%=HYHQZLWKUHGXFHG
cell proliferation showed high levels of LDH release in the medium (fig 8.7D). 
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Fig 8.7 Effects of VPA and CBZ on NSC derived neurons. A) LDH assay for 
VPA, B) resazurin cell viability for VPA, C) Kenacid blue total protein content 
estimation for VPA, D) LDH assay for CBZ, E) resazurin cell viability for CBZ 
and F) Kenacid blue total protein content estimation for CBZ. * represents a 
significant difference from control. 
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8.4.5.3 Bupropion hydrochloride 
The antidepressant molecule bupropion (BPN) showed similar effects to those 
observed with cardiomyocytes (fig 5.3). Increasing the dose of bupropion decreased 
cell viability (fig 8.8B). Compared to the control the drug dose effects were 
significant at 200µM. The drug effects on total protein content indicated reduced cell 
proliferation. As the drug dose was raised from 25-ǋ0VRPHVLJQLILFDQWGLIIHUHQFH
ZDV REVHUYHG DW KLJK GRVHV ǋ0 ILJ &. With respect to LDH release (fig 
8.8A), an increase in BPN dose resulted in an increase in LDH release in spite of 
reduced cell number.  
8.4.5.4 Lithium Carbonate 
When the differentiating neurons were treated with antidepressant molecule lithium 
carbonate, in the blood therapeutic serum range (600-ǋ0LWVKRZHGQRVLJQV
of toxicity or changes in cell viability (fig 8.8E and F). The effect of the drug at doses 
of 500 and 1000µM were comparable to control, but as the dose was increased 
above serum therDSHXWLF OHYHOV ǋ0 WKH FHOO YLDELOLW\GHFUHDVHGEXW IDLOHG WR
achieve significant difference from control (fig 8.8E). The effects on protein content 
showed a similar trend to the cell viability results (fig 8.8 F). No significant changes 
in cell proliferation were observed at 500 -2000µM compared to control (fig 8.8F). In 
LDH assay an increased percentage of LDH release in the medium was observed 
compared to control at 500-ǋ0WUHDWHGJURXSVILJ' 
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Fig 8.8 Effects of BPN and Li2CO3 on NSC derived neurons. A) LDH assay for BPN,  
B)  resazurin cell viability for BPN, C) Kenacid blue total protein content estimation 
for BPN, D) LDH assay for Li2CO3, E) resazurin cell viability for Li2CO3 and F) Kenacid 
blue total protein estimation for Li2CO3. * represents a significant difference from 
control. 
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8.4.6 Effects of drugs on Neurofilament-L expression in NSC derived 
neurons 
 
8VLQJµ,QFHOO¶:HVWHUQEORW,&:WHFKQLTXHVWKHHIIHFWVRIWKHVHGUXJVRQQHXURQDO
differentiation were evaluated. The neurofilament-L protein levels were normalized 
from GAPDH representing the total amount of protein (see section 7.8.3). VPA 
showed no significant effects with increase in drug dose between 100-ǋ0 ILJ
8.9A). The negative control 5-Fu also did not alter the NF-L protein levels to 
significantly different values in differentiating neurons (fig 8.9A). With 
carbamazepine (50-ǋ0 QR VLJQLILFDQW DOWHUDWLRQ LQ WKH SURWHLQ OHYHOV ZHUH
observed in NSC derived neurons when analysed using ICW technique (fig 8.9B).  
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Fig 8.9C-H Represents neurofilament-L LQ DQ µ,Q FHOO¶ :HVWHUQ EORW SLFWXUH RI D
scanned plate. NF-L expression in differentiated neurons after VPA (fig 8.9C) and 
CBZ (fig 8.9F) treatment remained no different to control. The GAPDH (fig 8.9D and 
G) was used to normalize the total NF-L protein present in cells, while fig 8.9E and F 
represents the merge of NF-L and GAPDH.  
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The antidepressant drug bupropion effects were comparable for protein NF-L levels 
DIWHU  DQG ǋ0 WUHDWPHQW WKH KLJK GRVH ǋ0 DSSHDUHG WR UHGXFH SURWHLQ
levels but again failed to achieve statistically significant difference (fig 8.10A). The 
fourth drug tested in this system was lithium carbonate which exhibited an 
inconsistent decline in NF-L protein with increase in drug dose, none of which 
achieved a significant difference (fig 8.10B) from the control. 
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Fig 8.10A and B µ,Q FHOO¶ :HVWHUQ EORW UHVXOWV RI %31 DQG /L2CO3 effects on 
Neurofilament-L expression in NSC derived neurons. A) BPN showed no significant 
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B) Li2CO3 showed no significant difference from the control at any dose.  
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Fig 8.10C-H Represents the neurofilament-L µ,Q FHOO¶ :HVWHUQ EORW SLFWXUH RI D
scanned plate. The NF-L expression in differentiated neurons after BPN (fig 8.10C) 
and Li2CO3 (fig 8.10F) treatment remained no different to the control. The GAPDH 
(fig 8.10D and G) was used to normalize the total NF-L protein present in cells, while 
fig 8.10E and F represents the merge of NF-L and GAPDH.  
 
8.5 Discussion 
Neural stem cells in the nervous system provide a unique pool of cells that have the 
potential to develop into the entire nervous system and maintain tissue homeostasis  
throughout adulthood (Ahmed et al., 2009; Taupin et al., 2000). The neural stem 
cells, similar to other stem cells, have the ability to proliferate and self-renew to 
maintain the primitive cell pool and differentiate into CNS lineages to replace 
malfunctioning and dead cells (Reynolds & Weiss, 1996). During development NSC 
are derived from neuroepithelium cells (NEP). These cells upon activation of 
particular signalling pathways direct their fate to nervous cell lineages - neurons, 
astrocytes and oligodendrocytes (Sommer & Rao, 2002). Earlier studies by Cajal 
suggesting no postnatal neurogenesis (Ming & Song, 2005) were disapproved by 
Joseph AltDPDQDQG*RSDO'DVLQWKH¶VE\H[KLELWLQJWKHSUHVHQFHRIGLYLGLQJ
cells in the adult central nervous system (Altman, 1962; Altman & Das, 1965 ). 
Reynolds and Weiss further confounded this old idea by isolating and culturing NSC 
from adult brain which proliferated in response to the mitogen EGF (Reynolds & 
Weiss, 1992). During fetal neurogenesis a large number of NSC are present but as 
development proceeds these cells migrate and differentiate into their committed cell 
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types, and in the adult brain the neurogenesis continues only in SVZ and SGZ of the 
dentate gyrus (Bottenstein, 2003).  
The in vitro isolation of NSC provides a unique opportunity to elucidate the 
mechanism at the molecular level. NSC in vitro, in the absence of serum, respond to 
PLWRJHQV)*)DQG(*)DQGIRUPFORQDOSRSXODWLRQVRIFHOOVNQRZQDVµQHXURVSKHUHV¶
which represent a heterogeneous progenitor pool at different stages of development 
and differentiation (Ahmed, 2009; Wang et al., 2006). Providing the requisite growth 
factors and substrates these cells can be diverted towards different lineages. The use 
of neurotropic factors NT3, NT4 and BDNF along with low levels of FGF-2 has been 
shown to promote neuronal differentiation in vitro (Bottenstein, 2003; McAllister, 
2001). The addition of serum promotes GFAP expression in differentiating NSC 
FRPSDUHGWRǃ-tubulin III.  
As development of the brain proceeds the pool of NSC starts to decrease along with 
their proliferative potential, with an increase in lineage commitments (Brazel et al., 
2005). SOX2 has been shown to be the persistent marker present in fetal and adult 
NSC and has been used to quantify the presence of NSC. The embryonic Day5 chick 
brain expressed increased levels of SOX2 compared to earlier days. Later day brains 
also expressed almost same levels of the NSC marker but these are more developed 
and it might be that NSC have migrated to particular regions in brain. The decreased 
expression of SOX2 in chick after day 8 is confirmed by some earlier studies 
(Uwanogho et al., 1995). Charlotte Scott in earlier studies confirmed the ability of 
embryonic day 5 chick brain tissue to form neurospheres, but they were relatively 
scarce in numbers (Scott et al., 2010). In this study it was found that embryonic 
day5 chick (E5) neural tissues produced a substantial numbers of neurospheres. 
In this study the chick neural stem cells were grown and differentiated into a 
neuronal lineage using growth factors and supplements. The addition of drug to this 
system might provide a neurotoxic profile for the drug, in particular with respect to 
neuronal differentiation and the cytoskeletal protein neurofilament-L.  
The use of the antiepileptic drug VPA during the first trimester of pregnancy can 
result in neural tube and CVS defects (Ornoy, 2009). VPA is a HDAC inhibitor and 
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HDAC inhibition inhibits NSC proliferation and induces differentiation. VPA also shows 
protection against pro-apoptotic stimuli in neurons like lithium (Gurvich & Klein, 
2002). The effects of VPA in NSC were different compared to the embryonic stem 
FHOO GHULYHG FDUGLRP\RF\WH (6'& V\VWHP ,Q (6'& WKH KLJKHU GRVHV ǋ0
LQKLELWHG FDUGLRJHQHVLV EXW LQ16& WKH KLJKHU GRVH RI ǋ0 VKRZHGQR HIIHFW RQ
QHXURQDO GLIIHUHQWLDWLRQ 7KHǋ093$ZKLFK LV D WKHUDSHXWLFDOO\ relevant dose, 
result in increased percentage of LDH release in the medium that might be because 
VOLJKW LQFUHDVHG FHOO QXPEHU .HQDFLG EOXH DVVD\ ZDV REVHUYHG ZLWK 93$ ǋ0
WUHDWPHQW ,Q µ,QFHOO¶:% WKH1)-L showed no declining trend with increased drug 
dose, indicating increased VPA dose does not inhibited the neuronal differentiation. 
These types of result are observed with HDAC inhibitors (Hsieh et al., 2004). The 
other property of VPA to inhibit GSK3-ǃPLJKWKDYHSOD\HG UROHKHUH WRREHFDXVH
increased GSK3-ǃ ZDV IRXQG WR DOWHU QHXURJHQHVLV ZKLOH LWV LQKLELWLRQ SURPRWHV
neurogenesis. But the VPA mechanism of GSK3-B inhibition is different from lithium 
(Gurvich & Klein, 2002). The VPA activation of ERK pathway that stimulates 
neurogenesis cannot be ruled out here (Zhou et al., 2011). In earlier studies VPA 
was found to promote neuronal cell differentiation and inhibit glial differentiation 
(Hsieh et al., 2004), but VPA is also associated with neural tube defect production. 
Analysing the effects of VPA at gene level that promotes neuronal differentiation 
might provide a better elucidation of its effects. From the results observed here and 
in some earlier studies it can be concluded that VPA inhibits early NEP which results 
in NTD, while it does not inhibit the neuronal differentiation.  
The antiepileptic drug carbamazepine in the NSC system showed no significant toxic 
eIIHFWV DW ORZ GRVHV ǋ0 RQ FHOO YLDELOLW\ DQG SURWHLQ FRQWHQW EXW LQFUHDVHG
percentage of LDH release in the medium was observed. But at higher doses above 
ǋ0D GHFOLQLQJ WUHQG RI SUROLIHUDWLRQZDV REVHUYHG6LPLODU W\SHV RI UHVXOWZHUH
observed with (6 FHOOV ZKHUH WKH  DQG ǋ0 GRVHV VKRZHG GHFUHDVHG FHOO
SUROLIHUDWLRQDQGGLIIHUHQWLDWLRQ7KHDELOLW\DWKLJKGRVHVǋ0RI&%=WRDUUHVW
cell division might have played a role here, resulting in directly decreasing the cell 
viability (Perez Martin et al., 2008). Interestingly the reduced number of cells results 
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in increases in LDH release in the medium compared to the control; so the drug not 
RQO\ DUUHVWV FHOO GLYLVLRQ DW KLJK GRVHV ǋ0 Eut also affects cell membrane 
integrity, which ultimately results in cell death. The CBZ induction of apoptosis at 
KLJK GRVHV ǋ0 KDV DOUHDG\ EHHQ FRQILUPHG LQ SUHYLRXV VWXGLHV (Gao et al., 
1995). The drug effects on NF-L protein showed a different picture when normalized 
using GAPDH (see section 7.8.3). The increase in drug dose did not change the NF-L 
protein levels in the total neurons present. This means carbamazepine at low doses 
ǋ0 GRHV QRW SURGXFH WR[LF HIIHFWV RQ FHOO SUROLIHUDWLRQ DQG FHOO PHPbrane 
integrity, but at higher doses may arrest cell division, induce cell death and increase 
LDH release into the medium, while the drug itself does not affects neuronal 
differentiation. This is might be because of its HDAC inhibition effects which on one 
side induces apoptosis while also promoting neuronal differentiation (Gurvich et al., 
2004).  
In differentiating neurons the antidepressant drug bupropion shows strong 
DQWLSUROLIHUDWLYH HIIHFWV DW KLJK GRVHV ǋ0 WHVWHG EXW WKHVH GRVHV DUH PXFK
higher than normal serum therapeutic concentrations. As stated earlier in chapter 5 
the activation of the caspase pathway in bupropion treatment might have shown 
consistent results in all systems used in this study (Jang et al., 2011). Increasing the 
GRVHWRDQGǋ0VKRZHGPDMRUHIIHFWVRQWRWDOSURWHLQOHYHOVZKLFKUHSUHVHQW
cell proliferation. The effect on cellular oxidoreductase levels seems to be dependent 
on the number of cells. But the LDH assay clearly shows an increase in apoptotic 
DFWLYLW\DIWHUGUXJWUHDWPHQW7KHǋ0GRVHRI%31GHFUHDVHGWKHSURWHLQ OHYHOV
comparable to the effects of 5-Fu, but even the low number of cells released 
increased amounts of LDH into the medium. This shows the drug effects on cell 
membrane integrity, which result in increased apoptosis. When the BPN effects on 
NF-L were estimated the increased in drugs dose did not show any particular trend in 
protein levels. As neurofilament was used as marker of differentiated neurons, it 
means the drug is inhibiting cell proliferation but not affecting NSC differentiation 
LQWRQHXURQVLQSDUWLFXODUWKHSURWHLQHVWLPDWHGWKURXJKµLQFHOO¶ZHVWHUQEORWWLQJ,W
would be really interesting to analyse caspase activation after BPN treatment in NSC, 
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which would provide a better description of its antiproliferative effects on neuronal 
differentiation. 
The drug lithium carbonate acts by two mechanisms, the activation of the Wnt 
signalling pathway, which results in increased cell proliferation, especially in NSC 
with neuronal differentiation (Muroyama et al., 2004). The other mechanism of PI 
cycle inhibition is not clear in neurogenesis but it might have effects through 
disturbed Calcium regulation (Giles & Bannigan, 1999; King et al., 2010). In this 
study lithium showed no significant toxic effects on differentiating neurons at 
therapeutically relevant (600-ǋ0 DQG DW WR[LF GRVHV ǋ0 RQ FHOO
proliferation and neural differentiation. The lithium carbonate in NSC derived 
neurons showed an increased percentage of LDH release at therapeutically relevant 
serum levels but interestingly the cell proliferation was not dropped significantly. 
As discussed earlier, Lithium carbonate acts by two mechanisms the PI cycle 
inhibition and by mimicking the Wnt/GSK3-ǃ SDWKZD\ *6.-ǃ KDV SURDSRWRWLF
activity and its inhibition results in cytoprotection (Leng et al., 2008). The Wnt 
pathway activation normally results in increased cell proliferation which was found in 
ESDC but not in the case of neurons. Some earlier studies have shown that lithium 
has no effects on progenitor proliferation but protects from neurotoxic agents or 
conditions (Boku et al., 2011; Ishii et al., 2008). The Wnt protein in the presence of 
FGF-2 inhibits neuronal differentiation, (Bottenstein, 2003) which was not significant 
in this study. It would be interesting to see how lithium carbonate affects 
differentiating neurons in the absence and presence of FGF-2 at doses above 2mM. 
It can be concluded that the use of the in vitro chick NSC culture system provides an 
easy way to elucidate neurogenesis mechanisms. The chick NSC system is an easy 
and less expensive model compared to rodents. These neural stem cells are highly 
plastic and differentiate into various brain cell types and provide the opportunity to 
screen drug toxic mechanisms before marketing.  
)RUWKHDQWLHSLOHSWLFGUXJV93$+'$&LQKLELWLRQ*6.ǃLQKLELWLRQDQGDFWLYDWLRQRI
ERK signalling in combination decides the neural stem cell fate with direction either 
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toward apoptosis or differentiation, while the other AED CBZ does not affect 
neuronal differentiation but at high doses arrests cell division. The BPN activation of 
caspase pathways increases cell apoptosis, while the drug apart from inhibiting cell 
proliferation exhibits no significant inhibitory effects on neuronal differentiation. 
Lithium carbonate, like VPA, affects many signalling pathways but at drug doses 
above serum therapeutic levels, mainly activation of the Wnt pathway and in the 
presence of FGF-2 it may negatively regulate neuronal differentiation.  
With the addition of different growth factor combinations and differentiation to 
different neuronal and other CNS cell types, plus the identification of appropriate end 
points and molecular markers, the chick NSC system could be a reliable in vitro 
model to estimate teratogenic effects.  
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Chapter 9 
General Discussion  
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9.1 General Discussion, Conclusion and Future Work  
The study of embryo development is one of the most fundamental and fascinating 
areas of modern science (Levin, 2002), since it involves intricate signalling, 
transcription, differentiation, assembly and regulation. This complex web of events 
requires a continuous flow of information between cells and tissue systems (Levin, 
2002; Vinken et al., 2006). Any disturbance in normal regulation and information 
sharing could lead to a disastrous developmental outcome. The heart is the first 
mesodermal organ that starts function because of the high demand of nutrient 
supply in other developing regions. Any abnormal regulation at earlier stages of 
heart development directly affects the oxygen and nutrient supply to other 
proliferating and differentiating cells. Neural developmental defects lead to cognitive, 
motor and intellectual dysfunctions. Nervous and cardiovascular system patterning 
and migration during development are tightly regulated by various factors whose 
increased expression promotes one lineage and can inhibit others (Murashov et al., 
2005). Potential contact during pregnancy either by medication, food or by 
environmental factors affects normal development, which by disturbed regulation of 
signalling molecules may promote one lineage and affect others, as observed in the 
case of VPA and Li2CO3 ,QWHUHVWLQJO\ WKH GUXJ¶V HIIHFWV DUH QRW RQO\ UHVWULFWHG WR
lineage but also vary with the stage of development.  
In this study two lineages were targeted during development. Firstly the cardiac 
lineage, for which the chick embryonic cardiomyocyte micromass system has been 
used, which represents early embryonic heart cells (Ahir & Pratten, 2011) which 
have acquired the cardiac lineage but are anatomically underdeveloped (Bellairs & 
Osmond, 1998). Also mouse embryonic stem cells were differentiated into 
cardiomyocytes. The use of the ESDC system in tandem with a fibroblast cell line has 
been accepted and validated by ECVAM as a potential screening method for 
teratogenicity testing. However, in this study the ESDC protocol of differentiation 
was used without estimating effects on the fibroblast cell line which does not actually 
represent the in vivo maternal condition (Anneelieke et al., 2007; Marx-Stoelting et 
al., 2009). The third system is a newly developed chick Neural Stem Cell isolation 
     
217 
 
and differentiation of neurons. The chick NSC isolation system is easy and cheap 
compared to mouse, but there remains a problem with molecular markers in the 
chick system. The brain tissues isolated were grown in neurospheres, which 
represent the pool of neural stem cells at different stages of development and 
differentiation (Wang et al., 2006). Providing the requisite growth factors and 
supplements, the NSC cells were diverted into the neuronal lineage. In all three 
systems drugs were applied to estimate their effects at the cellular and molecular 
level. A number of endpoints have been used in in vitro teratogenicity testing. In this 
study the resazurin cell viability assay was preferred because of its ease of use in 
these systems and the same cells can be used for protein content estimation using 
the Kenacid blue assay. As the chick NSC is a newly developed method, LDH release 
in the medium was also estimated as a marker of cell membrane integrity after drug 
treatment. In cardiomyocytes, contractile activity was used as a marker to confirm 
the extent of cardiac differentiation and any drug effects. Two types of drug groups 
were selected based on the in vivo data available and the FDA pregnancy category: 
Anti-Epileptic Drugs and Anti-Depression Drugs. These drugs and their disease states 
during pregnancy present a conflict in drawing a clear conclusion on results, but in 
vivo data have confirmed the teratogenic nature of these drugs (Brewer et al., 2003; 
Kallen et al., 2006).  
Most of the antiepileptic drugs are shown to perturb normal development (Kaneko et 
al., 1999). AEDs affect Neural tube integrity, the CVS and show similar effects on 
facial development (Ornoy, 2009). Some common teratogenic mechanisms have 
been observed between AEDs, such as oxidative stress through the production of 
highly reactive epoxide intermediates. Their detoxification depends upon the 
enzymes present, which lead to different degrees of drug effect with strain and 
animal type. Low levels of antioxidant enzymes are detected in embryos, which may 
easily put the embryo on oxidative stress. Using the undifferentiated embryonic stem 
cells, no altered levels of ROS production were observed. This may mean the early 
stage pluripotent cells are not equipped with a metabolic system to produce ROS and 
induce oxidative stress. This may partly explain the lack of earlier embryopathies, 
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while during organogenesis (cardiogenesis) the differentiated cells shows stage 
dependant effects on ROS production. Secondly AED effects on Folic Acid metabolism 
or intestinal absorption have been suggested as possible mechanisms (van Gelder et 
al., 2010). Differences between the drug mechanisms for inhibition of FA metabolism 
might be the key to the diverse effects in the in vitro systems. For example, VPA 
inhibits FA metabolism, an effect for which there is efficient protection by adding FA 
supplements, while CBZ impairs FA absorption, which is an effect that cannot be 
seen in the in vitro system, consequently the addition of FA supplements failed to 
show protective effects. Phenytoin, which can decrease FA levels most compared to 
other AEDs, does not induce NTD to the extent of VPA or CBZ. There is a relation 
between AEDs, FA and NTD but the mechanism is not fully understood. The third 
possible mechanism observed with VPA and CBZ is HDAC inhibition which also 
promotes DNA methylation and induces epigenetic changes at the DNA level (Detich 
et al., 2003; Murabe et al., 2007b). Beside these mechanisms, drugs may act on 
various signalling pathways and on cellular biochemistry.  
Valproic acid is already known to produce toxic effects in the MM and ESDC system 
(Ahir, 2009; Murabe et al., 2007a). High levels of drug affects cardiac differentiation 
more compared to the differentiated cells of the MM system. Similar results were 
also observed with CBZ. This may mean VPA and CBZ use during cardiac cell 
differentiation is more lethal compared to later stages of heart cell development. It 
would be interesting to see how these drugs affect adult cardiomyocyte contractile 
activity in in vitro systems. During ES cell differentiation VPA and CBZ affect normal 
cardiogenesis by increased oxidative stress, which is not observed in the MM system. 
That is possibly due detoxifying enzyme levels which increase with developmental 
stage, while antioxidant supplements have shown a positive impact on detoxifying 
these intermediates (Zhang et al., 2010). CBZ, at doses above serum therapeutic 
levels, arrested ES cell growth, which has connotations with earlier studies. The 
effects of the same drugs appear to be different on neurogenesis, since earlier stage 
neural tube development is inhibited by VPA and CBZ and results in NTDs, while late 
stage neuronal differentiation remained unaffected as observed with chick NSC. The 
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drug effects on NTD were found to be the result of decreased neuroectodermal cell 
proliferation, but this is reversed by the addition of FA. HDAC inhibition properties 
could be the other source of reduced cell proliferation at the earlier stage 
commitments (Gurvich et al., 2004), while at later stages of neurogenesis HDAC 
inhibition was actually found to induce neuronal differentiation (Yu et al., 2009). 
In the in vitro systems ROS production takes place within the cells in the 24-well 
plates, without the need for cells to migrate to a target tissue. In vivo ROS produced 
in the mother cannot migrate to the embryo because the electrophiles have a very 
short half-life. There needs to be some mechanism to produce intermediates and 
reactive species either by placental metabolism or metabolism inside the embryo to 
produce toxic effects. Increased ROS production caused by VPA and CBZ may have 
effects on other proteins including Cx43, which shows reduced and disturbed dose 
dependent levels in both the systems. However, in the MM system the ROS levels 
were shown not to be significantly elevated after drug treatment, so effects might be 
attributed to some other mechanism, especially for VPA, VXFKDV33$5įǃ-catenin, 
activator protein 1, myo-inositol, PkC and Erk1/2 (Gotfryd et al., 2011; Gurvich et 
al., 2004). The role of AA to counteract CBZ cardio-toxic effects, especially in ES 
cells, is mainly due to the cardiac induction properties through production of low 
levels of peroxide, along with its antioxidant effects. SOD failed to be protective in 
ES cells, possibly because these cells either cannot respond to SOD or it does not 
reach the target site. 
In the MM and ESDC cardiomyocytes PHT showed a dose and stage dependent effect 
on cardiogenesis. PHT effects on contractile activity are mainly attributed to its 
inhibitory effects on potassium channels (Danielsson et al., 2007), while increasing 
ROS production through epoxide intermediates (Ozolins et al., 1995) might result in 
toxic effects which were more prominent in the ESDC system. The toxic effects on 
cell proliferation and to some extent on viability were only evident in the ESDC 
system. This shows the role of PHT in producing malformations before cardiac 
lineage commitment compared to the treatment of the differentiated cells of the MM 
system. These different effects with PHT were not only observed at stages of 
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development but also in different strains mainly due to enzyme levels that 
metabolize PHT or detoxify the highly reactive intermediates (Ozolins et al., 1995).  
The fourth anticonvulsant molecule primidone in the MM system showed dose and 
time dependent effects on contractile activity, while in ESDC increased dose resulted 
in decreased contractile activity at all intervals observed. The ESDC exhibited 
inhibitory effects on contractile activity at lower doses compared to the MM system. 
It may be that the effects of the drug on development are through some unknown 
mechanism compared to the contracting cardiomyocytes of the MM system. In vivo 
primidone is metabolized to PEMA and phenobarbital, and the phenobarbital is 
mainly responsible for its anticonvulsant effects (Pizzi et al., 1996). Whether 
primidone is metabolised in this system is unknown, while its metabolite 
phenobarbital when tested in MM and ESDC was found to affect cardiomyocyte 
contractile activity (Ahir, 2009). Primidone itself is less toxic compared to its 
metabolite in the in vitro cardiomyocytes system, while in in vivo the drug itself and 
its metabolite synergistically may induce toxicity. If the drug is not metabolised it is 
comparatively less toxic, but its therapeutic activity is mainly due to phenobarbital 
production. In order to avoid toxic effects, it may be possible to increase the efficacy 
of the parent molecule itself without its metabolism or may be by drug metabolism 
to a phenobarbital analogue with reduced toxic effects. 
In humans the use of FA and AA supplements at the start of pregnancy may 
eliminate the risk of producing NTDs and CVS defects with AEDs. But AA at high 
doses was found to act as pro-oxidant through the Fenton reaction in in vitro 
systems, so maintaining adequate levels of AA is also necessary to avoid any 
unwanted effects. Less teratogenic analogues like methyl valproate may provide an 
alternative with reduced drug induced toxic effects.  
In ADP the toxic effects produced did not show any common outcome. BPN had 
effects on cell proliferation in all systems. The chick cardiomyocytes isolated from 
day five old embryos or the embryonic stem cells derived cardiomyocytes both 
exhibit a reduced cell proliferation after BPN treatment. When the drug was used to 
treat NSC derived neurons the effects on cell proliferation were not very different 
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from the cardiomyocyte system. Interestingly in the ES cells, the size of EBs was not 
affected as much as observed in CBZ treated groups, where reduced EBs size was 
seen from the start of the experiment. In MM the cultured cardiomyocytes ability to 
proliferate and form connections was seriously affected after drug treatment. BPN 
has been reported to affect cell proliferation without producing metabolites but by 
increased cell apoptosis (Jang et al., 2011). This means the mechanism of decreased 
cell proliferation is independent of the cell type used and stage of development. BPN 
effects on cell viability seemed to be dependent on cell proliferation, but the 
increased LDH leakage into medium with increase in drug dose might have been the 
result of increased apoptosis. Estimating the caspase activity with BPN treatment in 
these systems might provide a better elucidation. Drug effects on cell proliferation 
also affect the establishment of the contractile unit, especially in the case of the MM 
system, where cultured cardiomyocytes proliferate and make contact and then 
establish gap junctions so they can share information. The connexin43 levels after 
BPN treatment were reduced in both systems and especially a disturbed localization 
was observed in the MM system. BPN affects the Ca2+ levels in the cells and Ca2+ is 
involved in the regulation of gap junction permeability (Lurtz & Louis, 2007). 
Reduced permeability might have affected Cx43 turnover and reduced gap junction 
levels in the cardiomyocytes, which in turn affects the contractile activity. Early 
cardiac and neuronal differentiation markers analysis will provide the better 
explanation that drug only inhibits cell proliferation or also its commitment to 
different progeny. BPN drug treatment with high doses of BPN during pregnancy 
carries the risk of producing convulsions and antiproliferative effects, which both 
may confound the pregnancy outcome. Maintaining the serum therapeutic levels 
during pregnancy or chemically modifying the Bupropion structure specially to 
prevent the effects on proliferation might provide solution to these side effects.  
The effects of the second antidepressant molecule, lithium carbonate, on 
cardiomyocytes were observed through two different mechanisms. Firstly inositol 
synthesis - the drug affects inositol synthesis through inhibition of the IMPase 
enzyme which results in reduced recycling of free inositol at the cell membrane. This 
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eventually results in reduced production of IP3 in the cells (Giles & Bannigan, 1999; 
Klug et al., 1992; Segal, 2004), a molecule that has an important role in cell 
contraction and initiation of pace maker activity in the heart (Kockskämper et al., 
2008). When the effect of lithium on contractile activity was compared in MM and 
ESDC systems, the results were very different because cells at same the dose were 
contracting in the MM system while in ESDC no contraction was observed. Two 
things are important here: firstly MM cardiomyocytes have already differentiated and 
contract and exhibit GJIC at the time of isolation, while ESCs are unspecialized cells 
which can acquire any lineage. When lithium treatment was given to cells, the MM 
cardiomyocytes had already experienced contractility, so contractile activity re-
establishment was not affected much compared to ESDC, where the early 
mechanism to start the first beat relies on IP3, which was eliminated by lithium 
treatment. Myo-inositol supplementation compensated for the effect of Lithium, by 
providing the requisite inositol. The other important potential mechanism is lithium 
DFWLYDWLRQ RI :QW SDWKZD\V ZKLFK UHVXOWV LQ DFFXPXODWLRQ RI ǃ-FDWHQLQ DQG ǃ-
catenin has an important role in Cx43 regulation (Zhaowei et al., 2000 ) and embryo 
hyperdorsalization (Eisenberg & Eisenberg, 2007; Martin et al., 2011). When the 
results for Cx43 in MM are analysed, the cellular localization appeared disturbed 
after lithium treatment compared to ESDC, where protein content was increased. 
This means that it is likely that lithium acting by some other mechanism has 
disturbed Cx43 localization in MM, while in EDSC the activation of Wnt negatively 
regulates cardiogenesLVDQGǃ-catenin accumulation, which induces CX43 expression. 
Wnt signalling has a role in producing hyperdorsalized embryos which might parallel 
the fact that in ESDC differentiated cells there was increased cell proliferation. In 
NSC lithium exerted a neuroprotective effect on neural differentiation, with no 
altered effects on cell viability, which is in accordance with the results observed 
earlier (Ishii et al., 2008). Lithium activation of the Wnt pathway can affect the cell-
lineage fate (Sommer, 2004), which was observed in both cardiomyocytes and the 
neuronal system. The lithium molecule exhibits cardiac inhibition and with no effects 
RQQHXURQDO GLIIHUHQWLDWLRQ$OWHULQJ WKHPROHFXOH¶VSURSHUWLHVPD\QRWSURYLGH WKH
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solution because it is thought that lithium acts by these mechanisms to produce 
antidepressant effects. Maintaining lithium therapeutic levels during pregnancy will 
reduce the risk of producing malformations. 
6W -RKQ¶VZRUW DFWLYH FRQVWLWXHQWV K\SHULFLQDQGK\SHUIRULQZHUH VKRZQ LQ VRPH
cases to affect normal development. When evaluated in the MM system the effects of 
hypericin, as observed in other studies, seemed to be light dependent, and initiate 
ROS formation that induced toxic effects (Theodossiou et al., 2004; Wurglics & 
Schubert-Zsilavecz, 2006). The other constituent hyperforin, with caspase activation 
properties (Hostanska et al., 2003), showed some inhibitory effects on contractile 
activity at levels above the normal serum concentration of the drug. Synergistically 
both drugs affected cardiomyocyte proliferation and contractile activity significantly 
EXWDJDLQDERYHWKHGUXJ¶VVHUXPWKHUDSHXWLFOHYHOV7KH00V\VWHPVXJJHVWVWKDW
HP and HF use at low doses showed no significant toxic effects on cardiomyocytes, 
but the mixtures effects on development need to be proved before making any 
definite conclusion.  
Most pregnancies are unplanned; thus when the mother finds out that she is 
pregnant she has already been exposed to teratogens. $ GUXJ¶V HIIHFWV RQ
development depend on the molecular mechanism with which they interfere, and 
this varies with lineage and the stage of development. The proper elucidation of the 
molecular mechanism of teratogenicity may help to counteract drug induced toxicity. 
Adding various markers and genetic exploration will make more clear the toxic 
profile of the drug, especially in the case of contractile activity by using some 
automatic scoring system or contractile protein markers to estimate the extent of 
effects on cardiac differentiation will make the EST more reliable. The chick NSC is a 
newly developed system and it needs more evaluation at the molecular level to 
become a better and more reliable screening method. Differentiation into different 
neuron types using growth factors and supplements and drug treatment during 
differentiation would provide an easy system for screening neuroteratogens. Using 
     
224 
 
different molecular markers and biochemical analyses in all three systems can 
provide a better explanation of toxic effects.   
By increasing the molecular size of the drug molecule so that it cannot cross the 
placenta, without losing its efficacy would be another way to reduce the risk of drug 
exposure to the embryo, but on the other side it may affect passage of the drug 
through the blood brain barrier. Before the formation of the placenta drug transfer 
directly to the embryos poses another threat. Planned pregnancies and 
supplementing the mother with counteracting molecules or chemically attaching 
these molecules to the drugs, which on metabolism resulted in the availability of 
these detoxifying agents at the site of production, may be a more sophisticated 
solution to the problem.  
The toxic effect of a drug during development depends on exposure conditions, time, 
dose, tissue and developmental stage. The complex effects produced by epilepsy, 
depression and their medications during development remained unresolved.  
Induction of oxidative stress by AEDs, antiproliferative effects of BPN or effects of 
Li2CO3 acting via IP3 /Wnt pathway interactions might have affected cell 
differentiation. These effects were more pronounced in differentiating cells (ESC) 
compared to primary culture of embryonic cardiomyocytes. The same molecule may 
produce different, even opposite, effects with different cell lineages. This totally 
depends on the molecular pathways with which it is interacting and their role in 
development. By counteracting or eliminating the exact toxic molecular mechanism, 
tissue injury and developmental defects as a whole can be prevented. 
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Fig 9.1 Flow chart for possible future research direction in these in vitro systems 
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Appendix 1. Materials 
All the chemicals were purchased from Sigma-Aldrich.UK unless otherwise stated. 
1.1 Plastic and Glass wares 
24 well plates   Nunclon, UK 
25cm2 tissue culture flasks         SLS, UK 
90mm round Petri dishes         Nunclon, UK 
96 black well plates (clear bottom)         Costar, UK 
96 well plates         Nunclon, UK 
Aero disc filter (0.2µM)            Sartorius, UK 
Bijou bottles (7ml)             Sterilin, UK 
Chamber slides (8 well)         Thermo scientific, UK 
Cover slips         SLS, UK 
Cryovials         Sarstedt, UK 
Eppendorf tubes 0.5ml and 1.5ml          Sterilin, UK 
Serological pipettes             Greiner bio-one, UK 
Square Petri dishes             Sterilin, UK 
Syringes 50ml, 10ml and 1ml         BD Biosciences, UK 
Universal tubes 20ml                 Sterilin, UK 
Universal tube 15ml and 50ml         Greiner bio-one, UK 
1.2 Equipment 
Assorted dissecting tools            A. Dumont, Switzerland 
ASYS HITEC Expert 96 plate reader           SLS, UK 
Autoclave              Denley, UK 
Automated egg turner            MFG, USA 
Balance D40T              Stanton, UK 
Calibrated pipettes             Gilson, France 
Centrifuge (centaur 2)            Fisons, UK 
Class I sterile laminar flow hood                                Glossop, UK 
Class II sterile laminar flow hood           Thermo scientific, UK 
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CO2 incubator              Sanyo, UK 
Confocal microscope TCS4D            Leica, Germany 
Cooled egg incubator             Gallenkamp, UK 
Dissecting microscope (Nikon SMZ-10a)          Nikon, Japan 
Dymax 30 aspirator vacuum pump           Charles Austen Pumps 
Eggs Incubator (38oC)            LEEC, UK 
Fluorescence microscope            Olmpus 1X70, Japan 
FLUORStar Galaxy plate reader           BMG Cambridge, UK 
Freezer (-80oC)             New Brunswick, UK 
Haemocytometer              Hawksley, UK 
Inverted phase microscope            Nikon, Japan 
Liquid nitrogen Dewar            Dilvac, UK   
Mr Frosty          SLS, UK 
Plate shaker              Luckham Ltd, UK 
Stirrer hot plate             Gallenkamp, UK 
Warming block             Camlab, UK 
Water purifier              Egga, UK 
1.3 Western blot materials 
Cassettes               Millipore, Uk 
Centrifuge Cold              Sigma, UK 
Centrifuge (RT)              Sanyo, UK 
Electrophoresis module            Bio-Rad laboratories, UK 
Filter paper              :KDWPDQ¶V/WG8. 
Fish skin gelatine (FSG)            Sigma-Aldrich, UK 
Loading marker             Lonza, UK 
Nitrocellulose membrane            Shleicher & Schuell, Germany 
Odyssey scanner             Licor, UK  
Plate reader              Spectra, Max, UK 
Polytron homogenizer            Heildolph, UK 
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Precast gels (10% 1mm)            Lonza, UK 
Transfer module             Bio-Rad laboratories, UK 
Tanks               Bio-Rad laboratories, UK 
Transfer cassettes             Bio-Rad laboratories, UK 
1.4 Consumables 
Autoclave bags             NHS supplies 
Pipette tips (200µl and 1000µl)           Sarstedt, UK 
Scalpels              SLS, UK 
Universal graduated glass bottles           SLS, UK 
Vinyl gloves              Ansell, UK 
Yellow biohazard bags            NHS supplies 
1.5 Software 
EndNote X5              Thomson Reuters, USA 
Odyssey V3.0               LI-COR Biosciences, UK 
Prism statistical software, V5.0                  Graph pad, USA 
Volocity workstation             PerkinElmer, Inc, USA 
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Appendix 2. Preparation of cell culture media 
2.1 Culture medium for chick embryonic cardiomyocytes (Micromass) 
)RU FKLFN HPEU\RQLF FDUGLRP\RF\WHV FXOWXUH PHGLXP 'XOEHFFR¶V 0RGLILHG (DJOHV
Medium (DMEM) was supplemented with 10% heat inactivated fetal bovine serum 
(FBS), 2mM L-glutamine and 50unitsml-1 penicillin/50µgml-1 streptomycin. The 
medium was stored at 4oC and used within two weeks. 
2.2 D3 mouse embryonic stem cells culture medium (ESDC) 
The D3 mouse ESCs culture medium was prepared by supplementing DMEM with 
20% heat inactivated FBS, 2mM L-glutamine, 50unitsml-1 penicillin/50µgml-1 
VWUHSWRP\FLQ P0 ǃ-Mercaptoethanol and 1% X100 non-essential amino acids. 
Leukaemia inhibitory factor (LIF) (Chemicon international, UK), was aliquoted and 
stored at 40C. LIF 1000Uml-1 was directly added to the culture flask. 
2.3 Preparation of NSC culture medium 
For the preparation of NSC culture medium, equal amounts of DMEM high glucose 
DQG +DP¶V ) ZHUe supplemented with B27×50 (2%) (Invitrogen, UK), N2×100 
(1%) (Invitrogen, UK), EGF 20ngml-1 (BD, Bioscience, UK), bFGF 10ngml-1 (BD, 
%LRVFLHQFH 8. +HSDULQ ǋJPO-1, 2mM L-glutamine and 50unitsml-1 
Penicillin/50µgml-1 Streptomycin.  
2.4 Preparation of NSC differentiation medium 
For the preparation of NSC differentiation medium Neurobasal medium (Invitrogen, 
UK)  was  supplemented  with  B27×50  (2%),  N2×100  (1%),  bFGF 5ngml-1, 
+HSDULQ ǋJPO-1, NT3 5ngml-1 (Abcam, UK), NT4 5ngml-1 (Abcam, UK), BDNF 
5ngml-1 (Abcam, UK), 2mM L-glutamine and 50unitsml-1 Penicillin/50µgml-1 
Streptomycin. 
Note: The culture media quality was checked by placing 5ml prepared medium in 
bijou bottle for 2-3 days at 37oC, 5% CO2 (British oxygen company) in an incubator. 
The medium was inspected microscopically for contamination. If contamination was 
present, the medium was discarded.  
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Appendix 3. Preparation of stock solutions 
3.1 Immunohistochemistry Stock solutions 
3.1.1 Bovine serum albumin (1% BSA w/v) solution 
1g BSA was added to 100ml PBS and agitated until dissolved. The solution was 
stored at 4oC.  
3.1.2 Normal goat serum (5% NGS v/v) 
5% v/v NGS solution was prepared by adding 500µl NGS in 9.5ml PBS immediately 
before use. 
3.1.3 Paraformaldehyde (4% PFA) solution 
4g of PFA was added to 100ml PBS inside the fume cupboard, the solution was 
heated at 60oC with continuous agitation until completely dissolved. The solution was 
filtered and stored at -20oC. 
3.1.4 Triton X-100 Solution (1% v/v) 
100µl Triton X-100 was added to 9.9ml PBS prior to use. The solution was vortexed 
and stored at 4oC. 
3.2 Preparation western blot Solutions 
3.2.1 Lysis Buffer pH 7.6 
20mM (12.1g) Tris (Invitrogen, UK), 1mM (19.1g) EGTA, 0.1% Triton X-100 (500µl), 
P0J1D)P0Jǃ-Glycerophosphate dissolved in 500ml Distilled 
water. One tablet of protease inhibitor (Roche, UK) was added to 10ml lysis buffer 
prior to use. 
3.2.2 2X Solubilisation Buffer 
0.5M (2.5ml) Tris (Invitrogen, UK), 2ml Glycerol, 10% (2ml) SDS (Fisher Scientific, 
8.POǃ-mercaptoethanol (Fisher Scientific, UK), 2.5% (40µl) Bromophenol Blue 
(Fisher Scientific, UK).  
3.2.3 TBST (0.1% Tween-20) 
25mM (30.29g) Tris and 125mM (73.12g) NaCl were dissolved in 1L distilled water, 
pH was adjusted to 7.6 using HCl (approximately 17ml conc HCl), total volume was 
made up to 10L and 10ml Tween-20 (0.1%) was added. 
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3.2.4 10X Electrophoresis buffer 
Tris 30.3g, Glycine 144g and SDS 10g were dissolved in 1L distilled water. The 
solution was stored at 4oC. 
3.2.5 Transfer buffer 
Tris 30.3g and Glycine 144g were dissolved in 8L distilled water and 2L methanol 
was added. The solution was stored at 4oC. 
3.2.6 Lowry A and B 
500ml Lowry A solution was prepared by dissolving 2g NaOH (Fisher Scientific, UK), 
1g SDS, 10g Na2CO3 (Fisher Scientific, UK) in 500ml distilled water. For Lowry B 1% 
CuSO4, 2% NaK Tartrate (Fisher Scientific, UK) were dissolved in distilled water. 
3.2.)ROLQ¶V5HDJHQW 
Folin reagent solution was prepared by dissolving 1:1 of reagent in dH2O. 
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Appendix 4. List of antibodies 
4.1 Immunohistochemistry (IHC) 
4.1.1 Primary antibodies for immunohistochemistry 
Antigen 
Specificity 
Host 
Species 
Antibody 
Type 
Reactivity Dilution Source 
Connexin43 Mouse Monoclonal Bovine, chicken, 
mouse, human, 
hamster, rat 
1:500 Sigma-
Aldrich.UK 
SOX-2 Rabbit Polyclonal Human, mouse, 
chicken 
1:100 Sigma-
Aldrich.UK 
Myosin heavy 
chain 
Mouse Monoclonal Chicken 1:100 DSHB, 
Iowa, USA 
Troponin T Mouse Monoclonal Broad species 1:100 DSHB, 
Iowa, USA 
Neurofilament-L Mouse Monoclonal Pig, rat, 
chicken, human 
1:400 Sigma-
Aldrich.UK 
Table 4.1 The primary antibodies used for immunostaining.  
 
4.1.2 Secondary antibodies for immunohistochemistry 
Antigen 
specificity 
Host Type Reactivity Label Dilution Source 
Rabbit 
IgG 
Goat Monoclonal Rabbit Alexa  
488 
1:1000 Invitrogen,  
UK 
Mouse 
IgG 
Goat Monoclonal Mouse Alexa 
488 
1:500/1000 Invitrogen,  
UK 
Table 4.2 The secondary antibodies used for immunostaining. 
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4.2 Western blot  
4.2.1 Primary antibodies for western blot 
Antigen 
Specificity 
Host 
Species 
Antibody 
Type 
Reactivity Dilution Source 
Connexin43 Mouse Monoclonal Bovine, chick, 
mouse, human, 
hamster, rat 
1:3000 Sigma-
Aldrich.UK 
Phospho-
Connexin43 
Rabbit Monoclonal Chick, murine, 
human, bovine, 
zebra fish 
1:750 Thermo 
scientific, 
UK 
SOX2 Rabbit Polyclonal Human, mouse, 
chicken 
1:1000 Sigma-
Aldrich.UK 
ǃ-Tubulin 
III 
Mouse Monoclonal Mouse, Pig, 
Rat, Chicken, 
Human 
1:1000 Abcam, 
UK 
GFAP chicken Polyclonal Mouse, Rat, 
Chicken, Cow, 
Cat, Human 
1:15000 Abcam, 
UK 
GAPDH Mouse Monoclonal Human, mouse, 
rat 
1:10000 Sigma-
Aldrich.UK 
GAPDH Rabbit Monoclonal Human, mouse, 
rat 
1:20000 Sigma-
Aldrich.UK 
Table 4.3 Primary antibodies used in Western blot analysis. 
4.2.2 Secondary antibodies for western blot 
Antigen Specificity Host Species Antibody 
Type 
Dilution Source 
IRDye800CW Mouse Polyclonal 1:10000 LICOR, UK 
IRDye680CW Mouse Polyclonal 1:10000 LICOR, UK 
IRDye800CW Rabbit Polyclonal 1:10000 LICOR, UK 
IRDye680CW Rabbit Polyclonal 1:10000 LICOR, UK 
IRDye800CW Chicken Polyclonal 1:10000 LICOR, UK 
Table 4.4 Secondary antibodies for NSC Western blot. 
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4.3 In cell western blot 
4.3.1 Primary antibodies for In cell western blot 
Antigen 
Specificity 
Host 
Species 
Antibody 
Type 
Reactivity Dilution Source 
Neurofilament-L Mouse Monoclonal Mouse 1:300 Sigma-
Aldrich.Uk 
GAPDH Rabbit Monoclonal Human, 
mouse, rat 
1:3000 Sigma-
Aldrich.UK 
Table 4.5 Primary antibodies for NSC In cell western blot. 
4.3.2 Secondary antibodies for In cell Western blot 
Antigen Specificity Host 
Species 
Antibody 
Type 
Dilution Source 
IRDye800CW Mouse Polyclonal 1:3000 LICOR, UK 
IRDye680CW Rabbit Polyclonal 1:3000 LICOR, UK 
Table 4.6 Secondary antibodies for NSC In cell Western blot. 
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Appendix 5.  Calculation of cell number 
The cell number was determined using the Neubauer Haemocytometer. 20µl cell 
suspension was incubated with 20µl of Trypan Blue (0.4%w/v) (1:1 dilution) for few 
min at room temperature. The dead cells take up the dye and were stained blue. Cell 
viability is determined by counting the number of live and dead cells.  
Total cells ml-1 = Average of squares counted × dilution factor × 104 
For total percentage of viable cells: 
Percentage viability =     Live cell count ×100 
               Total cell count  
 
  
Fig 5.1 Appearance of the Haemocytometer grid visualized under the microscope. 
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